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Thesis Abstract 
 
This PhD thesis examines the integration of complex computational methodologies with 
the surveillance and research of a genus of viruses implicated in a wide variety of clinical 
conditions, ranging from asymptomatic infection to death. These viruses, known as the 
enteroviruses, are some of the most studied viruses in history and as a result are 
represented by a vast body of literature. The fact that enterovirus research and 
surveillance rests upon such an extensive foundation of published material, makes 
enteroviruses a perfect candidate for the experimental application of modern 
computational methods, or in-silico experimentation. 
 
Fundamental to the understanding of virus behaviour is the determination of molecular 
structure and function, a fact which applies not only to viruses, but also to biological 
entities in general. As computational power has increased, the potential for the 
application of advanced analytic and predictive in-silico methods to further our 
understanding of virus behaviour, cannot be ignored. A practical example of this advance 
in computational power can be found in the one million atom in-silico reconstruction and 
simulation of Satellite Tobacco Mosaic Virus (STMV). This particular experiment, 
performed in 2006, required a supercomputer to calculate 50 nanoseconds of data at a rate 
of 1 nanosecond per day
1
, a feat that can be now performed on a modern desktop 
computer in the same time-frame. 
 
In-silico experimentation, similar to that applied to STMV, has resulted in the 
formulation of this thesis and of the hypothesis that computational power currently 
available can be utilised for multiple stages of virus study incorporating identification, 
epidemiology and atomic structure prediction. Extensive work was performed during the 
course of this thesis in adapting classical molecular dynamics techniques to the large 
scale simulation of a prototype poliovirus, using millions of simulated atoms. The 
successful application of these techniques has resulted in microsecond-timescale, 
atomistic simulations of complete virus particles. These simulations represent the first 
published instance of the simulation of a biologically complete pathogenic 
microorganism, incorporating the encoding genetic information
2
.  
 
 2 
This thesis also examines the use of bioinformatics methods in the development and 
application of an advanced quantitative multiplex real-time reverse-transcription 
polymerase chain reaction (qRT-PCR) methodology, for the primary screening of 
samples from patients suffering acute flaccid paralysis (AFP), which is one of the most 
debilitating presentations of enterovirus infection. The application of this novel qRT-PCR 
method reduces the initial screening time of samples derived from a symptomatic patient 
from 4-5 days using virus culture, to four hours using the novel qRT-PCR. This novel 
qRT-PCR method can be rapidly scaled-up in response to an outbreak situation. The 
ability to screen large numbers of samples during an outbreak situation is important and is 
hampered when using virus culture methods exclusively. 
 
In Australia and the Western Pacific region over the last decade, the rate at which non-
polio enteroviruses in cases of AFP have been identified, is on average 18%. With the 
introduction of PCR screening methods, a number of non-cultivable enteroviruses were 
identified, along with newly described and a previously undescribed enterovirus. Little is 
known about these newly described and novel enteroviruses. This thesis aimed to 
investigate the identification of viruses that may represent a significant public health 
threat and to then use their genetic sequence information to recreate major virus structural 
components in-silico. This reconstruction process was achieved by exploiting advances in 
comparative protein modelling and molecular dynamics simulation methods. In order to 
apply these methods to the reconstruction of previously undescribed viruses for which no 
structural data exist, validation of different comparative protein modelling techniques was 
required.  
 
The validated methods examined in this thesis were applied to the newly described 
species-C Enterovirus, EV-C96 and a novel species-A Enterovirus EV-A120, which was 
discovered during the PhD candidature period. The predictive in-silico methods generated 
reliable atomic coordinates, representing structures suitable for the reconstruction of virus 
capsid models for further study. Examples of potential applications for these models are 
provided in the form of the observation of anti-viral binding activity in poliovirus and in 
the examination of spatial data for putative receptor binding domains using proposed 
receptor binding motifs from homologous enteroviruses. 
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Chapter One 
 
 
Literature Review 
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“It was believed that without parental genomes, 
no daughter cells or progeny viruses would arise. 
We have broken this fundamental law of biology 
by reducing poliovirus to a chemical entity, 
which can be synthesized on the basis of 
information stored in the public domain”  Ekard Wimmer, 2006. 
 
 
 
 
* Chemical “formula” for Poliovirus3
Chapter 1: Literature Review 
4 
1.1 Introduction 
Diseases caused by viruses have likely plagued man since before recorded history. 
Viruses belonging to the genus Enterovirus (including poliovirus) offer possibly the 
oldest evidence to support the observation of viral infection. Evidence of enterovirus 
(EV) infection has been observed in Egyptian skeletal remains dating back to 3700BC
4
, 
and evidence of possible polio infection dating back to 1400BC has been identified 
(Figure 1.1)
5
. 
 
Figure 1.1 Egyptian Funerary stele 1403-1365BC. Funerary stele (stone slab) depicting the Doorkeeper 
Ruma, exhibiting a typical presentation of poliomyelitis. Note the atrophy of the right leg, also known as 
equinus foot
4,5
. Figure derived from global polio eradication initiative website. Accessed, 15
th
 December 
2013. 
 
The term “virus” first appears in 1599 and is the Latin term for slimy poison or venom6. 
Experiments with viruses that caused disease in plants, specifically tobacco mosaic virus 
(TMV), by Dimitri Ivanovsky in 1892, showed that the agents responsible for tobacco 
mosaic disease could be passed through very fine filters which would remove the smallest 
known bacteria, resulting in a solution containing a “filterable agent” that was found to 
induce disease when applied to healthy plants
7
.  Whether or not this “filterable agent” was 
a living entity or a toxin was initially a scientific question, but is today a philosophical 
one. 
 
Upon the widespread availability of antibiotics (a termed first coined by Selman 
Waksman in 1942)
8
, cells cultured on the outside of an animal host could be used for the 
propagation of viruses. Antibiotics permitted the propagation of cells without the 
problems associated with extraneous growth of contaminating fungal or bacterial agents. 
These cell culture techniques allowed researchers to investigate virus growth and 
Chapter 1: Literature Review 
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pathogenesis as an adjunct to, and subsequently in replacement of, methods such as live 
animal inoculation
9
. During this time it was discovered that members of the genus 
Enterovirus exhibited diversity in cell tropism, leading to the initial characterisation of 
these viruses being determined on this basis
10-12
. 
 
After the successful crystallisation of TMV in 1935 by Wendall Stanley
13
, x-ray 
diffraction data describing the atomic structure of the virus was obtained by Bernal and 
Fankuchen in 1941
14
. The advances in plant virus structure determination ultimately lead 
to the elucidation of the first structures for viruses affecting mammalian hosts, 
specifically the enteroviruses - rhinovirus and poliovirus - in 1985
15,16
. 
 
Among the pivotal events that drove the laboratory-based investigation of virus infection 
in the western world, were the massive outbreaks of poliomyelitis that occurred in the 
United States in the mid-20th century, peaking in the 1950s, when tens of thousands of 
paralysis cases occurred with thousands of deaths
17,18
. Initially it was thought that the 
disease was the result of a single virus type and this idea complicated the development of 
vaccines to combat the disease. It was later determined that there are in fact three separate 
and distinct serotypes of poliovirus 
19
, an observation that was first indicated by Burnet 
and MacNamara in 1931
20
. This discovery rapidly resulted in the production of two 
effective vaccines against all three serotypes, which remain in current use
21,22
. 
 
The intensity of research related to enterovirus identification, pathology, epidemiology, 
structure and function means there is an extensive body of literature derived from over 
100 years of observation and experimentation, making enteroviruses the perfect candidate 
for modern in-vitro experiments. Recent advances in bioinformatics and computational 
biology now permit the researcher to combine 2-dimensional results, in the form of 
sequence data, with 3-dimensional results from structural analysis and to perform 
experiments computationally, termed in-silico experimentation.  
 
The following literature review examines historic and biologic aspects of infectious 
agents belonging to the genus Enterovirus, specifically members of the species A, B, C 
and D enteroviruses, and examines common methods used to derive structural data The 
literature review also examines an increasing role being played by modern bioinformatics 
and computational biology, specifically in the field of computational biophysics, and 
provides specific examples of their utility with respect to the examination of virus 
structure.  
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1.2 The Viral Pathogen: Enterovirus 
Members of the genus Enterovirus incorporate established human pathogens responsible 
for a diverse range of clinical conditions, ranging from subclinical infection to severe 
illness and occasionally death
23-25
. The epidemic potential of members of the genus is 
well established
26-31
. Rhinovirus and poliovirus are well known examples of enteroviruses 
with epidemic potential, the latter being responsible for millions of paralysis cases 
throughout history
32
. 
 
Enteroviruses, in particular the polioviruses, are among the most studied viruses in 
history. Indeed, with respect to animal disease, one of the first virus structures to be 
elucidated using x-ray crystallography was derived from poliovirus type 1
16
. Poliovirus 
has a long history of firsts; it was the first mammalian RNA virus to be cloned and 
sequenced
33,34
, the first RNA virus infecting animals to be reconstructed in the form of an 
infectious clone
35
 and the first virus to be constructed entirely from synthetic 
oligonucleotides
36
. 
 
The study of poliovirus continues to be of benefit to the infectious disease research 
community to this day. A significant point to note is the relatively tiny size of the 
enterovirus genome. At approximately 7,500 nucleotides, the entire genome can be easily 
displayed on a single A4 page (Figure 1.2). It is humbling to realise that such a relatively 
simple and efficient piece of “biological code”, can be responsible for such complex 
disease presentation and be the source of wide-spread global morbidity and mortality.  
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Figure 1.2 The complete poliovirus genome. Text representation of the complete poliovirus type 1 
(Mahoney strain) genome derived from GenBank Accession Number  NC002058, with the addition of 57 
adenosine residues to illustrate the “polyA tail” located after the 3´ non-translated region of the genome. 
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1.2.1 Enterovirus Taxonomy 
Enteroviruses are a genus of viruses classified in the order Picornavirales, family 
Picornaviridae. There are 17 genera classified within the picornavirus family- 
Aphthovirus, Aquamavirus, Avihepatovirus, Cardiovirus, Cosavirus, Dicipivirus, 
Enterovirus, Erbovirus, Hepatovirus, Kobuvirus, Megrivirus, Parechovirus, Salivirus, 
Sapelovirus, Senecavirus, Teschovirus and Tremovirus
37
.  
 
With the introduction of new classifications by the International Committee for the 
Taxonomy of Viruses (ICTV) proposed in 2011 and published in 2013
37
, the structure 
and nomenclature of the family Picornaviridae, now based on genomic sequence data, 
have changed significantly. With the inclusion of the rhinoviruses in the genus 
Enterovirus, more than 200 enterovirus types exist and are classified within twelve 
species, Rhinovirus A, B, C, Enterovirus A, B, C, D, E, F, G, H and J (Figure 1.3)
37
. The 
family Picornaviridae include pathogens with vertebrate and invertebrate hosts. This 
literature review will discuss only members of the genus Enterovirus that are known to be 
associated with disease in humans, specifically EV- A, B, C and D. 
 
Prior to the reclassification of the genus Enterovirus, human rhinoviruses were classified 
in their own genus, Rhinovirus
38
. This was based on physiochemical properties of the two 
viruses and to a certain extent, the presentation of symptomatic disease indicating a 
variation in the sites of replication. Rhinoviruses were for the most part acid labile
39-41
 
and thought to be unable to survive passage through the alimentary canal in the same 
manner as the human enteroviruses, with which replication has been associated with 
Peyers’ patches in the small intestine42. In the National Enterovirus Reference Laboratory 
of Australia (NERL) a number of rhinoviruses have been identified in stool samples using 
polymerase chain reaction (PCR) techniques (refer to chapter 2), an observation also 
made in other laboratories
43
. The significance of this finding is poorly understood. It may 
indicate a resistance of these particular rhinoviruses to acid destabilisation, but may 
certainly warrant further investigation by a rhinovirus laboratory. 
 
Many of the initial discoveries of new members of the genus Enterovirus have been in 
response to actively searching for poliovirus in samples from outbreaks of paralytic 
disease or via surveillance programs aimed at polio eradication
44-46
. In 1948, the 
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coxsackieviruses were isolated from samples derived from children during an outbreak in 
Coxsackie New York, USA
11
. The samples were inoculated into the cerebrum of suckling 
mice and the viruses isolated were subsequently named Coxsackievirus after the location 
from which they were derived. In 1951, echoviruses were identified after the introduction 
of cell culture methods. The derivation of the name echovirus is derived from the term 
enteric cytopathic human orphan viruses, since no disease was attributed to the virus at 
the time of their discovery
12
. However, the echoviruses are now known to be an important 
pathogen associated with neurological illness and cardiomyopathy
47,48
. Subsequent 
enteroviruses are named numerically and are characterised based on sequence analysis
49
. 
 
 
 
Figure 1.3 Enterovirus taxonomy. Nucleic acid maximum-likelihood radial phylogram, indicating genetic 
relationships of the VP1 encoding region between representative members of the genus Enterovirus. Node 
labels are described as follows: Species EV-A (Serotype CV-A24, Accession No. AY421760), EV-B (CV-B2, 
AF081485), EV-C (PV-1, NC_002058), EV-D  (EV-68 AY426531), EV-E (BEV-1, KC667561), EV-F (BEV-2, 
NC_021220), EV-G (PEV-9, HM131607), EV-H (SEV-4, AF326759), EV-J (SpVN203, NC_013695), RV-A (RV-A1, 
FJ445111), RV-B (RV-B3, DQ473485), RV-C (RV-C1, EF077279), Scale bar indicates nucleotide substitutions 
per site. Alignment performed using the “Muscle” algorithm within the MEGA software package version 
5.2
50
. Branch lengths calculated using the Hasegawa, Kishino and Yano (HKY)
51
 model with discrete 
variables for gamma distribution and invariant sites (HKY+G+I). Bootstrap analysis performed with 1000 
psuedoreplicates  
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1.2.2 Enterovirus structure 
Enteroviruses are approximately 30 nm in diameter, roughly spherical and follow an 
icosahedral symmetry
52
, a configuration that is likely a result of a favourable energy 
minima and is observed in a number of biological systems including bacterial 
organelles
53
. Observation of virus particles in infected cell culture material, indicate a 
honeycomb-like aggregation, arranged in a manner that is indicative of the virus’s 
icosahedral symmetry (Figure 1.4). The capsids, which are non-enveloped, contain a 
positive-sense single-stranded RNA molecule roughly 7,500 base pairs in length. The 
RNA molecule contains a 22 amino acid viral protein (VP) which is covalently bound to 
the 5´ non-translated region (5´NTR) of the genome, abbreviated as VPg (Viral Protein 
genome-linked)
54,55
.  
 
 
 
Figure 1.4  Electron photomicrograph of enterovirus aggregates. Negative stained transmission electron 
micrograph of aggregated enterovirus particles. Image courtesy of the Electron Microscopy Unit VIDRL 
(reproduced with permission 2012), scale bar = 100nm. 
 
Also covalently bound within the capsid structure are 60 myristate molecules attached to 
the amino termini of the VP0 structural protein
56
, which in the majority of enteroviruses, 
is cleaved to form the VP4 and VP2 structural proteins
57,58
. The virus genome is 
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translated in the cytosol of the infected cell and acts in a similar manner to that of mRNA 
without the requirement for capping
59,60
. The genome contains a complex structure within 
the 5´NTR (approximately the first 740 bp in poliovirus) that acts as an internal ribosome 
entry site (IRES)
61-63
. This site initiates the formation of translation complexes which 
synthesize a polyprotein containing structural and non-structural proteins, which undergo 
post-translational proteolytic self-cleavage, (refer to section 1.2.3)
64
. 
 
The genome is sub divided into five main sections; the 5´NTR, three polyprotein regions 
P1, P2, P3 and a 3´ non-translated region (3´NTR), (Figure 1.5). The 5´NTR region 
contains an internal ribosome entry site (IRES) encoding sequence, essential for initiation 
of translation by host ribosomes. The P1 region encodes structural proteins VP0, VP1 and 
VP3, with VP0 undergoing further cleavage to VP2 and VP4 in the case of members of 
the genus Enterovirus. Region P2 encodes non-structural proteins in the form of 
proteinases 2A, 2B and 2C, whilst region P3 encodes 3A, 3B (VPg), the proteinase 3C 
and the RNA dependant RNA polymerase 3D
52
, which occurs in a 3CD
pro
 precursor form. 
 
 
Figure 1.5 Schematic diagram of enterovirus genome. Simplified representation of the enterovirus 
genome showing the virus protein VPg on the distal aspect of the 5´NTR (pink diamond), 5´ NTR, capsid 
encoding region P1 (VP1, VP2, VP3, VP4), P2 and P3 regions encoding non-structural proteins 
(proteinases and the RNA-dependent RNA polymerase), 3´NTR incorporating a poly-A tail. Adapted from 
Roberts et al (2010)
65
. 
 
During processing of the polyprotein phase of replication, the P1 region begins folding 
the structural proteins and is cleaved by protein 3CD
pro
 to form VP0, VP1 and VP3. It is 
not until RNA encapsidation that VP0 is cleaved to form VP2 and VP4, in a process not 
completely understood. It is hypothesised that proteinase activity or RNA mediated 
autolytic cleavage mediates this cleavage event
66,67
. Once cleavage of VP0 has occurred, 
the capsid structure is “set” and is irreversible, as opposed to the pro-capsid phase, which 
describes the reversible formation of virus pro-capsid particles which do not contain 
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genomic material
66,68
. Other picornaviruses such as parechoviruses differ from 
enteroviruses, in that VP0 is not cleaved to form VP2 and VP4
69
. 
 
The most important advance in the understanding of enterovirus atomic structure 
occurred in 1985, when the simultaneous determination of structure using x-ray 
diffraction techniques for poliovirus type 1 and rhinovirus type 14 were published
15,16
. 
The atomic structures revealed that the structural proteins follow a common theme of 
β-barrels configured in a “jelly-roll” formation, as seen in many virus coat proteins and 
pore-forming toxins such as bacteriolysins
70-72
. Combined, the three major virus capsid 
proteins, VP0 (VP2+VP4), VP1 and VP3, comprise a single protomer. Each of these 
capsid proteins exhibits a similar gross structural morphology (Figure 1.6)
16
. Such 
phenotypic presentations are not discernible at the genomic level when performing 
sequence alignment and comparative phylogenetic analysis, but the conservation of 
structure may infer a common ancestor or provide evidence of convergent evolution
15,73
. 
 
 
Figure 1.6 Jelly-roll β-barrel similarity between major protomer subunits. Illustration of the primary 
protein chains associated with a single structural subunits or protomer, Colouring, Blue= N-terminus, 
Red= C-terminus (derived from the poliovirus type 1 capsid structure file 1HXS and reconstructed as 
described in chapter 4), highlighting the homogeneity of the β-barrel structural core of VP1, VP2 and VP3, 
interspersed with flexible loop regions.  
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The loop like structures that are interspersed between alternating beta strands form 
important surface structures, such as the BC loop of VP1 and the EF loop of VP2, which 
are involved in neutralising antibody binding (Figure 1.7)
74,75
. 
 
 
Figure 1.7 Neutralising antibody (Fc region) bound to BC loop antigenic determinant. A) 
3-dimensional representation of a complete poliovirus with antibody fragment bound to a major antigenic 
determinant; a single virus protomer is represented. Blue – VP1, yellow – VP2, red – VP3, purple and green 
– variable region of neutralising antibody.  B) Breakout Figure showing the protomeric subunit with a 
section of the VP1 protein highlighted (solid blue colour) which is targeted using PCR amplification 
techniques and sequencing to identify virus type. Note the variable region of neutralising antibody shown 
interacting with the BC loop of VP1. Reconstructed from Protein Data Bank x-ray crystallography files 
1FPT 
76
 and 1HXS (poliovirus type 1) 
16
. 
 
 
The enteroviruses are roughly spherical and conform to an icosahedral symmetry, 
consisting of 60 protomers arranged in a pseudo T=3 architecture. The resulting structure 
consists of 12 vertices and 20 faces (Figure 1.8). VP1 proteins are assembled around the 
five-fold axis of symmetry, with alternating VP2 and VP3 protein chains
16
. This 
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configuration results in distinct surface features that are consistent across all members of 
the genus Enterovirus. A prominent feature of the solvent accessible virus landscape, is a 
canyon-like structure that exists between the VP1 five-fold axis of symmetry and the 
raised surfaces of the loop of VP2 and VP3 (Figure 1.8).  
 
 
Figure 1.8.  Picornavirus structural features. A) 3-dimensional representation of a complete poliovirus 
particle, breakout on the right indicates structural highlights, arrow indicates the canyon, 5- indicates the 
five-fold axis of symmetry, 2- indicates the two-fold axis of symmetry and 3- indicates the pseudo 
three-fold axis of symmetry, B) Coloured section shows the relative positioning of a single protomer 
(1 of 60) within the icosahedral virus capsid. Dark grey shading indicates the relative position of pentamers 
intersecting at the 2-fold axis of symmetry. The breakout image on the right of “B” shows a cartoon 
representation of a protomer coloured by chain. C-F) Individual protomer subunits with selective amino 
acid residues numbered C) VP1=blue, D) VP4=green, E) VP3=red, F) VP2=yellow. N-terminal myristate is 
shown in cyan and red, attached to VP4 (D) An adaptation of this image appears in Fields Virology
52
 and 
the Journal of Molecular Graphics and Modelling
2
.  
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An important structural feature of enteroviruses is the formation of a hydrophobic pocket 
which lies at the base of the canyon, with a solvent accessible opening that typically 
contains a fatty acid such as myristate, palmitate or sphingosine, although in some viruses 
this pocket is thought to be empty
77
. The hydrophobic pocket has been the subject of 
study for anti-picornavirus agents such as the WIN compounds, an example of which 
(known as Pleconaril) was trialled as a potential treatment for the common cold
78
, with 
the possibility of usage in other members of the genus Enterovirus. These compounds are 
hydrophobic structures with charged regions and are thought to bind tightly within the 
hydrophobic pocket, inhibiting the uncoating process and thus preventing the transfer of 
viral RNA to the host cell for replication
79
. 
 
1.2.3 The Enterovirus Replication Cycle. 
Enterovirus infection in the host is initiated in the upper respiratory tract and is spread via 
the faecal-oral route
80
, with the exception of some enteroviruses such as enterovirus 70, 
which can result in haemorrhagic conjunctivitis after coming into contact with the eyes
81
. 
Studies of poliovirus have yielded significant information regarding the specific 
processes of infection and pathogenesis in humans, in simians and in transgenic mice 
which express the poliovirus receptor CD155
82,83
. Initial infection occurs within the 
tonsils, with virus that is acid stable passing through the digestive tract and infecting 
mucosal tissue along that route, specifically the Peyer’s patches80,84. The virus can be 
detected in these sites typically within 1 to 3 days after infection. Approximately a quarter 
of all cases results in a viraemia after the virus migrates via the lymphatics
80
. In cases of 
central nervous system infection, invasion occurs typically during the viraemia phase
42
. 
Damage to the central nervous system is evident as either aseptic meningitis, which 
accounts for approximately 1% to 10% of cases, or paralysis, which accounts for 
approximately 0.1% to 1% of cases
80
. Invasion of the central nervous system by 
poliovirus has been demonstrated as a process of retrograde axonal flow
83
, with evidence 
of a possible receptor-mediated permeation of virus across the blood-brain barrier
85
. 
 
The replication of enteroviruses in cells is a relatively rapid process ranging from 5 to 10 
hours
36
 and occurs in cytoplasm of the infected cell after initial attachment and entry. The 
virus undergoes a conformation shift releasing the RNA into the cytoplasm, which is 
translated almost immediately due to the viral RNA mimicking that of the host’s 
messenger RNA
86
. 
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The different stages of enterovirus replication in the host cell can be broken down into the 
steps described in Figure 1.9 for poliovirus. The importance of theses stages of replication 
is emphasized in the discussion of picornavirus antivirals and their targets (refer to 
section 1.2.9). 
 
 
 
Figure 1.9  Picornavirus replication cycle (cellular). Simplified schematic representation of the stages of 
cellular replication of enterovirus. Numbered stages are described in further detail in the text below. 
 
 
1) Attachment: The virus is introduced into an environment where it can interact with a 
specific receptor or receptors and attachment occurs on the surface of the host cell. In 
the case of poliovirus, the primary receptor is CD155, which interestingly in a 
purified state when introduced to viruses in solution, is capable of inducing a 
conformational shift that results in the loss of genomic RNA. CD155 is an adhesion 
molecule which has a role in recognition for natural killer cells and interacts with the 
number of cell surface receptors on cells involved in activation of cytotoxic 
activity
87
.  
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2) Entry and uncoating: Once bound to a host cell, the virus almost immediately 
undergoes a conformational shift that results in extrusion of the RNA into the host 
cell cytoplasm. For this process to occur in some enteroviruses, a pH change is 
required. This change has been shown not to be the case for poliovirus and more 
recently coxsackievirus A9
88
. In the case of foot and mouth disease virus and 
rhinoviruses, entry to the cells is via receptor-mediated endocytosis
89
. In this 
instance, uncoating occurs as a result of pH mediated processes associated with the 
host’s endocytic pathway. It was previously thought that the uncoating process 
involved extrusion of viral RNA at the five-fold axis of symmetry
90
, however 
subsequent studies have shown that this may not be the case and that the RNA is 
released on the two-fold axis of symmetry
91
. As the single-stranded, positive sense 
viral RNA resembles that of eukaryotic messenger RNA, translation is able to 
proceed almost immediately
92
.  
3) Translation: In the case of poliovirus, up to 1500 base pairs of additional RNA can 
be added to the virus genome, implying that there is some available space within the 
capsid
52
. Such space is limited and no enzymes are carried over from the virion into 
the host cell. Protein translation therefore occurs primarily due to the secondary 
structure of the IRES and its ability to initiate translation by ribosomes
61
. This 
initiation is thought to occur due to specific binding of the IRES structure to the 40S 
ribosomal subunits
93
. The enterovirus genome is translated as a polyprotein, which 
undergoes post-translational cleavage into a number of structural and non-structural 
proteins once VPg has been removed
64,94
. 
4) Post-translational cleavage: Picornaviruses encode a number of structural and non-
structural proteins, specifically proteases and an RNA-dependent RNA polymerase. 
The three domains of the polyprotein can be broken down into P1, P2 and P3 regions. 
Cleavage of the P3 region is facilitated by the 3C proteinase whilst cleavage of P1 
from P2 is facilitated by the 2A proteinase. The P2 region contains a proteinase, 
whilst the P3 region contains a proteinase and the RNA-dependent RNA polymerase 
3D
52
. 
5) Genome replication: Strand synthesis of RNA occurs primarily on membrane 
vesicles, where the viral RNA polymerase 3D
95
  copies the positive stranded RNA 
into a negative stranded format, forming a template for the subsequent production of 
positive stranded RNA molecules, which are packaged into newly formed virions. 
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6) Virion assembly: Immediately upon translation of the viral RNA, formation of the 
beta barrels that comprise the structural proteins VP1, VP3 and VP0, occurs in the P1 
region of the polyprotein. The structural proteins are subsequently cleaved by the 
proteinase 3CD
16
. The first structure to be assembled is termed the 5S protomer and 
consists of VP1, VP3 and VP0. Five of these protomers are assembled to form a 14S 
pentamer. Once pentamers have been formed, they possess the ability to 
self-assemble, through a combination of electrostatic distribution and hydrogen 
bonding. The first stage at which the newly formed structural proteins resemble the 
final virus structure, occurs once 12 of the pentamers have aggregated to form an 80S 
empty capsid structure. At this stage, the empty capsid is still capable of disassembly 
and reassembly and it is not until the empty capsid contains the genomic RNA that 
the pro-virion undergoes hydrolytic cleavage of VP0 to VP2 and VP4, so that the 
structure is essentially locked into place and is termed a virion or 160 S particle
68
. 
7) Virus exit: Virion exit is achieved in less than 16 hours after the initial infection and 
occurs as a result of apoptosis induced by viral replication. Virus proteins involved in 
apoptosis include proteinases 2A, 3C, and the 2C NTPase, whereas inhibitors of 
apoptosis include 2B and 3A. Stages leading to apoptosis in the host cell can be 
uniquely identified microscopically and can be attributed to the cytopathic effect 
(CPE) characteristic of an enterovirus infection, following infection of susceptible 
mammalian cell lines
52
. 
 
In an immuno-competent infected host, virus shedding via the faeces can continue for 
weeks
96
. In patients suffering from primary immune disorders such as B-cell mediated 
immunodeficiency, virus replication and subsequent shedding of virus can occur for 
decades
97
. 
 
1.2.4 Cultivation and Serotype Identification of Enteroviruses 
The desire to detect and to characterise a pathogen, is ultimately determined by a need to 
understand the aetiology of a disease. Often, advancement in this understanding is 
proportional to the severity of the condition. Accordingly, the understanding of the 
“filterable agent” responsible for diseases such as Hand Foot and Mouth disease, 
meningitis and more importantly poliomyelitis among others, gained traction in the 
discovery of the viruses ability to transmit the between live hosts in-vitro
98
. Indeed, with 
the agent of poliomyelitis, great strides in the isolation and characterisation of the virus 
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were made in 1908 after the successful propagation of the virus in primate hosts by 
Landsteiner and Popper
99
.  
 
The history of cell culture methods in the propagation of human enteroviruses can best be 
outlined in the context of polio. The discovery that poliovirus could be propagated in 
non-neuronal tissue by Enders et al., (1949)
100
, led to the use of a variety of cell lines 
which displayed a CPE (Figure 1.10). The use of multiple cell lines for the propagation of 
poliovirus, combined with the use of antisera neutralisation techniques, was seminal to 
the ability to initially differentiate between virus types. The ability to further characterise 
enteroviruses by serotype, proved useful to the association of a virus serotype with 
disease presentation
80
. 
 
 
 
Figure 1.10 Microscopic morphology of enterovirus infected cells. Light microscope photomicrograph 
highlighting cytopathic effect of cells infected with poliovirus. (A) Uninfected RD-A (rhabdomyosarcoma) 
cells and (B) poliovirus infected RD-A cells. (C) Uninfected L20B (CD155 transgenic murine fibroblast) 
cells (D) poliovirus infected L20B cells at 100x magnification.  
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In the 1940s, the widespread introduction of antibiotics in primary cell culture methods 
permitted the efficient use of a variety of cell lines, both primary and continuous, for the 
propagation of viral agents. The use of cell culture methods was also pushed forward in a 
rapid manner in response to the large scale manufacture of the Salk inactivated polio 
vaccine
22
. Cell culture methods in this respect were useful not only in the detection and 
characterisation of viruses, but also provided a suitable platform for the mass production 
and purification of viral agents. 
 
Although enteroviruses have the potential to induce a CPE in cell culture when inoculated 
with extracts of clinical specimens, the results are not always consistent and include 
limitations. Primarily, the methods involved in the continued cultivation of cell lines are 
expensive and time consuming. Not all enteroviruses are cultivable by cell culture and it 
is necessary to use a variety of cell lines to identify the wide range that can be grown. 
Once a CPE is observed, a subjective association with virus infection is made and this 
association must be confirmed with a secondary method such as antibody-based typing or 
molecular characterisation, as toxicity derived from the inoculum can sometimes be 
misidentified as CPE
80
. Before the widespread adoption of molecular detection and 
characterisation techniques, cell lines exhibiting lytic CPE characteristic of enterovirus 
infection would be identified to the serotype level, by the use of serotype-specific 
antibodies. The most common of these methods are antisera neutralisation, 
enzyme-linked immunosorbent assay (ELISA) or fluorescent antibody staining
101
.  
 
Antisera neutralisation employs the principle of opsonisation of the virus particle with a 
virus specific antibody, resulting in the inhibition of cell infection, thus preventing the 
development of CPE. Antisera neutralisation methods for enterovirus serotype 
identification involved the use of intersecting specific antisera pools; the 
Lim Benyesh-Melnick (LBM) was the most widely implemented method with eight 
pools
102
. LBM antisera pools have become scarce not only in availability but also usage 
and are often reserved for use in reference laboratories performing enteroviral typing, 
with the use of molecular sequencing methods supplanting this method. 
 
Prior to the widespread use of PCR detection methods, rapid methods involving the use of 
cell-coated coverslips, inoculated with sample, incubated for a short period of time and 
combined with an immuno-fluorescence (IF) detection method, known as a “shell-vial”, 
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were commonly used in diagnostic laboratories for the detection of enteroviruses
103
. 
Although direct detection of rhinovirus species in respiratory samples using immuno-
flourescence staining methods was relatively common, this was not the case for the 
enterovirus species affecting humans. Immuno-fluorescence methods for the detection of 
enteroviruses were typically attempted, subsequent to amplification of virus particles 
using culture methods (Figure 1.11). 
 
 
 
Figure 1.11 Enterovirus infected cell immunofluorescence. Indirect fluorescent immunoassay staining of 
enterovirus infected rhabdomyosarcoma cells showing cell fragments and associated green fluorescence due 
to mouse-anti-enterovirus antibody conjugated with an anti-mouse antibody labelled with fluorescein. 
Photomicrograph at 40x magnification. 
 
Immunoassays which utilise ELISA or IF techniques, can use reporter molecules in either 
a direct or indirect manner. Direct assays are useful in that the time taken to perform the 
assay is minimal and the sensitivity can be considered appropriate for certain clinical 
settings, although the specificity of the antibody can be problematic with signal-to-noise 
ratios becoming unacceptable. This problem can be overcome with the use of indirect 
methods, employing an antibody directed typically to the Fc region of the original 
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antibody. The reporter molecule is placed on the second antibody as opposed to the 
original antibody. 
 
Overall, cell culture-based techniques can take days to weeks from the receipt of a sample 
for testing and the final reporting of an enterovirus type. This timeframe is not generally 
useful in the clinical management of a patient and as a result, cell culture based methods 
have fallen out of favour, being replaced by more rapid methods based on the PCR 
amplification of specific viral genome sequences in clinical samples. 
 
1.2.5 Enterovirus Detection and Characterisation using Molecular Methods. 
Contemporary methodology for the detection and characterisation of enteroviruses has 
moved from cell culture-based antisera neutralisation of virus to the more rapid PCR 
methods, the use of which became more widespread in the 1990s
104,105
. The combination 
of fluorescent moieties and genetic sequence-specific primers and probes, have allowed 
for the introduction of rapid detection methods
106,107
. These are becoming the mainstay of 
diagnostic virology laboratories globally, due to the high throughput nature of their 
implementation and the rapid turnaround times, which can be useful in situations where 
rapid clinical intervention decisions need to be made, such as the differentiation of 
herpetic or enteroviral aseptic meningitis
108
. 
 
The PCR method was originally developed by Kary Mullis when working for the Cetus 
Corporation as a chemist
109
. PCR methods rely on a combination of specific 
oligonucleotide primers that flank the regions of an area of interest on the complementary 
strands of DNA or RNA. When combined with a thermostable polymerase, typically 
variants of the Thermophilus aquaticus polymerase, transcription of the complementary 
strand in DNA form is achieved from the site of binding of the initiating oligonucleotide 
primer. The repetitive cycling of thermal conditions from high temperature, (typically 
95°C, which results in the denaturation of the DNA strands), followed by a lower 
annealing temperature (allowing the binding of the oligonucleotide primers), is then 
followed by an extension stage usually performed between 60°C to 72°C. As this process 
continues, the forward and reverse primers that flank the region of interest are bound in 
tandem on each amplified DNA product, resulting in an exponential increase in that 
particular fragment of interest (Figure 1.12). 
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Figure 1.12 Principle of real-time polymerase chain reaction. Figure showing a) template strand of 
DNA ready for amplification, b) Forward primer binds to the DNA template and is extended in a 
complementary DNA sequence by DNA polymerase, c) this process is repeated using forward and reverse 
primers resulting in an exponential replication of DNA copies, d) binding of a TaqMan probe to the target 
of interest, followed by, e) strand synthesis DNA polymerase, f) the probe undergoes hydrolytic cleavage 
due to the exonuclease activity of the DNA polymerase releasing the fluorophore, g) separation of the 
fluorophore from the quencher results in an increase in signal intensity. 
 
An adaptation of this method involves the incorporation of a probe sequence that is 
complementary to sequence located between primers of the target fragment. In the 
real-time implementation of this technique, alterations in fluorescent signals are exploited 
to indicate that amplification has occurred. A commonly used variant of this technique is 
termed the TaqMan probe system, and involves the 5´ labelling of the probe with a 
fluorophore and the 3´ labelling of the probe with a molecule that is specifically tailored 
to absorb or “quench” the fluorescence emitted by the 5´ labelled fluorophore. During 
DNA strand synthesis, the bound oligonucleotide probe undergoes hydrolysis by the 
polymerase enzyme releasing the fluorophore, resulting in an increase in fluorescent 
signal (Figure 1.12). Each cycle of the thermal profile results in the scanning of the 
reaction by a detector and the amount of fluorescence is calculated. This method allows 
for a quantitative assessment of the amplification process in “real-time” as opposed to 
standard “end-point” PCR assays. 
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In instances where the genetic target is not DNA-based, an initial process involving the 
reverse transcription of RNA to DNA using retrovirus derived RNA-dependent RNA 
polymerase (such as those obtained from the murine leukaemia viruses), is performed 
prior to PCR amplification. This process is termed reverse-transcription PCR (RT-PCR). 
When combined with real-time PCR amplification systems, they are termed rRT-PCR for 
qualitative assays, or qRT-PCR for quantitative assays. 
 
The most common enterovirus PCR detection methods employed in laboratories are 
based on the 5´NTR region (Figure 1.13), first targeted for detection by Olive et al., 
(1990)
104
. This region is highly conserved amongst all enteroviruses and although the 
method enables sensitive detection of enteroviruses from clinical specimens, further 
characterisation to the serotype level cannot be reliably determined from the PCR 
amplicon. In the context of public health surveillance, it is desirable to identify 
enterovirus type, particularly when dealing with enteroviruses associated with serious 
neurological syndromes such as those induced by poliovirus and EV-A71.  
 
 
Figure 1.13 Schematic diagram of enterovirus genome with primer binding sites. Depiction of the PCR 
primer annealing sites within the ~7,500 nucleotide enterovirus genome, based on poliovirus type 1 
Mahoney, Genbank accession number V01150 (not to scale). A viral encoded protein, VPg, is covalently 
attached to the 5´ terminus. Examples of the areas targeted for different levels of enterovirus 
characterisation are indicated. Adapted from Roberts et al., (2010)
65
. 
 
The application of PCR methods to the characterisation of enteroviruses, as opposed to 
the traditional methodologies based on antibody-based detection systems, has been a 
significant advance for laboratories providing detailed information for use by clinicians 
and public health authorities. 
 
The availability of rapid sequencing methods based on the Sanger dideoxy nucleotide 
sequencing principles
110
, has allowed the amplification and elucidation of sequence data 
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that are specific to phenotypic characteristics or antigenic determinants that determine 
virus type. In the case of the enteroviruses, one of the most useful areas for phenotypic 
examination and characterisation is the BC loop, which appears on the external surface of 
the virus on the five-fold axis of symmetry (refer Figure 1.7). This region undergoes 
selective pressure in response to the host immune system and therefore is highly variable, 
making it a useful target for use in the assessment of molecular epidemiology, using 
sequence analysis in phylogenetic inference
111
. 
 
Guidelines have been established by Oberste et al., (1999),  relating to the determination 
of homologous serotypes when compared to prototypic enterovirus sequences of the VP1 
region
112
. Sequence matches greater than 75% from nucleic acids, or 85% from amino 
acids, are indicative of a homologous serotype (Figure 1.14). Percentage identities below 
these figures can be used to infer heterologous serotype, heterologous clusters or 
heterologous genera. A proposal has to been made to apply the same identification 
criteria to rhinoviruses
113
. 
 
 
Figure 1.14 Criteria for the determination of enterovirus serotype. The Figure indicates the guidelines 
used for the determination of homologous serotypes for unknown sequences. Chart A) indicates the 
percentage identity (y-axis) calculated for nucleic acids for all available prototype enteroviruses (x-axis) 
when compared to an unknown sequence. Sequence matches above 75% indicate a homologous serotype. 
Chart B) indicates the percentage identity calculated for amino acids from available prototype enteroviruses 
compared to unknown sequence. Matches above 88% indicate a homologous serotype
112,114
. 
 
Given that there are in excess of 100 enterovirus types, there is significant difficulty in 
determining the etiological basis of a particular clinical manifestation in a rapid manner. 
Standard laboratory protocols based on 5´NTR detection methods are useful only in 
determining the presence of enterovirus. More specific methods based on sequencing of 
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the VP1 genomic region are most commonly applied and specifically the CODEHOP 
protocol, as described in Figure 1.15. Serotype identification methods based on VP2 and 
VP4 genomic regions also exist
115,116
. Sequencing of the VP1 region using the 
CODEHOP method is used primarily in the research related to this thesis (chapter 3) 
 
 
 
Figure 1.15 Schematic Diagram of the COnsensus DEgenerate Hybrid Oligonucleotide Primer 
Methodology (CODEHOP). A) Schematic diagram of the region amplified by the CODEHOP PCR 
primers, as relates to the type identification of enteroviruses. Reverse transcription of the capsid encoding 
region of the virus genome using a series of six base pair reverse transcription primers, followed by two 
round PCR. Sequencing is performed using non-degenerate primers targeted at the conserved ends of the 
second round product defined by the second round hybrid primers. B) 3-dimensional representation of an 
enterovirus protomer with all four protein chains identified VP1 (blue), VP2 (yellow), VP3 (red), VP4 
(green), target sequence for the CODEHOP assay
117
 is indicated by solid blue colouring in the VP1 region. 
The BC loop antigenic determinant can be identified by its interaction with antibody (purple, green).  
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Once sequence data are available, comparative analyses can be performed using multiple 
sequence alignment methods, combining data for comparison from the public domain 
with local data. Sequence alignment methods based on similarity are available, with the 
initial steps involving a progressive pair-wise construction process, involving the use of a 
simplistic tree used to guide the subsequent alignment (guide tree)
118,119
. 
 
An important component of multiple sequence alignment concerns the introduction of 
gaps in nucleic acid or amino acid sequence data during the alignment process, 
particularly in areas of heterogeneity. These gaps are required to represent insertion or 
deletion events which may have occurred during the evolutionary processes. The correct 
alignment of multiple sequences that contain gaps is crucial and the most common 
approach to the problem of where a sequence should be “broken” in order to 
accommodate a gap, is to assign numeric penalties which accumulate and then mandate 
insertion of a gap after a predetermined threshold has been reached
118
.  
 
Typically, sequences are aligned based on a scoring method with the least homologous 
sequences scoring a higher value
120
. Various scoring mechanism exist, such as the 
PAM
121
 and BLOSUM
122
 substitution matrices for amino acid substitutions, or the 
HKY
51
 model for nucleic acid substitutions, which provide a value that represents the 
likelihood of a substitution event occurring. The accumulation of these values is used as a 
scoring mechanism for later pairwise alignment. One of the most widely used programs 
for sequence alignment is the Clustal family of alignment algorithms, which uses a 
scoring mechanism combined with a progressive pair-wise construction process
123
. 
 
In order to convert multiple sequence alignments into a visual representation that is 
illustrative of sequence similarity, the use of phylogenetic trees is the most common 
methodology, with the first recorded instance sketched by Charles Darwin appearing in 
his first notebook on the “Transmutation of Species” in 1837. Generally there are two 
methods for the calculation of phylogenetic trees, the first based on algorithmic methods 
(distance matrix) and those based on discrete data methods (tree searching methods) 
124,125
. 
 
The inference of phylogeny using the distance matrices essentially calculates the 
difference between sequence data, which is calculated for all pairwise combinations of 
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the sequence being analysed. The value for each pairwise alignment is then used to 
construct a tree with branch lengths based on values represented as distances. 
 
Although discrete data methods can be more computationally expensive, they can also be 
more informative and allow for the incorporation of information related to the 
evolutionary history of the data being analysed. These methods incorporate techniques 
such as parsimony, maximum likelihood and Bayesian inference
126
. Essentially these 
methods examine each column of an alignment and determine a phylogenetic tree that 
best represents this grouping of information. An example of such a tree used to determine 
enterovirus type and ancestral lineage, is shown in Figure 1.16. 
 
Scoring methods for variation in each column vary widely, with a number of methods 
incorporating empirical evidence of the rates of change in nature related to the probability 
of a particular variation occurring
121,122
. For example, an adenine to guanine mutation is 
more likely to occur than an adenine to cytosine change or in the case of amino acid 
alignments, the probability of an alanine to glycine change will have a greater impact than 
an alanine to histidine change, given the physical difference in size and charge of the 
side-chains. In the case of virus sequence analysis, the rate of change or introduction of 
mutations is vastly greater than that of the eukaryotes; this is particularly evident for the 
RNA viruses as opposed to DNA viruses. Therefore the incorporation of dates of 
collection (historic time point) and the geographic location, as discrete data, enhances the 
investigation of virus ancestral lineages from a temporal and geographic perspective. 
Such investigations are termed phylogeography
127
. 
 
Phylogeographic analyses of viral outbreaks have been used to determine ancestry of the 
rabies and influenza viruses
127,128
. These methods can be useful in a public health sense to 
assist in determining the source of epidemics, or chains of transmission, and can help in 
planning to restrict or prevent disease spread. The representation of phylogeny using trees 
can be further enhanced when combined with global mapping programs such as Google 
Earth 
129
. This technique can give the observer an efficient and simplified overview of 
virus transmission with respect to a particular global region of interest. (refer to section 
3.3.5 and 3.4.2 for information and examples of Bayesian phylogeography). The use of 
phylogenetic inference methods was critical to the investigations of 5´NTR heterogeneity 
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in the design of novel PCR methods (chapter 2) and to the examination of the molecular 
epidemiology of enteroviruses associated with severe disease (chapter 3). 
 
 
 
Figure 1.16 Phylogenetic analysis of members of the genus Enterovirus using the VP1 encoding 
region. Analysis performed using the Maximum Likelihood method with 1000 bootstrap psuedoreplicates, 
and the HKY+G+I nucleotide substitution model. Sequences aligned using ClustalW. Polar representation 
with scale indicating nucleotide substitutions per site. 
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1.2.6 The Association of Enteroviruses with Human Disease 
The majority of enterovirus infections are asymptomatic. In cases where symptomatic 
infection does occur, disease states range from mild febrile illness to more serious 
sequelae such as neurological illnesses, paralysis and death. The enterovirus most 
synonymous with serious neurological illness involving devastating outcomes such as 
permanent paralysis or death is without doubt, poliovirus. Poliovirus infection involving 
the spinal cord is termed “poliomyelitis” and is derived from the Greek words grey 
(polio) and marrow (myelon).  
 
Poliomyelitis, or anterior horn cell disease, is not necessarily restricted to infection by 
poliovirus, but is a condition that can be attributed to infection with other members of the 
genus Enterovirus such as the echoviruses, coxsackieviruses and enterovirus A71 
(EV-A71)
130,131
, the clinical syndrome exhibited by poliomyelitis, acute flaccid paralysis, 
may also be attributed to other causes including, but not limited to, auto-immune 
processes such as Guillain-Barré syndrome or acute disseminated encephalomyelitis 
132
. 
An historic example of a polio-like disease outbreak due to a non-polio enterovirus can be 
attributed to the circulation of coxsackievirus A7. In the 1950’s this virus was responsible 
for large outbreaks and was, for a time, referred to as Russian type 4 poliovirus 
133
. 
Recently, serious neurological outcomes associated with infection by enterovirus A71, 
particularly in China and Southeast Asia, have become more prevalent
134,135
. In Australia 
in 2012 to 2013, infections resulting in AFP and death have occurred. Such a high 
number of reported AFP cases have not been seen in Australia since the endogenous 
circulation of poliovirus in Australia in the 1960’s. 
 
Approximately 90% of all poliovirus infections are asymptomatic with less than 10% 
involving abortive infection, 1% suffering aseptic meningitis and 0.1% suffering acute 
flaccid paralysis and sometimes death
80
. Neurological sequelae are usually evident after a 
short period of a flulike illness and thus are referred to as a bimodal disease 
presentation
136
. 
 
Paralysis is typically a result of widespread damage to neural cells in the anterior horn 
region of the spinal cord. The damage is visible in magnetic resonance imaging as an 
increase in signal intensity with a characteristic “owls eyes” appearance137. Paralysis 
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typically presents as initial weakness involving single or multiple muscle groups, 
gradually progressing to paralysis in one or more limbs. Some patients do not recover full 
use of the affected limb(s) over time and in the case of cranial nerve involvement (also 
referred to as bulbar paralysis), may suffer resulting disturbances of speech, swallowing 
or breathing. Paralysis of the muscles of the diaphragm results in the patient being unable 
to breathe without the assistance of a ventilator. In the case of medullary centre 
involvement, the outcome can be fatal
138
. This has been seen in cases of EV-A71 
meningo-encephalitis
139,140
. 
 
The most common neurological manifestation of enterovirus infection is meningitis
141
. 
Typically, meningitis is a self-limiting infection, with the exception of infection within 
the first two weeks of birth, with such cases having a poor prognosis
142,143
. 
 
The majority of enterovirus-related respiratory illnesses are caused by rhinoviruses, 
making them the most commonly isolated member of the genus Enterovirus when 
investigating cases of the common cold. The identification of rhinoviruses in clinical 
samples has been observed more frequently since the introduction of PCR detection 
methods. This has also resulted in the identification of species C Rhinoviruses, which 
were previously uncultivable
144,145
. Recently, enterovirus 68 has been associated with 
severe cases of pneumonia
146
 and has also been isolated from cases of acute flaccid 
paralysis (refer to chapter 3), although its role in this clinical condition is poorly 
understood. 
 
Enterovirus 68 is a member of the species D Enteroviruses and is thus related to 
enterovirus 70. In the late 1960s and early 1970s, acute haemorrhagic conjunctivitis was 
pandemic in Asia and Africa
147
. During this pandemic, it was observed that cases of 
haemorrhagic conjunctivitis due to enterovirus 70 infection, were associated with 
significant neurologic sequelae
148
. Coxsackievirus A24 has also been involved in 
widespread outbreaks of haemorrhagic conjunctivitis
80
. 
 
Perhaps one of the most visually striking clinical presentations of enterovirus infection in 
early childhood would be that of hand, foot and mouth disease (HFMD). Patients can also 
present with herpangina which involves the appearance of greyish white vesicles in the 
mouth and throat. HFMD is usually mild, beginning with a sore throat and low-grade 
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fever and is typically associated with members of the Enterovirus species A
149-152
. The 
majority of patients develop vesicles 3 to 5 mm in diameter and erythematous in 
appearance, typically occurring on the palms of the hands and soles of the feet consistent 
with the naming of the disease
134
. Recent outbreaks of HFMD in Australia have been 
associated with coxsackievirus A6, coxsackievirus A16 and EV-A71 (Chapter 3.4.1). 
HFMD is typically associated with members of the Enterovirus species A
149-152
. 
 
Members of the species B Enteroviruses, specifically the echoviruses, are often 
associated with neurological illness
141
. However other members of the species B 
Enteroviruses including coxsackievirus B1 to B5, are not only associated with 
neurological illness such as meningitis, but also with cardiomyopathies such as acute 
myocarditis. Neonates and younger infants have a higher susceptibility to coxsackievirus 
B associated myocarditis and associated systemic infection, which can be fatal
141,142
. 
Approximately 0.01% of acute myocarditis cases may progress to chronic dilated 
cardiomyopathy
80
. In a similar manner to acute myocarditis, chest pain arrhythmias and 
potentially heart failure are symptomatic of chronic dilated cardiomyopathy
141
. 
 
The coxsackieviruses B1 to B5 have been implicated in the onset of juvenile diabetes 
mellitus (type 1 diabetes), with evidence of enterovirus RNA in pancreatic tissue samples 
coincident with patients developing anti-islet-cell antibodies
153,154
. The apparent 
seasonality of type 1 diabetes presentation supports a post-infectious disease mechanism, 
preceding an autoimmune response
155-157
. 
 
1.2.7 Enterovirus as a Public Health Consideration 
The primary means of transmission for enteroviruses is via the faecal-oral route
80
. 
Transmission from person-to-person is efficient in environments where personal hygiene 
and environmental sanitation are poor. 
 
In the context of public health considerations for enterovirus infection, poliovirus has 
served as the prototype virus for over 100 years. The first clinical descriptions of 
poliomyelitis occurred in Europe in 1784 by Dr Michael Underwood in which he 
described children suffering weakness and paralysis of the lower extremities
158,159
. 
Subsequent outbreaks were described early in the 19
th
 century in Europe and the United 
States in the late 19
th
 century
80
. By 1938, significant funding had been established in an 
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attempt to curb cases of paralytic poliomyelitis, with the announcement of the Salk 
inactivated vaccine, licenced in 1955
22
, followed by the Sabin attenuated vaccine, 
licenced in 1961-1962
21,80,160
. As a result of the introduction of these vaccines, the 
incidence of paralytic poliomyelitis dropped dramatically in the countries where it was 
used. The last case of poliomyelitis due to wild poliovirus infection in the United States 
was reported in 1979 and the last indigenous case of wild poliovirus infection reported in 
Australia was in the 1960s
161
. 
 
Whilst enterovirus infection occurs on a global scale, the majority of studies into the 
public health considerations of enterovirus infection have been performed in the United 
States and typically in response to large outbreaks of poliomyelitis. Of particular interest 
are the “virus-watch” programs performed during the 1960s and 1970s, in which the 
prevalence of enteroviruses, predominantly the coxsackieviruses and echoviruses, were 
observed to be the highest in children
162
. As these studies were performed using virus 
culture methods, non-cultivable enteroviruses would not have been identified. Only those 
viruses of a high enough titre and tropism for the cell lines used would have been 
observed. 
 
Typically, the public health response to non-polio enterovirus infection is considered to 
be a low priority, given that it is usually a self-limiting illness with a low mortality rate. 
Since the late 1990s, emergence of EV-A71 causing HFMD has garnered international 
attention, due to the associated risk of developing meningo-encephalitis with bulbar 
involvement and death
134,140,163-165
. Although mostly restricted to China and Southeast 
Asia, Australia has in recent years reported significant neurological illness and fatalities 
associated with EV-A71 infection and as a result, has established enhanced surveillance 
for the virus (refer to section 3.4.2). It is now a primary focus of the Enterovirus 
Reference Laboratory Network of Australia (ERLNA), established in 2009 by the NERL 
and funded by the Commonwealth Government of Australia. 
 
There is concern that EV-A71 may continue to evolve and that widespread periodic 
outbreaks of HFMD associated with severe neurological sequelae may become 
commonplace. Recently, vaccines for enterovirus EVA-71 subgenogroup C4 have 
become available
166-168
; some of these vaccines have undergone clinical trials in China, 
but remain unavailable for use at this time
169
. Subgenogroup C4 has been responsible for 
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a larger number of fatalities in China and Southeast Asia, and there is evidence in animal 
models that these new vaccines may provide a degree of cross-protection from other 
genogroups of EV-A71 such as genogroup B. Cross protective-immunity in humans is 
unknown and investigations are ongoing
170
. 
 
The ERLNA, in conjunction with the respective State and Federal departments of health, 
continue to monitor the situation with EV-A71, but such surveillance is not just restricted 
to this virus. All enteroviruses identified by serotype are collated and significant events 
are investigated and reported to the relevant parties (Chapter 3). 
 
1.2.8 The Polio Eradication Initiative and the Evolution of VDPVs 
In 1988, the World Health Assembly passed a resolution to eradicate poliomyelitis 
worldwide. Since then, the annual global disease burden of poliomyelitis has been from 
reduced from 350,000 cases to 406 in 2013 representing a 99.9% reduction (Figure 1.19). 
The World Health Organization (WHO) Global Polio Eradication Initiative
171
 is based on 
maintaining high levels of polio vaccine coverage, clinical surveillance for cases of AFP 
in children less than 15 years of age, and laboratory confirmation of wild poliovirus 
infection. Each country has a WHO accredited polio reference laboratory, to which 
specimens from AFP cases can be referred. 
 
  
Figure 1.19 Global map of polio cases 1988 and 2013. A) Polio affected countries 1988 highlighted in 
red, B) polio affected countries September 2013. Images obtained from the global polio eradication 
initiative website March 2014. Source: www.polioeradication.org
171
. 
 
So far, the polio eradication initiative has been successful in the eradication of wild 
poliovirus types 2 (last identified in India in 1999) and apparently type 3 (most recent 
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identification in Nigeria in November 2012), despite significant difficulties and 
challenges maintaining funding
171
. The most recent success was the declaration that India 
was certified free of wild poliovirus transmission in 2012
172
, an event which is considered 
to be possibly one of the most difficult public health challenges
173
. With India’s success 
in eradicating the virus comes the next challenge, that of dealing with the three remaining 
countries with circulating wild type poliovirus, where interruption of transmission has 
never occurred. These three countries, Afghanistan, Pakistan and Nigeria, are currently 
beset by military conflict or geopolitical instability. One outcome of this circumstance has 
been the murder of polio vaccinators and doctors associated with the eradication program, 
making continued efforts to maintain high vaccination levels extraordinarily difficult
174
. 
 
Indigenous viruses from these three countries have been identified in surrounding 
countries and have initiated large outbreaks from reintroduced viruses, the most recent 
being Somalia where over 194 cases were reported in 2013
171,175
. With public and private 
financial support wavering, such introductions are potentially devastating to the 
eradication of poliovirus. Calls have been made to change the program from an 
eradication program to one of control, but costings for a control-based approach to 
poliovirus have shown that over the long term, the resultant suffering and financial 
burden to the global community far outweighs the financial costs of eradication, even in 
instances where virus introduction into previously virus free countries occurs
176
. 
 
A side effect of the use of live attenuated vaccine strains in the vaccination of children, 
typically in poorer nations where multiple factors conspire against making the safer 
inactivated form of the vaccine available, is the emergence of vaccine derived 
polioviruses (VDPV)
177
. There are three categories of VDPV; circulating VDPVs 
(cVDPV), immune-deficient associated VDPVs (iVDPV) and ambiguous VDPVs 
(aVDPV). 
 
Circulating vaccine derived polioviruses (cVDPVs) are typically found in areas where 
poliovirus vaccination uptake is poor or significant gaps in maintaining vaccination 
campaigns are evident (Figure 1.20). Such an instance occurred in Nigeria in 2002, when 
community leaders in northern Nigeria advocated that the vaccine was being used for 
nefarious reasons, specifically the transmission of human immunodeficiency virus (HIV), 
and was being touted as a potential cause of sterility in young people, none of which were 
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true
178-180
. During this time of non-compliance with recommended dosage schedules, the 
live attenuated virus may have transmitted between naïve hosts and accumulated point 
mutation to such a degree (approximately 1% per annum) that there was a concomitant 
loss of attenuation. cVDPVs are considered to be as threatening to human health as that 
of a wild virus. In northern Nigeria cVDPV type 2 accounted for 392 cases of polio, 
between 2005 and 2013
171
.  
 
 
Figure 1.20 Map indicating global vaccine derived poliovirus distribution 2001 to 2013. Source: March 
21, 2014 / 63(11);242-248
181
. 
 
Revertant viruses need not only be the result of community-wide transmission amongst 
non-vaccinated individuals. In the case of an iVDPV, the patient is typically suffering a 
primary immunodeficiency involving  B-cells. This immune deficiency results in failure  
to completely clear the poliovirus infection and patients have been known to excrete virus 
for periods greater than 20 years
97,182
. In 2009, a patient with an underlying 
immunodeficiency was found to be suffering from poliomyelitis; the virus was examined 
and thought to have originated from the vaccination of a close contact many years prior. 
Due to the lack of specific antiviral therapies for such an instance, the patient 
subsequently died
183
. 
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As the polio eradication initiative has progressed, enhanced surveillance measures are 
being implemented. One method used to improve surveillance for poliovirus, is 
environmental testing, involving the testing of sewage samples for the presence of 
poliovirus. If a vaccine-derived poliovirus is detected in such an environmental sample 
and its origin cannot be traced, it is deemed to be a VDPV of ambiguous origin or an 
aVDPV. aVDPVs have been identified in sewage samples in Israel as part of routine 
environmental surveillance
181
. However, during this course of this surveillance, wild 
poliovirus type 1 has also been identified
184
, highlighting the importance of 
supplementary surveillance systems as an adjunct to AFP surveillance. 
 
Once thought to be an advantage of using live attenuated poliovirus strains in a vaccine, 
the transmission of vaccine strains from recipients to non-vaccinated hosts is of serious 
concern and is an element of the OPV paradox. The OPV paradox refers to the live 
vaccine that prevents poliomyelitis, but can also cause poliomyelitis. Furthermore, once 
the wild strains of poliovirus are eradicated, Vaccine Associated Paralytic Poliomyelitis 
(VAPP) cases and VDPV cases resulting from live attenuated vaccine strains will become 
the only sources of poliomyelitis. Challenges exist in the removal of live attenuated 
strains, because the persistence of live virus in the community or environment represents 
the potential for reintroduction of the viruses
185
. This is a potent reminder, considering 
that the only paralysis cases caused by a type 2 poliovirus are those of vaccine origin. 
 
As described above, the lack of a standard approach to the treatment of a patient with an 
acute presentation of poliomyelitis in the background of chronic infection is of significant 
concern. As a result an initiative has been formed to focus on the creation of strategies for 
the treatment of infection with poliovirus
186
. 
 
Upon the interruption of transmission of wild-type poliovirus, a period of time will pass 
before the WHO announces the cessation of the use of oral poliovirus as a vaccination 
strategy. This will be done in order to minimise the risk of the emergence of VDPVs and 
the associated reduction in risk of paralytic disease associated with these viruses. 
 
1.2.9 Poliovirus Endgame Strategy and the Poliovirus Antiviral Initiative 
In 2006, the Poliovirus Antiviral Initiative (PAI) was established in response to the 
approaching endgame strategy for the eradication of poliovirus
186
. The emergence of 
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Sabin vaccine poliovirus strains in an unvaccinated population is a serious concern to the 
eradication initiative. Such events are possible, in particular in the case of individuals 
with a primary immunodeficiency, who are unable to clear a chronic poliovirus infection. 
Such an infection can be sub-clinical and the patient may be excreting virus into the 
environment or to close contacts. Over time, the chronic replication of the virus in the gut 
can lead to point mutations that confer an increase in neurovirulence
177,182,185
. At present, 
no therapeutic options exists for the treatment of individuals with a chronic enteroviral 
infection.  
 
In response to the formation of the PAI, a number of small molecules developed for the 
treatment of picornavirus infection have been examined for their efficacy in treating 
poliovirus infection. Figure 1.21 indicates some examples of these antivirals and their 
activity on multiple targets within the replication cycle. Specific information relating to 
the defined stages of the picornavirus replication cycle can be found in section 1.2.3. 
 
 
 
Figure 1.21 Antiviral targets and the picornavirus replication cycle. Simplified schematic 
representation of the stages of cellular replication of enteroviruses, highlighting stages of virus replication 
targeted for inhibition using antiviral agents. Figure adapted from De Palma et al., (2008)
187
. 
1) Attachment or uncoating inhibitors such as the capsid binders Pleconaril, BTA-798 or V-073
188,189
.  
2) Inhibitors of replication targeting proteins 2C (eg. Guanidine Hydrochloride)
190
, 3A (eg. Enviroxime)
191
 
or the 3D polymerase (eg. Gliotoxin, nucleoside analogues)
192
.  
3) Inhibitors of post-translational proteolytic cleavage (eg. Rupintrivir)
193
.  
4) Assembly and release inhibitors such as Hydantoin
194
. 
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It was the opinion of an expert panel that a multipronged approach would be taken to use 
antivirals in this manner. Specifically, the choice of antivirals with different targets such 
as capsid binders and enzyme inhibitors
195
 (see Figure 1.21), which is similar to the 
approach taken for HIV, utilising multiple antivirals targeting different virus products or 
regions, in order to minimise the risk of drug resistant mutants being created. 
 
The development of potential agents for the inhibition of enterovirus replication and the 
understanding of their mode of action is aided significantly by the observation of the 
interactions of drug and target at the atomic level. A significant amount of work has been 
performed in the determination of enterovirus structure, typically via the use of x-ray 
diffraction methods, in order to gain a “snap-shot” of virus-drug interactions at the atomic 
level. The earliest example of the examination of picornavirus-antiviral interaction using 
x-ray diffraction methods was in 1988, showing the atomic details of WIN compounds 
binding  to rhinovirus capsids
196,197
. 
 
The following section 1.3 examines common in-vitro experimental methods used to 
determine the atomic structure of molecular structures. A brief historical background for 
each method is provided, with specific information relating to the principles of the 
methodology. More importantly, the advantages and limitations of each method are 
examined. Specific examples are given, relating to the application of these methods with 
respect to the investigation of virus structure. 
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1.3 The Determination and Visualisation of Virus Structure. 
The elucidation of structural virus components at the atomic or near-atomic level is 
pivotal to our understanding of virus macromolecular structure. The first indications of 
the macromolecular configurations of a virus was attributed to TMV and was determined 
using X-ray diffraction patterns derived from the methods of Stanley and Wendall in 
1935
13
 and electron microscopy by Kausche et al., (1939)
198
.  
 
The ability to provide detailed structural data has progressed hand-in-hand with an 
increase in computer processing power. The ability to automate data recording and 
analysis has resulted in the accumulation of data many orders of magnitude greater than is 
possible by manual methods. The subsequent analysis of these data using highly efficient 
software algorithms has also yielded massive increases in resolving power for structural 
components of viruses
199,200
. 
 
Combining the power of modern computer technology with traditional methods for 
structure resolution, has resulted in methods such as transmission electron microscopy 
(TEM) being capable of resolving complete adenovirus capsids at resolutions matching 
that of X-ray crystallographic methods
201
. However, even with the latest in computational 
prediction methods, it is still not possible to predict the structural elements in all 
proteins
202,203
. The deduction of final protein conformation must still be performed 
experimentally and the resultant outputs can be refined when combined with amino acid 
sequence data. 
 
1.3.1  X-ray Crystallography 
X-ray diffraction is the physical outcome of the interaction of X-rays with a crystalline 
lattice. The principle of x-ray diffraction is based on the passing of very narrow parallel 
beams of x-ray radiation through a crystalline substrate of protein (or material to be 
examined)
204
. If no atoms are encountered, the x-rays pass through unaffected. Where 
x-rays encounter an atom, the x-rays will be scattered. If the crystalline lattice is well 
ordered, then the resultant backscatter will occur in an ordered manner and can be 
captured as a diffraction pattern
205
. 
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X-rays form part of the electromagnetic radiation spectrum with a wavelength of 
approximately 1.0 Å (0.1 nanometres), but unlike electromagnetic radiation in the visible 
light range, x-rays cannot be refracted with any known lens. This becomes a significant 
problem when employing x-rays to examine the atomic structure of a molecule using 
diffraction methods. In order to reverse calculate the diffraction point of an x-ray and 
identify the electron cloud responsible for this diffraction in 3-dimensional space using 
the Fourier transform algorithm, three key points of information are necessary. 1) The 
angle of diffraction as it relates to the source of the x-rays and the collection point, 2) the 
amplitude of the x-ray which is derived from the intensity of the data point collected in 2-
dimensions and 3) the phase of the x-ray as it makes its way through the crystalline 
lattice. Data relating to phase, resulting from the absence of any available lens apparatus, 
remains absent from the collected diffraction data in x-ray diffraction methods. This is 
referred to as the “phase problem” and present a significant issue in the application of the 
Fourier transform algorithm required to reverse calculate the derived 2-dimensional data 
to a 3-dimensional space. Different approaches have been used historically to assist in the 
elucidation of large macromolecular structures. The multiple isomorphous replacement 
(MIR) “Patterson” method, was used in the first determination of protein structures in 
1958, specifically haemoglobin (Perutz)
206
 and myoglobin (Kendrew)
207
, earning them 
both the Nobel Prize in 1962. Subsequent methods to solve the “phase problem” are the 
multi-wavelength anomalous diffraction (MAD)
208
 and molecular replacement (MR) 
methods
209
. The methods are computationally very intensive and the resultant electron 
density maps are then used to fit the amino acid sequence data for the specific protein 
being investigated. 
 
The theoretical experimental resolution of a density map is a function of the quanta of 
data points obtained, versus the size of the unit cell examined. For example, a unit cell 
size 100x100x100 Å would require 1000 points in each unit cell to achieve 0.1 Å 
resolution for each direction, so 1000x1000x1000 points (one billion points) would be 
required to resolve a 100 Å cubic cell. This theoretical limit is restricted by the intensity 
of the x-ray source and the rate of destruction of the material being examined over time. 
One of the most important advances afforded by powerful computer systems and 
automation, is the ability to approach the theoretical limit of resolution, by rapidly taking 
thousands of diffraction patterns from a single crystal moved along multiple axes and, 
using the “Fourier transform“ method, back-calculate the positions of individual atoms 
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with a potential resolution of less than 1 Å to form an electron density
210
. Such resolving 
capacity obviously requires the assistance of powerful computers and much progress has 
been made in the automated collection and interpretation of X-ray diffraction data
211-213
. 
The final resolution is very important, as it enables the recognition of structural motifs 
which can facilitate the fitting of amino acid sequence data. 
 
Although the theoretical limit for the resolution of x-ray diffraction methods is less than 
1 Å, this figure varies considerably depending on the type of structure being examined 
and the quality of the crystals available. Spatial variation within the molecule being 
examined is significant, as disordered or mobile elements of the molecule will result in 
unreliable density data, for which in the case of proteins, affects the ability to fit amino 
acid sequence data. The observation of fluctuations in spatial coordinates is referred to as 
Debye-Waller factors
214
 or “B-factor”, with low values indicating lower vibrational 
(thermal) states, correlating with better quality data.  
 
In the case of viruses, which are relatively large macromolecular structures with complex 
interaction often involving repeating subunits, the actual resolution derived using x-ray 
diffraction methods can be significantly higher than 1 Å. An examination of the RCSB 
Protein Data Bank at the time of writing, indicates that the resolution of x-ray diffraction 
derived capsid structures for members of the genus Enterovirus the range from 2.2 Å for 
the wild-type poliovirus structure (PDB ID 1HXS) originally examined in 1985
16
, to 
4.0 Å for the empty capsid structure of EV-A71 (PDB ID 3VBU) released in 2012
215
. 
 
X-ray crystallographic methods, whilst being able to provide very high resolution data 
relating to protein structure, are unable to provide a large scale biological juxtaposition of 
the protein (or virus) being examined. Often the relative positioning of a molecule within 
a biological system is important. For this purpose, electron microscopy methods are 
useful, as described in the following section 1.3.2. 
 
1.3.2 Transmission Electron Microscopy 
In 1933, Ruska and Knoll created the first prototype transmission electron microscope
216
. 
In much the same manner as a light microscope passes light through a sample and then a 
series of lenses which magnify the specimen, transmission electron microscopy (TEM) 
channels a fine stream of electrons in a vacuum through a thin sample preparation. The 
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occlusion of these electrons by electron dense material results in an image represented on 
a fluorescent screen (Figure 1.22). 
 
 
Figure 1.22 Schematic diagram of an electron microscope. A simplified diagram of an electron 
microscope, indicating the major components and their relative positioning. Electrons for use are generated 
by a high voltage electron gun (Red). The electrons are accelerated along the tube length and focused using 
magnetic lens assemblies. Once the electron beam has passed through the specimen, the scattered electrons 
are detected using a fluorescent screen creating an image which is then recorded using a high resolution 
camera. 
 
The introduction of the transmission method of electron microscopy enabled the 
visualisation of TMV virus particles in 1939 by Kausche et al.,
198
, thereby settling a long 
standing debate as to whether the TMV agent was a liquid or a particle. 
 
The resolving power of TEM is measured in the millions, with resolutions of 0.5 Å 
theoretically achievable using high energy systems and methodologies involving 
crystallography and diffraction, although these methods are not in routine use and in 
reality, result in structures between 1-10 Å
217,218
. Typically, lower power TEM systems in 
the range of 80-300 kVA are used and represent a useful adjunct in virus structural 
determination, in that they provide a gross morphological description of a virus at 
resolutions of 20-40 Å and when combined with thin section methods, can also provide a 
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biological context. These thin section methods can be performed on samples such as cell 
culture positive material and the virus can be visualised in various stages of its life cycle 
at an effective resolution of between 50 to 75 Å (Figure 1.23) with ultra-low power 
versions (5kVA) capable of 100 Å resolutions
219
. 
 
 
Figure 1.23 Thin section transmission electron micrograph of an L20B cell. An endogenous retrovirus-
like particle (arrow) is depicted budding from the cytoplasm of an L20B mouse fibroblast, a cell line 
expressing the CD155 receptor that is commonly used in the isolation of poliovirus. Scale bar: 100nm. 
Image courtesy of John Marshall, Electron Microscopy Division, VIDRL
220
 (appendix A8.2.4). 
 
Disadvantages of this method include the costs associated with purchasing, maintaining 
and operating a TEM system. For a period of time, electron microscopy methods were 
becoming less prevalent, particularly after the introduction of antibody-based virus 
detection systems coupled with light microscopy and the advent of the PCR era. 
However, combining TEM with cryogenic freezing methods, computer based imaging 
and 3-dimensional reconstruction, there has been resurgence in the use of TEM
221
. 
 
1.3.3 Cryogenic Electron Microscopy 
Electron microscopy is a destructive process for the subject matter being examined. 
Damage to biological specimens begins during the preparation process and may be 
caused by dehydration, or while attaching the specimen to be examined onto the substrate 
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before observation. As a result, the specimen observed using TEM techniques does not 
necessarily reflect the actual biological state of the original sample. Given a long enough 
time, the sample examined under a stream of electrons will be irreparably damaged
222,223
. 
 
Initial experiments by Taylor et al., (1975), showed that the process of cryo-electron 
microscopy (cryo-EM) was capable of preserving frozen hydrated catalase crystals, which 
were destroyed when prepared in an air dried manner
222
. Critical to the process of 
cryo-EM microscopy was the discovery that rapid cooling of pure water would prevent 
the formation of ice crystals. Techniques for rapid freezing using liquid nitrogen and/or 
helium, such as those described by Dubochet et al., (1982)
223
 and McDowall et al., 
(1984)
224
, resulted in a resurgence of electron microscopy techniques, producing results 
which rivalled those of x-ray crystallography. 
 
Given the appropriate resources, it is possible for cryo-EM to be used under optimal 
conditions to resolve structures at a resolution of less than 3 Å in vitreous (glass-like) ice 
at liquid nitrogen or helium temperatures (4K to 77K)
225,226
. To examine virus structures 
at high resolutions, the techniques most commonly encountered in laboratories are 
cryo-electron tomography and single particle cryo-EM
225
.  
 
Tomography is the process of imaging via sections. The word tomography is a derivative 
of the Greek words tomē or tomos (cut, part or section) and graphein (to write). In the 
context of cryo-electron tomography, a series of images are obtained from the specimen 
typically frozen in vitreous ice and placed on an electron microscopy stage which is able 
to tilt. Using computational methods, these images can be reconstructed into a 
3-dimensional density, the resolution of which is dependent on the thickness of the 
original specimen. Typically this requires specimens to be 0.5  µm in order for the 
electron beam to penetrate the specimen
227
. Such work is also typically suited to electron 
microscopes with accelerating voltages of 200 to 300 kV. For microscopes of low 
voltages, samples prepared using traditional methods such as negative staining can also 
be useful for tomography. 
 
Cryo-electron tomography methods can easily produce images with resolutions of 50 to 
100 Å which can be useful for cellular structures and bacteria, but in terms of resolving 
virus structures, these resolutions are not suitable
228
. One method that can be applied to 
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increase the resolution is sub volume averaging, which can provide structural information 
at 20 Å resolutions. These methods have been applied to viral surface proteins such as 
HIV trimers and other envelope glycoproteins
229
.  
 
One of the most commonly used forms of cryo-EM techniques is the single particle 
method. This method involves the aggregation of numerous 2-dimensional images 
showing the particles of interest in different orientations, which are then reconstructed to 
generate a 3-dimensional representation of the particle (Figure 1.24). This method also 
involves the plunge freezing of high titre preparations of the particle of interest in order to 
create a thin layer of vitreous ice. With respect to the examination of viruses using single 
particle methods, the exploitation of high symmetry such as the icosahedral 60-subunit 
symmetry found in members of the family Picornaviridae, allows averaging of subunits 
to refine the final structure. This can result in structures of 4 Å or better, approaching the 
resolution conferred by x-ray diffraction methods
226,230
. 
 
 
Figure 1.24 Principles of single particle cryo-EM methods. Highly simplified, schematic representation 
of the principles used in single-particle cryo-EM methods, for the reconstruction of a virus particle. A) 
Simple representation of the initial electron micrograph containing the molecule of interest in differing 
axial rotations and planes. B) highlights the differing axial rotations as they relate to C), D) represents the 
final density constructed from a large number of sample sets similar to those represented in A) and B, 
subunit averaging of protomers around the five-fold axis of symmetry results in an increase in 
resolution
226,230
. 
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The acquisition of 2-dimensional data and the 3-dimensional reconstruction process is 
demanding for the researcher and is computationally intensive, but advances in 
computational software and hardware technology allow more efficient gathering of a 
larger number of quality 2-dimensional images, which can be used to increase the 
signal-to-noise ratio, critical to the reconstruction process
228,231
. Once knowledge of the 
relative orientation of the particle is established, the Fourier transform of each 
2-dimensional projection can be extrapolated to a 3-dimensional object
225,232
. This 
method can also be combined with tilt-imaging methods, allowing the inclusion of more 
2-dimensional images with known variations in orientation
233
.  
 
Hybrid methods, involving the derivation of cryo-EM densities with atomic coordinate 
data obtained using nuclear magnetic resonance (NMR) techniques and/or x-ray 
crystallography, are becoming more frequently used and can result in very high resolution 
structures
228
. The resolution of publicly available enterovirus capsid structures obtained 
using cryo-EM methods range from 6.09 Å (CV-A7, PDB ID 4AGY)
234
 to 30 Å 
(Poliovirus with receptor, EMDB ID EMD-5144)
235
. 
 
1.3.4  Nuclear Magnetic Resonance 
NMR or Nuclear Magnetic Resonance spectroscopy is frequently used in the elucidation 
of small molecules such as proteins, advances in technology and methodologies, such as 
those incorporating the use of isotopic labelling, have resulted in the determination of 
structures approaching 100,000 daltons in mass
236
. Unlike x-ray crystallography, a 
crystallised version of the structure (such as a small protein) is not required, nor is the 
sample required to be fixed in or on a solid substrate as in electron microscopy. In fact all 
that is required is an aqueous version of the target in a pure and concentrated form. 
 
NMR has been used to examine the structure of the uridylated form of the VPg molecule, 
which is critical to the reproductive cycle of the virus family Picornaviridae. In 
poliovirus, a member of the family Picornaviridae, the VPg is a 22 amino acid protein 
that is covalently bound to the 5´ non-translated region of the virus genome 
237,238
. 
 
NMR relies on the principle of atomic “spin” and the potential of atomic nuclei to be 
aligned to a strong magnetic field. In sufficiently high quantities, “magnetic moments” of 
atomic nucleic in molecules can be deliberately misaligned and “tipped of axis” by the 
use of radio frequency (RF) radiation. The resulting alterations in magnetic field in 
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response to a specific RF frequency can be observed and recorded in the form of spectral 
data for analysis. The apparatus that maintains the strong magnetic field, RF control 
pulses and the detection of magnetic induction is referred to as an NMR spectrometer
239
. 
The emission of RF data by atomic nuclei is directly influenced by neighbouring nuclei 
and thus information relating to the positioning of hydrogen atoms can be extrapolated. 
The size of shift in RF signals indicates the distance between atomic nuclei and when 
combined with sequence data. the 3-dimensional structure can be derived along with 
information pertaining to variations in conformational state of the protein
240
. Structures 
solved using NMR are typically presented as “sets” of data. 
 
Although NMR allows the inference of differing conformational states of a protein, none 
of the methods described using x-ray diffraction or cryo-EM can enable the observation 
of large-scale molecular movement and interactions over a given time-frame. End-point 
observations of molecular structures are obtained and often the methods described above 
are combined to provide a detailed and complete picture of macro-molecular structures
241
. 
A significant amount of effort and resources are required to observe virus structures at the 
atomic level, using the techniques just reviewed. Thus, it may not feasible to elucidate the 
capsid structure of an enterovirus identified to have the potential to be a public health 
threat, in a timely manner. It is for these reasons, that the prediction of virus structure 
using methods such as comparative protein modelling is useful. 
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1.4 Virus Structure Prediction Using Comparative Protein 
Modelling Methods 
The elucidation of structures using conventional methods such as x-ray crystallography or 
cryo-electron methodologies, rely upon the availability of large amounts of highly 
purified protein to be investigated. In the case of cultivable viruses this is not necessarily 
an issue, as large numbers of virus particles can be produced in the laboratory using 
standard cell culture methodology, combined with high speed centrifugation and 
purification techniques. The amount of time to perform these procedures is still a 
significant consideration, and this is particularly evident in the case of x-ray diffraction 
methods, which are reliant upon the availability of a crystal for examination. The 
production of crystals for x-ray diffraction has evolved significantly over time and a 
number of viable commercial applications are available. With respect to enteroviruses 
from high titre cultures, a number of x-ray diffraction-derived structures representing 
virus particles in different states are available and a lot has been learned from the early 
days of virus structure prediction, but such work remains nonetheless time-consuming 
and expensive. 
 
In the case of non-cultivable viruses, such as the recently described Rhinovirus species C 
and other members of the genus Enterovirus affecting humans, high virus titre methods 
are not available for purification and for use in x-ray diffraction methods or cryo-EM 
methods
242
. The use of comparative protein modelling methods, which will now be 
reviewed, is a viable alternative in the absence of methods using infectious DNA clones 
for the production of complete virus particles, such as those described by Racaniello et 
al., (1981)
34
. 
 
The application of 3-dimensional structural prediction methods for protein sequences 
derived from nucleic acid sequence data, has allowed the reconstruction of novel proteins 
by comparison with homologous data
243
. The Protein Data Bank (PDB) is an 
ever-growing resource of 3-dimensional structural data that can be used to predict 
homologous structural motifs
244
. These methods can be used to reconstruct novel proteins 
with homologous regions such as enzymatic active sites, or structural motifs such as beta 
barrels, commonly found in the capsids of viruses. Whilst the reconstruction of common 
motifs such as β-barrels or α-helices results in models of an acceptable quality, a problem 
arises when loop regions of a protein are modelled using comparative methods.   
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The problem of modelling these loops can be attributed to three main causes:  
 
Firstly, missing data in the template structure due to thermal fluctuation or spatial 
disorder, that cannot be resolved using methods such as x-ray diffraction, complicates the 
prediction of appropriate loop positioning
245
. Secondly, if an analogous loop structure is 
available for comparative modelling, insertions or deletions may exist in the query 
sequence when compared to the template structure (as a consequence of evolution), 
complicating the threading of query sequence within the 3-dimensional coordinates 
afforded by the template structure
246
. Thirdly, it may be that some “loop” regions contain 
sequences that are highly flexible and exhibit numerous conformations at finite 
temperature, or have no intrinsic structure
247
, in which case x-ray diffraction may not be 
useful. Conditions required to force a loop into a particular conformation, so it that can be 
resolved, might not be biologically relevant and in these cases, molecular dynamics (MD) 
simulation is necessary. 
 
These problems are particularly evident in the loop-like structures that are interspersed 
between the extended-beta formations that comprise the “jelly-roll” structures, central to 
the subunits of a protomer in the capsid of enteroviruses, as described in section 1.2.2. 
Loops such as the BC loop of VP1 and the EF loop of VP2 are known antigenic 
determinants and as such, undergo selective pressure by the host, resulting in 
hyper-variability of the amino acid sequence
248
.  
 
Previous study of virus proteins in the early 1990s, utilised comparative protein 
modelling techniques that were initially limited to the investigation of non-structural 
proteins, such as viral proteases or polymerases, based on homology with previously 
elucidated structural information
249,250
. It is not surprising that the complexity of 
comparative protein modelling efforts has had a strong correlation with the increased 
availability of computational power, which in the 1990s was beginning to make 
significant inroads due to reduced cost. 
 
By the latter half of the 1990’s, comparative protein modelling techniques had extended 
to the examination of interactions of multiple molecules such as receptor molecule 
interactions and virus glycoproteins
251-253
. Computer limitations still existed in at this 
stage, which made the reconstruction of structures measuring hundreds of Å in diameter 
not only difficult, but essentially impossible.  
Chapter 1: Literature Review 
51 
 
In 1999, Yoneda et al., described the reconstruction of an icosahedral viral capsid using 
symmetry methods in the reconstruction of poliovirus, using rhinovirus X-ray crystal data 
as a template for comparative protein modelling
254
. Although not a complete capsid 
reconstruction, this work gave valuable insight into the limitations of modelling protomer 
subunits as opposed to that of a complete virus capsid, even when performed using 
symmetry methods to reconstruct a capsid. 
 
Enterovirus structural proteins were targeted for comparative protein modelling in 
2001
255
. This timing coincided with the emergence of an increased incidence of 
neurovirulence caused by EV-A71, which previously, was mainly associated with 
HFMD. The use of homology methods allowed the reconstruction of virus surface 
structures and the hydrophobic pocket associated primarily with the VP1 chain of the 
virus capsid. These EV-A71 models were reconstructed using homologous regions found 
within the structural regions of poliovirus and bovine enterovirus. 
 
Given the high degree of sequence identity between the human enteroviruses and the 
availability of verified structures in the form of x-ray crystallography, cryo-EM and 
nuclear magnetic resonance data, enteroviruses make ideal candidates for comparative 
protein modelling. The generation and validation of homology models derived from 
existing protein data has the potential to facilitate the application of MD simulation to 
elucidate the molecular mechanics underlying viral pathogenesis, including 
receptor-binding, cell entry, RNA release and temperature dependant stability of critical 
enzymes of viral origin. Such data would ultimately result in the recognition of new 
targets for the development of antivirals. 
 
An examination of the historical aspects of MD simulation methods and the application of 
these methods to virus structural research is presented in the following section 1.5. 
Comparative protein modelling methods combined with atomistic MD simulation are 
used extensively in the research work presented in this thesis, the results of which are 
presented in chapter 5.  
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1.5 Molecular Dynamics Simulation 
Molecular modelling and mechanics are based primarily on the concept that molecules 
can be represented as mechanical systems subject to Newtonian (or classical) physics, 
enabling various molecular properties to be calculated, including energy and particle 
juxtaposition in geometric terms. In essence, this involves solving Newton’s equations256 
(1.1, 1.2 below) for each atom (i) as defined by: 
 
  (1.1) 
 
   (1.2) 
 
Where: 
                           
                          
                                  
                                                
       
                   
 
Atomic interaction potentials (V) in classical molecular mechanics models can be 
described using a number of types of force fields. The most commonly applied force 
fields for biological systems involve only pairwise interactions of particles, where these 
force-fields are derived for the most part from empirical observations
257,258
. 
 
Force fields involve bonded and non-bonded terms. Bonded terms involve forces which 
act between bonded atoms and are approximated using harmonic “spring” potentials 
(balls and springs). These interactions can be expressed in terms of bond lengths, bond 
angles and torsional rotations (Figure 1.25)
258,259
.  
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Figure 1.25 Bonded particle interactions and the calculation of associated energies. A) bond stretching 
energies, B) bond angle energies, C) bond torsion energies. Figure adapted from Fox
259
 and Lindahl
258
. 
Empirical parameters kb = bond spring constant, kθ = angle spring constant,  A = torsion rotational energy 
barrier height. 
 
 
Figure 1.26 Non-bonded particle interactions and the calculation of associated energies. Van Der 
Waals energy calculations combined with electrostatic calculations. Figure adapted from Fox
259
 and 
Lindahl
258
. rij = interatomic distance between atoms i and j, Aij Bij Lennard-Jones coefficients for an atom 
pair (attraction-repulsion), qiqj Columb partial charges. 
 
 
In any molecular system there also exist non-bonded interactions for which the primary 
terms are van der Waals forces and electrostatic potentials (Figure 1.26). Indeed, 
molecular mechanics has its roots in the concepts of molecular bonding and van der 
Waals forces, with the fundamental ideas dating back to the early 1930s. In the molecular 
mechanics model, the potential energy V is written as a sum of bonded (Figure 1.25) and 
non-bonded terms (Figure 1.26) The solving of Newton’s equations in the context of 
molecular mechanics force-fields within a system of particles, enables the determination 
of atomic trajectories when the atoms “interact” over time, thus permitting the inference 
of motion to a static system
256,259
. Whilst this approach appears relatively straightforward, 
in reality, the calculations for large molecular systems are not feasible to solve in any 
meaningful time-frame. The solution to this problem is to achieve integration of these 
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equations at a number of discrete time steps, usually calculated at 1 to 2 femtoseconds, 
thereby generating step-wise atomic motions
260
.  
 
At present, only a relatively small number of atoms can be simulated, in the order of 
several million atoms. An example used in this research is a poliovirus and associated 
water and ions (~3.5 million atoms). This presents another problem, since any simulation 
would in essence be of a virus surrounded by a thin sheet of water, where the water would 
behave like it does at a surface, not in a submerged aqueous state. This is not biologically 
realistic, since surface effects would cause artefacts on the virus structure
261,262
. In order 
to partly solve this problem, periodic boundary conditions (PBC) have been created, 
which represent a simple rule that defines a finite box around the virus, solvated with 
water
249,250
. Any atom that crosses the edge of the box boundary is mathematically 
removed and transferred to the opposite boundary, with the same velocity (speed and 
direction) as before, essentially creating a hall of mirrors where each atom "sees" an 
infinite number of atoms as a reflection of themselves, thus approximating viruses 
solvated in an infinite "bulk" solution
256
. 
 
Periodic boundary conditions are an elegant solution, but they are still problematic. In an 
MD simulation, electrostatic effects on atoms must be taken into account. Since 
electrostatics are long-range forces, and each atom "sees" an infinite number of other 
atoms, then it becomes intractable to calculate electrostatic interactions in a PBC system. 
To counteract this problem, certain strategies have been devised. (i) Cut-off methods, 
where electrostatic interactions beyond a specified radius are reduced to zero, either 
abruptly, or using a smoothing function. (ii) Ewald summation such as the Particle Mesh 
Ewald (PME) summation
263
, which involves deconstructing electrostatic energy 
calculations into long-range and short-range components. Short-range components are 
summed within a defined radius in a manner similar to cut-off methods, whilst the 
long-range electrostatic components undergo Fourier-transformation and are thus 
summed in Fourier-space, enabling rapid convergence. The PME method, which is used 
in all simulations presented in this thesis, have been demonstrated to produce structures 
more accurately than simulations using cut-off methods
264
. An important aid to the 
progression of molecular dynamics simulation has been the evolution of computational 
power. The evolution of methods to utilise this power to generate simulation data, is 
discussed below. 
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In 1946, Frank Westheimer’s calculations of the stereoisomers of biphenyl derivatives 
enabled the definitive determination of molecular mechanics
265
. One of the primary 
reasons for the relatively slow progression of the field during this time was the lack of 
appropriate computational solutions. Quite simply, adequate computer systems were not 
available. This observation is confirmed by the fact that at the time of Frank 
Westheimer’s work in 1946, what is considered to be the first general purpose electronic 
computer was born. It was housed at the United States Army’s ballistic research 
laboratory and was known as the " Electronic Numerical Integrator And Computer” 
(ENIAC)
266
. Although it used decimal arithmetic, ENIAC still required manual rewiring 
via plug-board, to change its programming. 
 
In the 1950s, transistor-based systems began to replace vacuum tube counterparts, 
resulting in the first transistorised computer being demonstrated at the University of 
Manchester in 1953
267,268
. Increases in manufacturing efficiency resulted in wider 
availability of computational power in the 1960s to 1970s. This timing coincided with the 
initial development of systematic force fields, based on observational methods in the form 
of spectroscopic information, heats of formation and the sharing of small compound 
structures with similar chemical groups, combined with quantum mechanical information 
and other experimental data. These works were pioneered by Lifeson at the Weizmann 
Institute of science, Scheraga at Cornell University and Allinger at Wayne State 
University
269
. 
 
In 1969, Lifeson and Levitt reported the first energy calculation of myoglobin and 
lysozyme, which is the first instance of such calculations of entire proteins
270
. These 
experiments paved the way for the modern day implementation of energy minimisation 
methods. Subsequent to this, Rahman and Stillinger described the first method for the 
dynamics simulation of a polar molecule, water
271,272
. By the 1970s and the availability of 
supercomputers, Karplus at al at Harvard University had created the first generation of 
biomolecular force fields, on which modern force fields are based, including the force 
fields used for the work in this thesis - Chemistry at HARvard Macromolecular 
Mechanics (CHARMM)
273
. 
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Perhaps the most famous and widely referenced MD simulation was performed in 1977, 
on the relatively tiny protein bovine pancreatic trypsin inhibitor (BPTI)
274
. This 
simulation was within the picosecond timescale and indicated the atomic fluctuations that 
occur during such a timeframe. 
 
With respect to MD simulations, timeframe is extremely important. The amount of time 
required for a simulation, is dependent on the questions being asked. For example, to 
examine ion transport mechanisms, timescales in the order of nanoseconds would be 
required
275
. To examine tertiary structure formation of proteins, these timescales 
approach milliseconds in length and require very substantial computational resources as a 
result (Figure 1.27)258. 
 
 
 
Figure 1.27 Graph of common molecular activities and the associated timeframes. Timeline shown in 
seconds starting from simple atomic bond vibrations calculated in femtoseconds extending beyond protein 
tertiary structure formation in milliseconds. Figure adapted from Lindahl 
258
. 
 
For an example of how computational resource power limits the ability to simulate large 
structures for long timescales, consider the following comparison. A five base pair DNA 
simulation performed in 1985, consisting of 2800 atoms with a trajectory length of 0.5 ns, 
required 20 hours of simulation time on a Cray X-MP supercomputer
276
, which was 
capable of an estimated 0.8 giga-floating operations per second (GFLOPs) of double 
precision calculation capacity. Some 20 years later in 2006
1
, a one- million atom 
simulation of a complete virus particle was performed using a system with approximately 
0.8 terra-floating operations per second (TFLOPs) for a total trajectory time of 50 ns, 
over a period of 55 days, translating to approximately 1 nanosecond per day. This 
represented a simulation size increase of approximately 350 times with double the 
trajectory data calculated per day, compared to the work performed in 1985. Current 
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supercomputers are now capable of 10
15 
floating operations per second (PFLOPs) Figure 
1.28, with 10
18
 (EFLOPs) supercomputer systems on the horizon. 
 
 
Figure 1.28 Evolution of supercomputer computational power over time. Line graph depicting the 
increase in supercomputer calculation capacity expressed in TFLOPs (10
12
) using double precision data 
processing methods calculated using the LINPACK benchmark
277
. y-axis is logarithmic in scale. 
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1.5.1  Simulation of Virus Components 
The increase in computational capacity has served not only to facilitate the derivation and 
examination of static structural data such as those derived using x-ray diffraction 
methods, but has also allowed the incorporation of temporal variables via the use of MD 
simulation.  
 
Initial work in the simulation of virus structures was limited to relatively short timescale 
(picosecond) simulations, examining protein-drug interactions for rhinoviruses and 
3-dimensional predictions for amphipathic segments of the HIVgp41 envelope protein in 
1989
278,279
. Extension of these methods became more commonplace as a complementary 
feature of structure derivation for influenza virus hemagglutinin, and the examination of 
receptor binding in the 1990s
280
. Ultimately by the turn of the 21
st
 century, the use of 
computational methods had assisted in the refinement of potential antiviral agents termed 
“rational drug design”, which resulted in the development of the influenza neuramindase 
inhibitors amantadine (Symmetrel), rimantadine (Relenza) and seven years later, GS4104 
(Oseltamivir)
281,282
. During this same period, the simulation of rhinovirus capsid proteins 
had progressed to a more extensive examination of the vibrational states of the virus, in 
relation to the capsid inhibitor WIN52084s
283,284
. 
 
By 2008, the use of computational methods for the rational design of antiviral agents had 
become more widespread, resulting in the application of the technique to the design of a 
Hepatitis C drug (Boceprevir), targeting a shallow pocket within the virus protease. This 
was a challenging proposition, due to the shallow nature of the pocket with respect to the 
surface features of the protease
285
. Given the increases in computational power available 
to researchers in the 21
st
 century, the evolution of simulation methods for virus 
components into the simulation of complete virus structures, had become inevitable.  
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1.5.2  Simulation of Complete Virions 
In 2006, the first MD simulation of a structure representing a complete virion at the 
atomic level was published
1
. The virus simulated was that of STMV and consisted of 
approximately 1,000,000 atoms including water and associated ions required to suspend 
the virtual virus in solution (Fig 1.29). Although the protein’s composition was 
representative of the virus and was derived from x-ray crystallography experimental data, 
the encoding RNA in this simulation was not the actual genomic sequence for the virus. 
Instead, the RNA sequence consisted of multiple tracts of adenine and uracil, in order to 
facilitate ordered folding of the RNA. 
 
 
Figure 1.29 Illustration of the Satellite Tobacco Mosaic Virus simulation. Capsid represented as a 
density at eight Å in grey structural proteins represented in new cartoon (red – 70 Å, blue – 90 Å from 
centre. RNA displayed in a “tube and liquorice” representation, with associated magnesium ions in purple. 
Total simulation size was approximately one-million atoms. Representation derived from original data and 
rendered using tachyon renderer in VMD. 
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No other complete virus structures have been described in literature since, with the 
exception of an attempt to reconstruct influenza virus from partial x-ray diffraction data 
for picosecond timescales, from which limited information was published
286
. Other 
simulations of complete virus capsid structures have been performed, but this has been 
done using coarse-grained modelling (Monte Carlo methods), which is likely due to the 
very large simulation size (millions of atoms) and the associated amount of computational 
resources required to run the simulations for any relevant timescale
287
. For example, 
multi-million atom simulations require weeks of simulation time to achieve nanoscale 
times on high-end institution-based supercomputers, which is expensive and time 
consuming
2,266
 (refer to chapter 4). 
 
The trend of requiring institutionalised computational resources is beginning to change, 
with the increased incorporation of graphics processing unit (GPU) based parallel 
processing methods in high-end workstations, such as those used in graphics 
manipulation industries. Such systems lag by only five years behind the required 
computational resources for running multi-million atom simulations. For example, to run 
a 4 million atom simulation for a 100ns timescale within one month would require a 
50 TFLOPs system. Currently, it is possible to purchase a commodity system with a 
5 TFLOPs capacity, due to increases in computational capacity afforded by GPUs
288
. If 
this trend is to continue logarithmically, in a similar manner to that shown in figure 1.28, 
then it is reasonable to expect that commodity systems capable of exceeding 50 TFLOPs 
double precision computing capacity, will be available before the year 2020. 
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1.6 Project Aims 
This project aimed to exploit the advancements made in computational biology and 
bioinformatics and to apply them to the examination of viruses that are of significant 
public health concern, namely the genus Enterovirus.  
 
The areas of interest targeted by this research were development and enhancement of 
enterovirus detection and characterisation methods via the use of sequence data-mining 
and phylogenetic examination, in order to exploit similarities and differences in 
enterovirus genomes. It was anticipated that more specific detection assays could be 
developed by examination of hyper-variable regions related to major antigenic 
determinants for the rapid identification of serotype (chapter 2). Phylogenetic inference of 
these regions was performed and it was anticipated that these data would be amenable to 
the investigation of virus transmission patterns (chapter 3).  
 
The use of molecular epidemiological methods to determine enterovirus transmission 
patterns was of use in recognising enteroviruses that pose a specific threat to human 
health (chapter 3). Viruses of public health significance were subjected to further 
examination using in-silico methods incorporating predicted protein models of the capsid 
structure and MD simulation, to determine their integrity (chapters 4 and 5). Once 
appropriately capable computational models are developed, it is postulated that they will 
assist in the development of methods to predict the effectiveness of antiviral agents 
targeting the capsid region, specifically the hydrophobic pocket, for which a number of 
drugs already exist (chapters 4 and 5). 
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2.1 Introduction 
The continuous increase in computational power, combined with remote database 
accessibility via the internet, has had a direct and measurable effect on frontline 
diagnostics and public health surveillance
289-292
. The ability to store, access and process 
large amounts of data, specifically in the form of nucleic acid and amino acid sequences, 
gives diagnostic and public health laboratories the ability to examine pathogen diversity 
at the genomic level and to design specifically targeted genetic assays, typically in the 
form of PCR methods. This power, combined with the use of modern bioinformatics 
approaches, allows sequence data derived from PCR-based assays to be analysed in the 
context of a broader range of sequences available in the public domain, via databases 
such as GenBank (refer to section 1.2.5).  
 
The introduction of PCR techniques into the public health laboratory repertoire has 
enabled the rapid identification of pathogens of all descriptions from all sites of the body 
and is able to provide results in timely manner, with a beneficial impact on treatment 
strategy for clinicians (refer to sections 1.2.4 and 1.2.5).  
 
The use of PCR methods is not exclusively in the domain of human diagnostic pathology. 
PCR detection methods have been successfully applied to studies of the environment, for 
example in the examination of environmental samples from sewage, as an adjunct to 
public health surveillance programs
293
. Environmental surveillance, when integrated with 
PCR methods and sequence analysis, can be a powerful tool for public surveillance and 
epidemiology through the detection of specific pathogens. Such strategies are currently 
being implemented in the Global Polio Eradication Initiative for the surveillance of wild 
poliovirus and VDPVs
184,294
. 
 
In the context of public health surveillance, the high throughput nature of PCR methods, 
particularly in the form of real-time technology, makes the technique especially amenable 
to outbreak investigation and management. 
 
A suitable example involved the importation of wild poliovirus in 2007, by a traveller 
returning to Melbourne, Australia
137,161
. The patient returned to Australia from a polio 
endemic region in Pakistan, exhibiting mild symptoms of AFP. At the time, the standard 
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procedure at the National Polio Reference Laboratory in Melbourne was to perform virus 
culture of stool samples as per the WHO recommended procedures and wild poliovirus 
was isolated after four days. Relying upon cell culture as the principal test proved to be 
problematic, in that the requirement to rapidly expand testing of samples to the traveller’s 
close and public contacts, increased the work-load in a manner that stretched the 
capability of standard cell culture methodology. In such a situation, the turnaround time 
of sample results, including negative results, is critical to the coordinated public health 
response at the state level and potential at a national level
295
. 
 
A more suitable solution would have been to employ real-time RT-PCR methodology, 
which could accommodate up to 96 samples including controls per test, with a throughput 
of up to 384 samples a day. Such a method, for the specific detection of poliovirus direct 
from clinical specimens, did not exist. 
 
Due to the conservation of RNA sequence in the 5´NTR, a method based on existing 
pan-enterovirus 5´NTR detection would be unlikely to adequately differentiate poliovirus 
from other enteroviruses. Detection of poliovirus using PCR-based methods directed at 
the hyper-variable regions of the capsid encoding sequence lack sensitivity when 
compared to standard cell culture methods, as was the case of the 2007 importation event 
with a low titre wild poliovirus
137
. 
 
As a result of this experience, the development of PCR-based methods that could be 
easily scaled up, to differentiate potential poliovirus positive samples from other 
enteroviruses whilst maintaining sensitivity in a standard laboratory workflow, were 
investigated. It was also envisaged that such a method would be of value for surveillance 
in the immediate period after wild poliovirus eradication, to screen samples for the 
presence of poliovirus or species C Enteroviruses. A PCR-based method to screen for 
poliovirus directly in clinical specimens could drastically reduce the amount of time 
required when compared with sequencing, to identify the enterovirus type. 
 
In order to increase sensitivity, and specificity, it is possible to use PCR methods using 
nested approaches, that is, the amplification of nucleic acid sequence using two rounds. 
The first round of PCR primers, flank the second round PCR inner primers. When 
combined with probes selected to target variations of the amplicon sequence, multiple 
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targets can be identified in the same sample. Such methods, termed multiplex PCR, have 
previously been used in diagnostics laboratories
108
. 
 
The application of multiplex, nested or semi-nested PCR methods with a real-time second 
round PCR has the advantage of maintaining specificity and providing a high level of 
sensitivity. Real-time PCR also permits the differentiation of amplicons that are of equal 
length but contain variations in sequence, as the detection of PCR product relies on the 
detection of specific sequence motifs rather than the amplification of templates of a 
specified length as in end-point PCR methods, refer to section 1.2.5. 
 
The introduction of real-time PCR machines with multiple channel fluorescence 
detection, such as the ABI 7500 system, permitted up to five fluorescent probes emitting 
light of different wavelengths to be used in a single test. The use of multiple fluorescent 
channels allowed the incorporation of reagents containing a known quantity of a PCR 
target such as a virus, protected nucleic acid sequence or genomic sequence that is 
ubiquitous in the samples being tested. Examples of these internal controls include equine 
rhinitis virus, glyceraldehyde 3-phosphate dehydrogenase or β2-microglobulin 296,297. 
This addressed the reporting of false negatives due to PCR inhibition. If a clinical sample 
contains PCR inhibitors, the internal control will not be amplified, flagging the sample as 
invalid. This is important in the context of enterovirus detection, given that stool samples 
and CSF samples, which are the most commonly received samples when investigating 
neurological illness, are inherently prone to inhibition. 
 
This chapter describes the development of a novel real-time PCR assay that can be used 
to differentiate between Enteroviruses belonging to species A or B from those belonging 
to species C or D, termed enterovirus super-speciation. Initial development, in the form of 
primer and probe design, was achieved using bioinformatics methods, incorporating the 
acquisition of sequence data from the public domain and analysis using multiple sequence 
alignment and phylogenetic inference, to determine areas of the enterovirus genome that 
could be exploited to produce a suitable diagnostic method for routine use in a diagnostic 
laboratory.   
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2.2  Materials and Methods 
 
2.2.1 Sample Preparation 
Upon receipt, two grams of faecal specimen were treated with Minimum Essential 
Medium containing Earle’s salts, chloroform (9.1% v/v) and foetal bovine serum (2%) in 
a final volume of 10 mL. The suspension was clarified using a refrigerated centrifuge at 
4°C and 1500 g for 20 minutes. The supernatant was removed and 200 µL inoculated 
onto a series of mammalian cell lines. The remaining supernatant was stored in a -30°C 
non-cyclic defrost freezer for subsequent use. For reagent and equipment details, refer to 
appendices A1 and A2. 
 
2.2.2 Growth of enteroviruses in cell culture 
Cell lines used for the isolation of enteroviruses were: 
 
 BGMK (buffalo green monkey kidney) 
 HEL (human embryonic lung). 
 Hep2C (human epidermoid carcinoma) 
 L20B (a transgenic mouse epithelial cell line expressing the human poliovirus 
receptor, CD155) 
 RD-A (human rhabdomyosarcoma) 
 
Cell culture media was prepared using the following ingredients (table 2.1): 
 
 Eagle MEM 
(Hanks) With  
L-Glutamine 
Heat 
Inactivated 
FBS 
NaHCO3 
(7.5%) 
1M 
HEPES 
 
Penicillin/ 
Streptomycin 
100x 
2% Growth  
Medium 
500 mL 10.5 mL 3.6 mL 5.3 mL 5.3 mL 
10% Growth 
Medium 
500 mL 57.5 mL 5.1 mL 5.7 mL 5.7 mL 
 
Table 2.1 Cell culture medium ingredients: Preparation of cell culture 10% growth media containing 
10% foetal bovine serum (FBS) and 2% maintenance media containing 2% FBS was prepared using the 
concentrations listed. 
 
Inoculated cell cultures were observed for up to 10 days for changes in monolayer 
appearance indicative of a viral CPE. The infected cells were harvested when CPE 
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involved 50 to 100% of the cell monolayer. The infected cells were then subjected to a 
freeze-thaw cycle at -30C to lyse any remaining intact cells. The tubes containing the 
infected cells were then centrifuged at 1500 g for 10 minutes and the supernatant 
separated and stored at -30
o
C in preparation for re-inoculation onto fresh cells. Upon 
observation of viral CPE, the passaged cells were harvested and stored at -30
o
C for 
further examination. 
 
2.2.3 Nucleic acid extraction 
Viral RNA was extracted using either the High Pure Viral Nucleic Acid Kit (Roche cat# 
11 858 874 001), QIAamp Viral RNA kit (QIAGEN cat# 28704), or MagMax (Life 
Technologies cat#AM1836) automated robotic extraction system using the 
manufacturer’s recommended procedures. For each RNA extraction, 50-200 µL of cell 
culture supernatant was used, depending on the system used, and a final volume of 50 µL 
was collected. For reagent and equipment details, refer to appendices A1 and A2 
 
2.2.4 Preparation of Control Material 
Sabin poliovirus controls for each serotype were obtained from the National Institute for 
Biological Standards and Control in the United Kingdom. Virus stocks for EV-A71 
sub-genogroup B5 were obtained from my son, William Roberts, during the course of an 
acute infection, and then propagated in RD cell lines.  
 
The determination of virus titre was performed as follows: Serial dilutions of control 
material was performed by dispensing 900 µL of 2% maintenance medium to 6 tubes and 
4.95 mL medium to an additional 4 tubes. Virus control material was thawed rapidly and 
100 µL of the virus solution added to the first tube containing 900 µL of medium and 
mixed. This tube represented working stock solution at a 10 
-1
 dilution. Subsequent 
dilutions were made from this stock solution to a final dilution of 10 
-10
. The titrated virus 
preparations were added to a microtitre plate with rows A-H and columns 1-12. 100 µL of 
2% maintenance medium was added to wells A11 to H12, representing  negative cell 
controls and 100 µL of virus dilutions from 10 
-7
 to 10 
-10
 were added to wells  in rows A 
to H using 20 wells per virus dilution. For EV-A71 the dilution series was made 
representing 10 
-5
 to 10 
-9
. 
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Once the titrated virus and negative control solutions were added to the mirotitre plate, 
100 µL cell suspension containing 1.5 x 10 
5
 cells / mL were added to all wells. The plate 
was then covered with a non-toxic sealer and incubated at 36°C. The plates were 
examined for development of CPE, using an inverted microscope at 5 and 7 days. At the 
7
th
 day reading, virus titre was calculated using the Kärber formula and recorded. 
 
Negative controls consisted of nuclease free water or 2% growth medium. The inclusion 
of an internal control to account for PCR inhibition was vital and bovine viral diarrhoea 
virus (BVDV), which has a single-stranded positive sense RNA genome, was included in 
the RT-PCR amplification steps. The BVDV RNA and initial guidance for primer design 
were provided by Dr Julian Druce of the Viral Identification Laboratory, VIDRL. The 
BVDV control material was originally obtained from the Elizabeth MacArthur Institute, 
NSW. 
 
 
2.2.5 Super Speciation Pan-enterovirus Reverse Transcription Polymerase Chain 
Reaction. 
 
The potential inhibition of PCR products due to substances found in template material is a 
significant issue. In addition to the detection and differentiation between members of the 
A/B and C/D Enterovirus species (super-speciation), the assay also accounted for the 
presence of inhibitory substances via the use of BVDV as an internal control. The PCR 
primers and probes for the enterovirus super-speciation assays are listed in table 2.2 and 
the internal control primers and probes for the detection of PCR inhibition are listed in 
table 2.3. 
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Name Oligonucleotide Sequence 5′ to 3′ Position1 
EV1F (Sense) CAAGCACTTCTGTTTCCCCGG 162-182 
EV2F (Sense) TCCTCCGGCCCCTGAATGCG 443-462 
EV3R (Anti-sense) ATTGTCACCATAAGCAGCCA 596-577 
EV probe FAM-AACCGACTACTTTGGGTGTCCGTGTTTC-BHQ1 535-562 
EV-AB probe CR610-ACTCYGCAGCGGAACCGACTACT-BHQ2 523-545 
EV-CD probe FAM-AGTCYGTGGCGGAACCGACTACT-BHQ1 523-545 
 
Table 2.2 Primer sequences for EV Semi-nested Super-speciation PCR. 
1
 position relative to poliovirus 
1 Mahoney, Genbank accession number V01150. 
 
Name Oligonucleotide Sequence 5′ to 3′ Position1 
BVDV85for (Sense) CGAAGGCCGAAAAGAGGCTAGC 85-107 
BVDV390rev (Anti-sense) TCCATGTGCCATGTACAGCAGAG 369-391 
BVDV107for (Sense) CATGCCCTTAGTAGGACTAGCA 107-129 
BVDV246rev (Anti-sense) CCTCGTCCACGTGGCATCTC 231-250 
BVDV probe CO560-AGTACAGGGTAGTCGTCAGTGGTTCGA-BHQ1 181-207 
 
Table 2.3: Inhibition control primer sequences for EV Super-speciation assay. 
1 
Position relative to 
bovine viral diarrhoea virus 2 (BVDV) genome Genbank Accession Number KC963968 
 
Preparation of the round 1 EV Super-speciation snrRT-PCR primer mix was as follows. 
EV1 primer (50 µM)   20.0 L 
EV3 primer (50 µM)   20.0 L 
Nuclease Free Water   60.0 L 
Total (40 reactions)   100 L 
 
Inhibition control primer mix (BVDV) 
BVDV-85for primer (50µM)  20.0 L 
BVDV-390rev primer (50 µM)  20.0 L 
Nuclease Free Water   60.0 L 
Total (66 reactions)   100 L  
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10 µL of template RNA was added to a master mix containing 2X SuperScript™ III 
reaction mix, 0.4 µM each of primers EV1F and EV3R and 0.2 µM of BVDV-85for and 
BVDV-390rev, 2 µL SuperScript™ III RT/ Platinum® Taq Mix, 20 units Roche 
Protector RNAse inhibitor and nuclease free water to a final volume of 50 µL. 
Amplification was performed on an Applied Biosystems Verti thermocycler under the 
following amplification conditions: 45°C for 30 minutes then 94°C for 2 minutes 
followed by 35 cycles of 94°C for 15 seconds, 57°C for 45 seconds, 68°C for 60 seconds 
and a final extension at 68°C for 5 minutes. For reagent and equipment details, refer to 
appendices A1 and A2 
 
Preparation of the round 2 EV Super-speciation snrRT-PCR 20x TaqMan probe/primer 
mix was as follows. 
 
EV2 primer (50M)   20.0 L 
EV3 primer (50M)   20.0 L 
EV-AB Probe CO560 (20M)  25.0 L 
EV-CD Probe FAM (20M)  25.0 L 
Nuclease Free Water   3.0 L 
Total (80 reactions)   100 L 
 
Inhibition control primer/probe mix (BVDV) 
BVDV-107for primer (50M)  18.0 L 
BVDV-246rev primer (50M)  18.0 L 
BVDV Probe TAMRA (20M)  12.5 L 
Nuclease Free Water   1.5 L 
Total (62 reactions)   50 L 
 
1 µL of first round product was added to a master mix containing 2X TaqMan Fast 
Universal PCR master mix with no UNG, 1.25 µL of EV 20x Taqman Probe/primer mix, 
0.8 µL of BVDV 20x Taqman probe/primer mix and nuclease free water to a final 
volume of 25 µL. Amplification was performed on an Applied Biosystems 7500FAST 
real time thermocycler under the following FAST amplification conditions: 95°C for 
10 minutes followed by 45 cycles of 95°C for 15 seconds and 60°C for 60 seconds.  
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2.3  Results 
 
2.3.1 Novel Super-Speciation Semi-Nested Real-Time RT-PCR Assay 
5´NTR sequences from 276 members of the genus Enterovirus were obtained from the 
GenBank via the NCBI website
298
 and aligned to examine areas of conservation across 
members of the genus. Once aligned, the primer locations for EV2 and EV3 within the 
5´NTR used in a previously described generic PanEV snRT-PCR
65,108
 were identified and 
the sequence was cropped to the outer primer boundaries. After cropping the sequence 
alignment, a neighbour-joining tree was created using the Kimura-2-parameter method 
(Figure 2.1). The resultant tree displayed a clear demarcation of three clades representing 
Enterovirus species A and B, Enterovirus species C and D and HRV species A, B and C. 
 
 
 
Figure 2.1 Phylogenetic analysis of members of the genus Enterovirus based on 5´NTR sequence. 
Radial representation of 276 members of the genus Enterovirus, specifically EV A, B, C, D and HRV A, B, 
C. Partial 5´NTR fragment analysis (115bp). Clustal-W alignment, DNA distance algorithm with 
neighbour-joining, bootstrap analysis performed with 1000 psuedoreplicates, Phylip phylogenetic analysis 
package version 3.63. Scale bar indicates nucleotide substitutions per site.  
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The 5´NTR sequences were aligned by Enterovirus species, to identify sequence variation 
in the interior fragment of the pan-enterovirus RT-PCR amplicon. A region of interest 
was noted between the inner primers EV2 and EV3, upstream of the previous 
pan-enterovirus EV probe location (Table 2.2). This region was conserved between 
members of the EV A/B, C/D and HRV A/B/C species. A probe was designed with 
sequence complementarity to the EV A/B species and another to the EV C/D species 
(Figure 2.2). The probes were initially verified as specific for their respective Enterovirus 
genus species, by performing a BLAST search and examining whether the “expected 
value” correlated with listed members of the species for which the probe was designed. 
A clearly observable division in sequence similarity was present in the BLAST search 
results, differentiating the species A/B and C/D probes, with no apparent cross-reactivity 
with rhinoviruses. 
 
 
 
Figure 2.2 Sequence alignment indicating primer and probe binding locations. Multiple sequence 
alignment of representatives from each species of the Enterovirus genus. A fragment representing the 
amplicon from the newly designed EV super-speciation snRT-PCR method is shown. Pink – forward 
primer EV2, green – fluorescent probe location, blue – reverse primer EV3. 
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Two probes were synthesised with different colour fluorophores; EV C/D was paired with 
a 5´ FAM fluorophore and a 3´ BHQ1 quencher molecule whilst the EV A/B probe was 
synthesised with a 5´CO560 fluorophore and a BHQ1 quencher. The EV A/B probe was 
also synthesised using a 5´CR610 fluorophore as an alternative if problems were 
encountered with the channel selection and choice of quencher, such as cross-reactivity 
between the FAM and CO560 fluorophores.  
 
The super speciation enterovirus A/B and C/D probes were used in replacement of the 
generic PanEV probe (EV probe in table 2.2). The assay was developed with the BVDV 
probe containing TAMRA and BHQ2 and an internal reagent control of unbound ROX 
dye that was provided by the manufacturer. 
 
The EV super-speciation snRT-PCR assay was tested using known positive samples 
derived from a series of clinical samples with available VP1 sequence data that 
incorporated the antigenic BC loop region. The specificity of the assay was also tested 
with a series of samples that were determined as negative for enterovirus by virus culture 
and/or in-house PanEV snrRT-PCR used in the Enterovirus Reference Laboratory at 
VIDRL (Table 2.4). All developmental testing was performed in parallel with the above 
mentioned in-house PanEV snrRT-PCR, originally based on primers by Zoll et al., 
(1994)
105
. The assay had undergone rigorous examination of cross reactivity with a 
number of other viral pathogens, including adenovirus, HSV, VZV CMV among 
others
65,105,108
. For this reason, the super-speciation assay was only tested for specificity 
with members of the Enterovirus genus. 
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Enterovirus 
Species EV Type No. EV-A/B EV-C/D 
Enterovirus A 
(n=5) 
 
CV-A12 1 1 0 
EV-A71 4 4 0 
Enterovirus B 
(n=13) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CV-B1 1 1 0 
CV-B2 1 1 0 
CV-B4 1 1 0 
CV-B5 1 1 0 
E-6 2 2 0 
E-9 1 1 0 
E-15 1 1 0 
E-21 2 2 0 
E-25 1 1 0 
E-30 1 1 0 
E-33 1 1 0 
Enterovirus C 
(n=10) 
 
 
 
 
 
CV-A20 2 0 2 
EV-C96 5 0 5 
PV1 SL 1 0 1 
PV2 SL 1 0 1 
PV3 SL 1 0 1 
EV-A/B 
(n=18) 
 
5´NTR 
Sequencing 
18 18 0 
Rhinovirus 
(n=1) 
Untyped 1 0 0 
Negative for 
Enterovirus 
(n=24) 
PCR or 
Culture 
24 0 0 
Total  71   
 
Table 2.4 Enterovirus types tested using EV Super-speciation snrRT-PCR. Members of the genus 
Enterovirus used in the examination of specificity of the EV super-speciation snRT-PCR assay determined 
by sequence of the VP1 genomic region or 5´NTR, negative controls represented by samples with no 
enterovirus detected  by either virus culture or in-house pan-EV snrRT-PCR. 
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Limits of detection for the EV super-speciation snrRT-PCR assay were determined using 
serial dilutions of types 1, 2 and 3 Sabin-like poliovirus and EV-A71 subgenogroup B5 
control material, with dilutions from 10
-3
 to 10
-8
 depending on the virus titre (Figure 2.3). 
Limits of detection for the individual serotypes were: PV1SL 1.3 log CCID50, PV2SL 
1.0 log CCID50, PV3SL 1.9 log CCID50 and for EV-A71 0.9 log CCID50. 
 
 
 
Figure 2.3 EV Super-speciation snrRT-PCR results for serial dilutions of control material. A) 
Logarithmic representation of fluorescent signal increase for species A/B probe for a serial dilution of 
EV-A71 control material from 10
-3
 to 10
-7
 using CR610-labelled EV A/B probe B) Logarithmic 
representation of fluorescent signal increase for species C/D probe for a serial dilution of PV1, PV2 and 
PV3 Sabin-like control material from 10
-4
 to 10
-8
 FAM labelled EV-CD probe. x- axis = cycle number, y- 
axis = ΔRn (fluorescence) 
 
Enterovirus specificity was examined using five members of the species A Enteroviruses, 
13 of species B, 10 of species C and one rhinovirus. An additional 18 enteroviruses that 
could not be typed by amplification of the VP1 region due to low template, were 
examined. These viruses were determined by sequencing of the 5´NTR to be members of 
either the species A or B Enteroviruses when compared to prototype sequences and 
BLAST search of public sequence databases. An additional 24 clinical samples that were 
PCR negative using the standard in-house pan-EV snRT-PCR method were included and 
none were positive in the EV super speciation snrRT-PCR assay. All known enterovirus 
samples tested had a direct correlation with the expected EV species-specific probe. All 
members of Enterovirus species A, B and C were correctly identified, during the initial 
assessment process. Only a single rhinovirus was tested for cross-reactivity. This 
particular sample had provided a false positive result in the standard in-house 
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PanEV snrRT-PCR assay, and was not detected in the new super speciation assay 
(table 2.4). The internal BVDV control was detected in all cases.  As expected, there was 
evidence of BVDV signal inhibition for strongly positive enterovirus samples, indicating 
preferential amplification of target enterovirus sequence over that of the internal control 
as the amount of BVDV template added to the PCR mixture was designed to be limited. 
 
 
2.3.2 Novel Super-Speciation One-Step Real-Time PCR Assay 
The use of nested PCR assays is not ideal due to the extra costs in labour and reagents, 
but more importantly, the potential for cross contamination during the transfer of PCR 
product from the first to second round. A one step method was attempted using the 
Superscript III reagent (Life Technologies), but the limits of detection indicated the assay 
was unsuitable, with poliovirus type 1 at 2.3 log CCID50 and EV-A71 at 1.9 log CCID50 
compared to 1.3 log CCID50 and 0.9 log CCID50, respectively, with the semi-nested 
version. A new one step real-time RT-PCR kit became available (AgPath-ID, Life 
Technologies) that proved to have highly sensitive limits of detection. To determine the 
limits of detection with the AgPath,-ID reagent, types 1, 2 and 3 Sabin-like poliovirus and 
EV-A71 subgenogroup B5 were diluted from 10
-3
 to 10
-8
 (Figure 2.4). 
Limits of detection were as follows: PV1SL 0.3 log CCID50, PV2SL 1.0 log CCID50, 
PV3SL 0.95 log CCID50 and for EV-A71 -0.1 log CCID50. 
 
 
Figure 2.4 One-Step EV Super-Speciation qRT-PCR results for serial dilutions of control material. 
A) CR610-labelled EV A/B and B) FAM labelled EV-CD probes. EV-A71 (B5) control material 1:10 
dilutions from 6.9 to 0.9 log CCID50, PV1SL control material 1:10 dilutions from 8.3 to 2.3 log CCID50. x- 
axis = cycle number, y- axis = ΔRn (fluorescence) 
 
 
Enterovirus specificity was examined using 5 members of the Enterovirus species A, 13 
Enterovirus species B, 15 Enterovirus species C (including 6 wild type polioviruses from 
an Australian outbreak in the 1950s), 1 enterovirus species D and 6 members of the 
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species A and C rhinovirus. Among all samples tested, there was a direct correlation with 
Enterovirus species identity by sequence. All members of Enterovirus species A, B, C 
and D were correctly identified. One of six rhinoviruses that had previously tested 
positive with the standard in-house panEV snrRT-PCR was positive with the 
EV super-speciation qRT-PCR A/B probe assay, representing an 83.3% reduction in 
cross-reactivity (Table 2.5). An additional 15 samples that were RT-PCR negative using 
the standard in-house panEV snrRT-PCR method were included and none were positive 
with the assay. 
 
 
Species 
EV Super-Speciation qRT-PCR 
 EV-A/B Positive 
EV Super-Speciation qRT-PCR 
 EV-C/D Positive 
Enterovirus A (n=5) 5 0 
Enterovirus B (n= 13) 12* 1
§
 
Enterovirus C (n=15) 0 15 
Enterovirus D (n=1) 0 1 
Rhinovirus (n=6) 1
φ
 0 
Negative (n=15) 0 0 
 
Table 2.5 Enterovirus types tested using EV Super-speciation qRT-PCR. Members of the genus 
Enterovirus used in the examination of specificity of the EV super-speciation qRT-PCR assay determined 
by sequence of the VP1 genomic region or 5´NTR, negative controls represented by samples with no 
enterovirus detected  by either virus culture or pan-EV snrRT-PCR. 55 samples tested: Enterovirus 
Species A - CV-A10, EV-A71 (3), EV-A120, Enterovirus Species B - CV-B1, CV-B5, E-6, E-7, E-11, 
E-18, E-19(2), E-25, E-30, E-33(2), EV-B74, Enterovirus Species C - EV-C96(4), EV-C99, PV1Wild(4), 
PV1 Sabin-like, PV2 Wild, PV2 Sabin-like, PV3 Wild(2), PV3 Sabin-like, Enterovirus Species D – 
EV-D68. 
*One very low titre E-25 positive faecal sample tested negative. 
§
EV74 positive faecal sample tested positive for species A/B and C/D Enterovirus. Further testing of this 
sample using cell culture techniques indicated a mixed infection. 
φ
 Rhinovirus A49 sequenced using CODEHOP primers. 
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An alternative version of the EV-SS qRT-PCR was examined using FAM as the 
fluorophore for both EV A/B and EV C/D probes, to create a generic “PanEV qRT-PCR”.  
Specificity of the PanEV qRT-PCR was examined using 8 members of the Enterovirus 
species A, 13 Enterovirus species B, 15 Enterovirus species C, 1 Enterovirus species D 
and 6 members of the species A and C Rhinovirus. An additional 28 samples that were 
PCR negative using the standard in-house panEV snrRT-PCR method were included and 
none were positive with the assay. Among all samples tested, there was a direct 
correlation with the Enterovirus species identified by VP1 sequence (Table 2.6). 
 
Species Pan EV qRT-PCR Positive 
Enterovirus A (n=8) 8 
Enterovirus B (n= 13) 12* 
Enterovirus C (n=15) 15 
Enterovirus D (n=1) 1 
Rhinovirus (n=6) 1
 φ
 
Negative (n=28) 0 
 
Table 2.6 Enterovirus types tested using PanEV qRT-PCR. Members of the genus Enterovirus used in 
the examination of specificity of the EV PanEV qRT-PCR assay determined by sequence of the VP1 
genomic region (or 5´NTR for rhinovirus), negative controls represented by samples with no enterovirus 
detected  by either virus culture or pan-EV snrRT-PCR. 71 samples tested. Enterovirus Species A – 
CV-A5, CV-A6, CV-A10, CV-A16, EV-A71 (3), EV-A120, Enterovirus Species B - CV-A9, CV-B1, 
CV-B2, CV-B3, CV-B5, E-6, E-7, E-9, E-11, E-14, E-18, E-19(2), E-25, E-30, E-33(2), EV-B74, 
Enterovirus Species C - EV-C96(4), EV-C99, PV1Wild(4), PV1 Sabin Like, PV2 Wild, PV2 Sabin Like, 
PV3 Wild(2), PV3 Sabin Like, Enterovirus Species D - EV-D68. 
*One very low titre E-25 positive faecal sample negative. 
φ
 Rhinovirus A49 sequenced using CODEHOP primers. 
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The limits of detection for the newly described assays were determined using the 
quantitated in-house quality controls, EV-A71 and Sabin-like polioviruses type 1, 2 and 
3. (Table 2.7). 
 
Assay Log 
CCID50 /mL 
Infectious 
Particles/ mL 
PanEV snRT-PCR (Old method) 0.95 8.9 
EV-SS snrRT-PCR   
 EV-A71 (B5) -0.10 0.8 
 PV Sabin-like 1.00 10 
EV-SS qRT-PCR   
 EV-A71 (B5) -0.10 0.8 
 PV Sabin-like 0.09 1.2 
PanEV qRT-PCR   
 EV-A71 (B5) -0.10 0.8 
 PV Sabin-like 0.09 1.2 
 
Table 2.7. Limit of Detection Results for EV RT-PCR Assays. Limits of detection expressed as log 
CCID50 /mL and Infectious particles /mL, calculated using serial dilutions of control virus solutions. Assay 
abbreviations are as follows: In-house panEV snRT-PCR =  PanEV snrRT-PCR, EV Super-speciation 
semi-nested real-time RT-PCR = EV-SS snrRT-PCR, EV Super-speciation one-step real-time RT-PCR = 
EV-SS qRT-PCR, PanEV one-step real-time RT-PCR = PanEV qRT-PCR. 
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2.4 Discussion 
The ability to perform rapid testing on clinical samples and isolates is a strength of PCR 
technology and in particular, real-time PCR methods. The method is arguably less 
sensitive than cell culture, due in part to the high specificity of primer/probe sequences, 
which means that any significant divergence from the enterovirus target annealing 
sequence compared to the oligonucleotide sequence may result in false negative results, 
due to non-amplification of target sequence. This is not necessarily true for culture 
methods, with the most commonly used cell lines able to grow a broad range of 
enteroviruses. The limitations of cell culture include the time required to report the 
results, the laborious nature of the method, restrictions on rapidly scaling up the 
procedure and the fact that a number of Enterovirus species, such as coxsackievirus A1, 
are only cultivable in suckling mice. In addition, the cell tropism is unknown for the more 
than 40 new enterovirus types that were classified based on their nucleic acid sequence. 
 
It is for these reasons that although more prone to the pitfalls of specificity, RT-PCR 
methods are preferred for the rapid identification of enterovirus infection in humans. The 
EV super-speciation qRT-PCR method described in this chapter is a sensitive assay that 
can be scaled up to accommodate hundreds of specimens, with the advantage of being 
able to differentiate Enterovirus C/D species from Enterovirus A/B species. In Australia 
species A/B Enteroviruses are more frequently encountered in clinical specimens from 
cases of AFP (refer to chapter 3).  
 
The importance of discriminating between Enterovirus species becomes evident when 
considering the potential importation of poliovirus (a species C Enterovirus). As 
elaborated in the introduction, in the event of a polio importation, public health 
laboratories can quickly find themselves inundated with samples, not only from cases 
exhibiting symptoms of enterovirus infection, but also from close and secondary contacts. 
The ability to screen hundreds of samples and triage EV-C/D positive samples for priority 
characterisation by nucleic acid sequencing or cell culture is extremely useful. In 
Australia, Enterovirus species C/D were identified in 17.6% of enterovirus positive AFP 
cases between 2004 and 2013 (see Chapter 3). In Papua New Guinea and the Pacific 
Island countries, this proportion increased to 43.3% of enterovirus positive AFP cases, 
highlighting the benefit of an enterovirus RT-PCR screening assay that can also rapidly 
screen for Enterovirus species C. (refer to section 3.4).  
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For routine enterovirus surveillance and diagnostic testing, the super-speciation assay is 
appropriate for small diagnostic runs and will screen for any potential poliovirus that may 
be present in symptomatic or asymptomatic patients. This allows a public health 
laboratory to expedite the sample for further characterisation, with the potential to 
drastically reduce the time taken to notify the relevant public health authorities. 
 
The initial observation that a fragment of the 5’NTR sequence of the Enterovirus genus 
could be grouped into three major phylogenetic clusters-EV-A/B, EV-C/D and 
rhinovirus, led to the development of a highly sensitive single round pan-EV RT-PCR for 
Enterovirus species A/B and C/D. The super speciation pan-EV RT-PCR assay has a 
direct application in diagnostic virology laboratories and in particular those involved with 
the polio eradication program, who may need to rapidly and accurately screen clinical 
specimens for poliovirus. It was anticipated that the super speciation assay would also 
remove the inherent cross-reactivity with rhinoviruses that is a feature of many pan-EV 
assays. The recent reporting of rhinoviruses detected in stool specimens highlights the 
need to reduce false enterovirus positives associated with AFP cases
43,299
. While the super 
speciation assay still detected one of six rhinoviruses known to cross-react with the 
standard pan-EV RT-PCR, this represented an 83.3% increase in specificity. This 
particular rhinovirus sample is worth investigating further, as a fragment of the VP1 
genomic region was also amplified by the CODEHOP assay used to type enteroviruses. 
Further assay development may be able to remove cross-reactivity with rhinoviruses 
altogether, or it could also be indicative of the continuing evolution of the Enterovirus 
genus 
 
The flexibility of the probe configurations also allows for both the A/B and C/D probes to 
be labelled with FAM as a true pan-EV qRT-PCR, in replacement of the speciation 
method using different colour fluorophores. This generic pan-EV detection method would 
have high specificity for all species A/B and C/D Enteroviruses, as opposed to the various 
species of Rhinovirus. 
 
Having used bioinformatics methods to improve the detection and initial characterisation 
of enteroviruses in clinical samples, the next stage is to take positive samples detected 
using RT-PCR methods and determine if any specific serotype is associated with serious 
diseases such as AFP and may therefore represent a potential public health threat. This 
process is described in detail, in the next chapter. 
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3.2 Introduction 
Since the widespread adoption of PCR detection methodologies for viral diagnostic 
testing and research, the ability to obtain serotype specific sequence data has permitted 
the application of phylogenetic analysis techniques to enteroviruses of public health 
interest
27,112,115,116
. These data are particularly useful in the investigation of outbreaks and 
in the determination of enterovirus circulation on a global and national scale, as well as 
individual case-specific investigations
116
. 
 
Not all cases of AFP are due to poliovirus infection, with a number of enteroviruses such 
as CV-A7, Echo-19 and EV-A71 showing evidence of an association with the 
syndrome
42,133,134,300
. The identification of non-polio enteroviruses is also important, not 
only to exclude the presence of poliovirus, but also to delineate sporadic cases from those 
associated with epidemics
25,29,143,164
. Factors involved in determining whether or not a 
virus warrants further investigation relate to the clinical presentation of the case being 
Chapter 3: Characterisation of Enteroviruses Associated with Acute Flaccid Paralysis 
84 
investigated, the number of cases from which the virus has been identified, or the 
emergence of previously undescribed viruses detected from clinical samples. Analysis of 
retrospective sequence data, combined with contemporary sequence results, can be 
informative in determining virus transmission within Australia and the Western Pacific 
region, to assist public health authorities in identifying potential threats of communicable 
disease. 
 
Between 1993 and 2001, the NERL characterised enterovirus isolates from AFP cases by 
antibody neutralisation methods, using pooled and monotype specific antisera. From 
2001, enterovirus isolates were characterised by sequencing a fragment of the VP1 
genomic region, using single round PCR primers directed to amplify either the 5´ or 3´ 
aspects of the protein encoding sequence
112,114
. From 2009 onwards, the CODEHOP 
semi-nested RT-PCR assay was introduced, with the advantage of being specifically 
developed to detect enteroviruses directly from clinical samples as a semi-nested assay, as 
opposed to single round amplification requiring a higher titre of virus derived from cell 
culture isolates
117
. The CODEHOP PCR amplification method targets the hyper-variable 
region encoding the major antigenic determinant (VP1 BC loop) as shown in Figures 1.7 
and 1.14 of Chapter 1, section 1.2.5.  
 
This chapter describes the use of bioinformatics methods in a retrospective, systematic 
analysis of data derived from a regional surveillance system, aimed at the investigation of 
AFP in children under the age of 15. Given that AFP can indicate one of the most serious 
presentations of enterovirus infection, it is logical to examine these samples for the 
presence of enterovirus serotypes that may be associated with increased virulence and any 
associated morbidity, mortality and enhanced transmission. The identification of viruses 
displaying these traits is of interest to the public health community and would therefore 
represent strong candidates for further research including methods that examine virus 
structure, such as the in-silico reconstruction and simulation methods developed as part of 
this thesis and described in Chapter 5. 
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3.3 Materials and Methods 
 
3.3.1 Partial VP1 Sequencing of Enterovirus Positive Materials 
Enteroviruses for sequencing were derived either from culture supernatant or direct 
testing of clinical samples. RNA was extracted as described in section 2.2.3. The 
CODEHOP assay was developed by CDC USA and was performed according to the 
published protocol 
117
. The following PCR primers and cycling conditions were used to 
generate approximately a 350 base pair fragment of the VP1 region (Table 3.1): 
 
 
Table 3.1. Primers used in the “CODEHOP” assay. Primer locations based on the prototype sequence 
for Poliovirus type 1 Mahoney, GenBank accession number J02281. 
 
5.0 µL of extracted RNA template was added to a PCR amplification tube containing 
5.0 µL of cDNA mastermix: 
  
5xFS Buffer     2.0 µL  
10mM dNTP (40mM)    0.25 µL 
Nuclease free water    0.25 µL 
AN32, AN33, AN34, AN35 (10uM)  0.5 µL  
DTT 0.1M (Invitrogen #Y00147)   1.0 µL 
RNase inhibitor (Roche #03335402001)  0.5 µL 
SuperScript III RT (Invitrogen #56575)  0.5 µL 
Total      5.0 µL 
 
The tubes were placed in a thermalcycler and incubated for five minutes at 25°C, 
followed by one hour at 50°C to reverse transcribe single stranded RNA. First round PCR 
 Primer Sequence5´ to 3´ Position  
(PV-1 J02281) 
1 AN32 GTYTGCCA 3002-3009 
2 AN33 GAYTGCCA 3002-3009 
3 AN34 CCRTCRTA 3104-3111 
4 AN35 RCTYTGCCA 3002-3009 
5 SO224for GCIATGYTIGGIACICAYRT 1997-1996 
6 SO222rev CICCIGGIGGIAYRWACAT 2951-2969 
7 AN89for CCAGCACTGACAGCAGYNGARAYNGG 2602-2627 
8 AN88rev TACTGGACCACCTGGNGGNAYRWACAT 2951-2977 
9 AN232for CCAGCACTGACAGCA 2602-2616 
10 AN233rev TACTGGACCACCTGG 2963-2977 
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master mix was prepared as follows and 40 µL added to the each tube containing reverse 
transcription master mix and cDNA.  
 
Nuclease free water    23.5 µL 
10x Taq Buffer (Roche #1127138001)  5.0 µL 
(#61) SO224For (10 µM)    5.0 µL 
(#40) SO222Rev (10 µM)    5.0 µL 
10mM dNTP (40mM) (Promega #24975812) 1.0 µL 
Taq Polymerase (Roche #11418432001)  0.5 µL 
Total      40 µL 
 
First round PCR conditions consisted of 40 cycles of denaturation at 95°C for 30 seconds, 
followed by 42°C for 30 seconds annealing and a 45 second extension step at 60°C. 
Ramping rates for the transition from annealing step to extension step was programmed to 
occur at a rate of 1.5°C/sec. At the completion of cycling, samples were held indefinitely 
at a 4°C. Subsequently, 1 µL of first-round amplified product was added to the following 
master mix: 
 
2x FastStart Mix (Roche #04710444001)  25 µL 
Nuclease free water    16 µL 
(#136) AN89For (10 µM)    4.0 µL 
(#135) AN88Rev (10 µM)    4.0 µL 
Total      49 µL 
 
Second round PCR thermal cycler conditions consisted of a six minute DNA polymerase 
enzyme activation step at 95°C, followed by 40 cycles of denaturation at 95°C for 
30 seconds, annealing at 60°C for 20 seconds and a 15 second extension step at 72°C. At 
completion, the PCR products were held indefinitely at 4°C. 
 
The amplified product size and concentration was determined using an Agilent 
Bioanalyser microfluidic system that required 1 µL of PCR product or control per well of 
a Bioanalyser 7500 DNA microfluidic chip. The products were electrophoresed using a 
fluorescence-based microfluidic system, which allowed for the accurate determination of 
band sizes and concentrations. The Roche PCR product purification kit was used and 
20ng of double-stranded DNA was added to a sequencing reaction consisting of: 
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Applied Biosystems BDT v3.1   2.0 µL  
5x Buffer     3.0 µL 
Primer      1.0 µL 
Template     20 ng 
NFW for a final volume of   20 µL 
 
Sequencing reactions were assigned a unique number and forwarded to “Molecular 
Diagnostics” (formerly Applied Genetic Diagnostics) at the Centre for Translational 
Pathology, The University of Melbourne. The sequencing facility was certified to ISO 
certification standard by the Australian National Association of Testing Authorities 
(NATA). Sequencing results were received in electronic format via email before 
undergoing further analysis. 
 
3.3.2 Determination of Enterovirus Type. 
Reconstruction of contiguous sequence data was performed using the ChromasPro 
software package (Technylesium) and analysed using Bioedit version 7.0.1. A reference 
sequence database consisting of all enterovirus prototypes was constructed using data 
available from GenBank. Relevant sequences were downloaded via the National Centre 
for Biotechnology Information (NCBI) website
298
. 
 
Initial analysis involved a nucleic acid Basic Local Alignment Search Tool (BLAST) 
using the NCBI website
301
, with the top 10 hits used as an indicator of the relevant 
Enterovirus species, A to D. Subsequent analysis involved the alignment of the subject 
sequence with all prototypic members of the relevant species. Once aligned, percentage 
identity at the nucleotide level and amino acid level were calculated and an initial 
phylogenetic tree constructed using distance methods for nucleic acids and maximum 
likelihood methods for amino acid sequences. 
 
Enterovirus type was determined using established parameters for identification of a 
homologous virus when compared with prototype sequence (refer to Chapter 1, section 
1.2.5). Specifically, the criteria required for a homologous enterovirus typing required a 
sequence identity greater than 75% for nucleic acid and 88% for amino acid sequence, 
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combined with the sharing of a common ancestor or node for each phylogenetic tree 
generated for both nucleic acid and amino acid sequence. In circumstances where the 
virus sequence did not fully meet these criteria, complete VP1 sequences were amplified 
and the sequence reassessed against prototype sequences. In instances when the full VP1 
sequence still did not meet the criteria, sequences were forwarded initially to Polio and 
Picornavirus Laboratory Branch of the Centres for Disease Control and Prevention in the 
USA, which acts as a sequence repository for enterovirus identification on behalf of the 
ICTV Picornaviridae Study Group
302
. Sequence data derived from a putative novel 
enterovirus sequence was then forwarded to Dr Nick J. Knowles, Executive Committee 
member and Chair of the Picornaviridae Study Group of the ICTV. 
 
3.3.3 Sequencing of the EV-A71 Capsid Region 
Enteroviruses identified as EV-A71 were characterised by sequencing the VP1 region. 
EV-A71 viruses, identified within genogroup B5, were amplified using primers designed 
in-house (Table 3.2). For genogroup C viruses, a fragment of VP1 was amplified using 
published methods
165
 (primer and probe sequences are listed in Table 3.2). RNA was 
extracted as described in section 2.2.3 and the sequencing assays performed as per the 
manufacturer’s recommendations. 
 
 
 
Table 3.2. EV-A71 amplification and sequencing primers. Primers used for the detection and sequencing 
of EV-A7. Primer locations based on sequences for Enterovirus A71, 
a
GenBank accession number 
AM490160, 
b
GenBank accession number FJ461781. 
§ 
Denotes primers derived from Khanh, TH et al.,(2012)
165
 
¥
 Denotes primers designed “in-house”. 
 
 
  
 Primer Sequence5´ to 3´ Position 
1 EV71-VP1-634F
§
 GGAGAACACAARCARGAGAAAGA 634-657
a 
2 EV71-VP1-743R
§
 ACTAAAGGGTACTTGGACTTVGA 712-734
a
 
3 EV71-VP1-TaqMan
§
 FAM-TGATGGGCACGTTCTCAGTGCG-BHQ1 2602-2627
a
 
4 EV71-VP1-3F
§
 AGAYAGGGTGGCRGATGT 3-20
a
 
5 EV71-VP1-703R
§
 CTGAGAACGTGCCCATCA 686-703
a
 
6 EV71B5-F1
¥
 TCACCGGGTCCTTCATGGC 2042-2060
b 
7 EV71B5-F2
¥
 TCATCTGTCACCCTTGTGAT 2167-2186
b
 
8 EV71B5-R1
¥
 AGCTGACTGGATAGTGCTTTCT 3502-3523
b
 
9 EV71B5-R2
¥
 TCATTATGAGTAGCGAGGTG 3358-3377
b
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For the EV-71 genogroup C real-time RT-PCR method, the following conditions were 
used. 5 µL of extracted RNA template was added to the following master-mix. 
  
2x AgPath MasterMix Buffer    12.50 µL 
EV71-VP1-TaqMan probe/primer mix (0.12uM/0.4uM)
165
 0.60 µL 
NFW       0.60 µL 
25x RT-PCR Enzyme Mix     1.00 µL 
RNAsin       0.25 µL 
Template      10.00 µL 
Total       25.0 µL  
 
 The thermal cycler profile was 45 minutes at 45°C, followed by ten minutes at 95°C 
then, 45 cycles of denaturation at 95°C for 15 seconds, followed by an extension step of 
45 seconds at 60°C.   
 
Sequencing reactions for the EV-A71 genogroup C viruses consisted of a single round 
one-step RT-PCR. Master mix was prepared as follows with 10 µL of RNA extract.  
 
2x SSIII Reaction buffer  25.0 µL 
Nuclease Free Water  10.5 µL 
EV71-VP1-3F (10uM)  1.0 µL 
EV71-VP1-743R (10uM)  1.0 µL 
SS III Enzyme   2.0 µL 
RNAsin    0.5 µL 
Template    10 µL 
Total    50.0 µL 
 
The initial incubation consisted of 30 minutes at 50°C, followed by a polymerase 
activation step of two minutes at 94°C. The PCR amplification consisted of 40 cycles of 
denaturation at 94°C for 15 seconds, followed by 50°C for 30 seconds annealing and a 
1 minute extension step at 68°C. An amplicon “polishing” step was performed at 68°C 
for 5 minutes, after which samples were held at 4°C. 
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Viruses identified as EV-A71 genogroup B, by either the CODEHOP method or partial 
sequencing of the 5´NTR, were amplified using the following methods. Sequencing 
reactions for the EV-A71 genogroup B viruses consisted of a nested RT-PCR. A master 
mix was prepared as follows, to which 10 µL of RNA extract was added. 
 
2x SSIII Reaction buffer  25.0 µL 
Nuclease Free Water  7.5 µL 
EV71B5-F1 (10uM)  2.5 µL 
EV71B5-R1 (10uM)  2.5 µL 
SS III Enzyme   2.0 µL 
RNAsin    0.5 µL 
Template    10 µL 
 
The reverse transcription step consisted of 30 minutes at 42°C, followed by a polymerase 
activation step of 3 minutes at 94°C. PCR amplification consisted of 35 cycles of 
denaturation at 94°C for 30 seconds, followed by 50°C for 45 seconds annealing and a 
1 minute extension step at 65°C. At completion the samples were held at 4°C. 
 
2 µL of the first-round amplified product was added to the second round master mix: 
 
2x Roche FastStart  25.0 µL 
Nuclease Free Water  21.0 µL 
EV71B5-F2 (10uM)  1.0 µL 
EV71B5-R2 (10uM)  1.0 µL 
Template    2 µL 
Total    50.0 µL 
 
The second round PCR amplification conditions were: 2 minutes of enzyme activation at 
94°C, followed by 35 cycles of denaturation at 94°C for 30 seconds, 50°C for 30 seconds 
annealing and a 1:30 minute extension step at 72°C. An amplicon “polishing” step was 
performed at 72°C for 5 minutes and samples were held at 4°C. 
 
The Agilent Bioanalyser microfluidic system was used to determine the PCR amplified 
product size and concentration. Products were purified and sequenced as described in 
section 3.3.1.   
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3.3.4 Sequencing of Newly Described and Novel Virus Capsid Region. 
In order to increase the sensitivity of the methods being used to obtain clean amplicons 
for sequencing a putative novel enterovirus, a semi-nested method was employed. 
Forward and reverse primers (Novel_EVA-VP1for, Novel_EVA-VP1rev, listed as 
primers 3 and 4 in Table 3.3), were designed from the sequence derived from a fragment 
of VP1 using the CODEHOP fragment primers, which indicated the virus to be a member 
of species A. An initial amplification was performed using a single round RT-PCR, with 
primers (PanEV1_OS, No. 1 Table 3.3) and (Novel_EVA_2Crev, No. 5 Table 3.3). 2 µL 
of the RT PCR assay was added to 2 separate PCR reactions, with the first involving the 
forward primer (EV2_IS, No. 4 Table 3.3) from the 5´NTR and the reverse primer 
(Novel_EVA-VP1rev, No. 3 Table 3.3) designed from the CODEHOP sequence data. 
The second reaction involved using the forward primer (Novel_EVA-VP1for, No. 4 
Table 3.3) derived from the CODEHOP sequence data, with the reverse primer 
(Novel_EVA_2Crev, No. 5 Table 3.3) previously designed from the 2C NTPase 
consensus data, as highlighted in the multiple sequence alignment in Figure 3.1. This 
semi-nested RT PCR approach resulted in two fragments 1.8kb and 2.0kb in length that 
overlapped with the original fragment derived by the CODEHOP method. 
 
 
Table 3.3. Primers used in sequencing of the novel virus EV-A120. Primer locations based on the 
prototype sequence for Coxsackievirus A16 GenBank accession number U05876, (coloured positions refer 
to the colouring depicted in Figure 3.1). 
 
 Primer Sequence5´ to 3´ Position  
(CV-A16 U05876) 
1 PanEV1_OS CAAGCACTTCTGTTTCCCCGG 164-184 (A) 
2 PanEV2_IS TCCTCCGGCCCCTGAATGCG 446-465 (B) 
3 Novel_EVA_VP1rev TCCCCATTTGGAGTAGTAGC 2863-2882 (C) 
4 Novel_EVA_VP1for GGGCTTGTGGGAGTTATAGA 2707-2726 (C) 
5 Novel_EVA_2Crev GTGTTTGCTCTTGAACTGCATGTA 4414-4437 (D) 
6 EV-A120_4235for AAATTATACCAGCAGCCAAAGA 4235-4256 
7 EV-A120_3540rev GTGCTTCCTTTTAGAATTGCAG 3519-3540 
8 EV-A120_3450for AGTTTCCTCTACCACTGCTCAA 3450-3471 
9 EV-A120_2040rev GTAATAACGGCACAATTGACCT 2019-2040 
10 EV-A120_1930for ATACCGGTTAAAGTGCAAACAT 1930-1951 
11 EV-A120_1360rev ATACAGTGCCCAGCACATATTC 1339-1360 
12 EV-A120_1265for ATTTTGCATCCACGTTCAGT 1265-1284 
Chapter 3: Characterisation of Enteroviruses Associated with Acute Flaccid Paralysis 
92 
 
Figure 3.1 Schematic diagram of aligned enterovirus genomes of four prototype species A 
Enteroviruses CV-A7, CV-A14, CV-A16 and EV-A71, closely related to EV-A120. Black bars indicate 
areas of 100% identity across all four prototypes. A) forward primer EV1, B) forward primer EV2, C) 
forward and reverse primers derived from the CODEHOP fragment and D) consensus reverse primer from 
the 2C NTPase region. Colour scale: Red – 5´NTR, Orange – P1 (capsid encoding region), Green – P2 
(non-structural protein encoding region). 
 
The primers used for PCR amplification were also employed to sequence the respective 
fragments. Subsequent primers were designed using a primer walking methodology as 
sequence data were progressively obtained. The final contiguous fragment was 3.7k base 
pairs in length and incorporated a fragment of the 5´NTR, the entire P1 capsid encoding 
region and part of the P2 non-structural region including the entire 2A and 2B regions and 
partial sequence of the 2C region. The location of the primers used for PCR amplification 
and sequence analysis of the novel enterovirus are depicted in Figure 3.1 and are listed in 
table 3.3 (see also Appendix A4). Once these methods proved successful, the same 
process was applied to the design of primers for the amplification of sequence 
representing the capsid encoding region of EV-C96 viruses (refer to appendix A4). 
 
3.3.5 Phylogenetic Analysis of Enteroviruses 
Phylogenetic analysis of enteroviruses was performed using the MEGA 5.2 software 
package 
50
. Sequence alignments were created using the query sequence combined with 
prototypes representing historical and relevant contemporary sequences for comparison. 
The respective sequences were either derived from the GenBank repository using the 
National Centre for Biotechnology Information (NCBI) website interface
298
, or from 
members of the Enterovirus Reference Laboratory Network of Australia, or from 
sequences contained within the database held by Enterovirus Reference Laboratory of 
Australia. 
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Raw sequence data were trimmed at the nucleic acid level, in order to ensure that 
sequences were in-frame before analysis. Sequences were aligned using the MUSCLE 
algorithm from within the MEGA 5.2 software interface. Model testing was performed 
for each sequence alignment and the appropriate algorithm was selected on the basis of 
the lowest log odds score combined with the smallest number of parameters required 
50
. 
 
Once an appropriate algorithmic model was determined, phylogenetic inference was 
performed using the selected model combined with 1000 bootstrap psuedoreplicates. In 
the case of Bayesian analysis, 10,000,000 states were initially performed using the 
BEAST software package combined with the BEAGLE GPU extension. Effective 
sampling size (ESS) was determined for all parameters and in instances where the ESS 
was below 300, the analysis was increased to 30,000,000 states. Trees were examined 
using FigTree version 1.3.1 and for Bayesian phylogeography, the program SPREAD
303
 
was used to map the global distribution in a format compatible with Google earth .kml 
file extension 
129
. 
 
The ancestry of a virus was determined by using phylogenetic methods. Related viruses 
were selected from prototype sequence data for comparative analysis, in order to 
determine if any recombination events had occurred. This was done using the program 
Simplot
304
, which allowed for a visual representation of sequence identity at the nucleic 
acid level for the length of each sequence, termed a Simplot
305
. Subsequent analysis of 
multiple aligned sequences using this program allowed the inference of ancestral 
relationships to multiregional aspects of the sequence data, identifying regions of 
homology between virus species. In this particular instance, complete capsid sequence 
data representing the query sequence (EV-A120) and all available members of the species 
A Enteroviruses that affect humans were analysed using a 200 base pair window, which 
was then frame shifted by 20 base pairs, with each window being subjected to analysis 
using the Kimura-2-parameter model with 100 bootstrap psuedoreplicates. 
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3.4 Results 
 
3.4.1 Typing of Enteroviruses Associated with Acute Flaccid Paralysis 
As part of ongoing AFP surveillance in the WHO Western Pacific region, analysis of 594 
acute flaccid paralysis cases from Australia, Papua New Guinea (PNG) and the Pacific 
Island countries (PIC) was undertaken for the period 2004 to 2013. Prior to 2009, 
enterovirus positive samples were detected only by cell culture methods, with 
characterisation performed using sequencing methods targeted towards a fragment of the 
VP1 genomic region. In 2009, a semi-nested pan EV RT-PCR system was introduced and 
samples were tested in parallel with cell culture methods (refer to section 2.3.1). 
 
Of the 594 acute flaccid paralysis cases investigated, 109 tested positive for enterovirus 
by RT-PCR (table 3.4), this represents an enterovirus identification rate of 18% from AFP 
cases, a figure that is within the expected range of 5-25%, defined by WHO 
306
. Of all 
cases of AFP examined from Australia, PNG and the PIC, the dominant virus identified 
was EV-A71, with 10 cases representing 9.2% of all enterovirus positive cases and 1 in 
59 AFP cases (1.68%). This virus was only identified in Australia. This was followed by 
EV-C96 with 8 cases, representing 7.3% of enterovirus positive cases and 1 in 74 AFP 
cases (1.35%), detected in the PIC and PNG, but not Australia. In Australia, 11.1% of the 
342 AFP cases investigated yielded an enterovirus, while in the PIC, enteroviruses were 
identified from 24.5 % of 102 AFP cases and 30.6% of 150 cases were positive for 
enterovirus in PNG (Table 3.4). 
 
In terms of Australian AFP cases investigated during this period, EV-A71 was by far the 
most predominant virus identified representing 10 of 38 (26.3%) enterovirus positive 
cases and 10 of 342 AFP cases (2.92%). In the PIC, CV-A24 was the most commonly 
identified enterovirus at 4 of 25 (16.0%) enterovirus positive cases and 4 of 102 AFP 
cases (3.92%). In PNG the most commonly identified enterovirus associated with AFP 
was EV-C96 representing 6 of 46 (13.0)% of enterovirus positive cases or 6 in 150 
(4.0%) total AFP cases, (Table 3.5). In addition, three Rhinoviruses were identified in 
samples received from AFP cases.  
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Enterovirus 
Type 
Australia Enterovirus 
Type 
PIC Enterovirus 
Type 
PNG 
EV Negative 304 EV Negative 77 EV Negative 104 
EV-A71 10 CV-A24 4 EV-C96 5 
CV-A4 3 E-6 3 EV-C96+E-15 1 
CV-B5 3 EV-C96 2 CV-A13 4 
PV3-SL 2 CV-A13 2 CV-A24 3 
E-11 2 CV-B3 2 CV-A2 2 
E-30 2 E-1 2 CV-A20 2 
Rhinovirus 2 EV-B88 2 E-11 2 
CV-A10 1 E-11 1 E-13 2 
CV-A16 1 E-14 1 E-21 2 
CV-A24 1 E-25 1 EV-C99 2 
CV-A7 1 E-7 1 EV-A120 1 
CV-B2 1 EV-D68 1 CV-A1 1 
CV-B3 1 EV-B74 1 CV-A12 1 
E-18 1 EV-B75 1 CV-A4 1 
E-19 1 EV-C99 1 CV-A5 1 
E-25 1    CV-A6 1 
E-3 1    CV-B1 1 
E-7 1    CV-B2 1 
EV-D68 1    E-1 1 
PV1-SL+PV2-SL 1    E-13+EV-B74 1 
PV1-wild* 1    E-17 1 
     E-19 1 
     E-25+E11 1 
     E-27 1 
     E-6 1 
     EV-B74 1 
     EV-B76 1 
      EV-B97 1 
      PV3-SL 1 
      PV3-SL+E-3 1 
      Rhinovirus 1 
Total Cases 342 Total Cases 102 Total Cases 150 
EV Detected 
38 
(11.1%) 
EV Detected 
25 
(24.5%) 
EV Detected 
46  
(30.6%) 
 
Table 3.4: Breakdown of enteroviruses identified by country, a total of 594 AFP cases were investigated 
during the period 2004 to 2013 with a total of 109 positive enteroviruses (18.4%) identified from the 
Western Pacific Region. CV-A= Coxsackievirus A, CV-B= Coxsackievirus B, E= Echovirus, EV= 
Enterovirus, PV= Poliovirus, SL= Sabin-like. *2007 PV1-wild case detected in a person over the age of 15 
years (as described in section 2.1)
137,161,295
. Australian AFP cases and related reporting activity are available 
via the Commonwealth Government’s, Department of Health publication: Communicable Diseases 
Intelligence
307-314
.  
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EV Type EV Species Total (Percent of 109 EV’S) 
EV-A71 A 10 (9.2%) 
EV-C96 C 8 (7.3%) 
CV-A24 C 8 (7.3%) 
CV-A13 C 6 (5.5%) 
E-11 B 6 (5.5%) 
Total  38 (34.9%) 
 
Table 3.5 Top 5 enteroviruses identified from cases of acute flaccid paralysis. The five most frequently 
identified enteroviruses in cases of AFP for Australia, PNG and the PIC during the period 2004 to 2013 are 
listed in order of frequency. These five enterovirus serotypes represent 34.5% of all enteroviruses identified 
from the AFP cases examined. 
 
In Australia the most frequently identified Enterovirus species was A, constituting 16 of 
38 (42.1%) of all positive cases (Table 3.6). In the PIC, species B Enteroviruses were 
dominant with 15 of 25 (60.0%) enterovirus positive cases, while in PNG species C 
Enteroviruses predominated at 20 of 46 (43.5%) enterovirus positive cases (Table 3.6). 
 
Species Australia PIC PNG Total 
A 16 
 
8 24 
B 14 15 17 46 
C 5 9 20 34 
D 1 1 
 
2 
RhV 2 
 
1 3 
Total 38 25 46 109 
 
Table 3.6 Enterovirus species identified in Australia, Pacific Island countries and Papua New Guinea. 
Breakdown by species of 109 enterovirus positive samples from 594 cases investigated during the period 
2004 to 2013. 
 
The recent predominance of species A Enteroviruses in Australia included a significant 
EV-A71 outbreak in South-Eastern Australia in 2013, with sporadic identifications of 
EV-A71 prior to this event (Figure 3.2). Data derived from the ERLNA was compiled, 
enabling an observation that during the increase in EV-A71 cases, a concurrent increase 
in HFMD cases due to CV-A6 occurred in conjunction with an increase in meningitis 
cases due to E6. Between 2004 and 2011, no EV-A71 was identified from an AFP case in 
Australia. No evidence of AFP cases associated with enterovirus outbreaks was observed 
in the PIC or PNG from 2004 to 2013. 
 
A non-cultivable enterovirus was identified from an AFP case in PNG in 2009 using pan 
enterovirus PCR methods and was determined to be a novel enterovirus. Subsequent 
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investigations in 2013 identified this virus as a novel member of the species A 
Enteroviruses, and was assigned as EV–A120 by the international committee on 
taxonomy of viruses in that same year (refer to section 3.4.4). 
 
 
 
Figure 3.2, cumulative graph of the 10 dominant circulating enterovirus types Australia. Cumulative 
graph of major circulating enterovirus types during the period surveillance from 2009 to 2013 for Australia, 
data derived from multiple sources nationally as part of the Enterovirus Reference Laboratory Network. 
 
3.4.2 Characterisation of EV-A71 in Australia 
The initial detection in 2011 of EV-A71 subgenogroup C4 in Western Australia, 
prompted an initial investigation into the molecular epidemiology of a previous 
Australian EV-A71 outbreak in 1999 to 2001. Retrospective sequence data from 1997 to 
2003 were obtained from GenBank and used to create phylogenetic trees for the 
genogroup B and genogroup C EV-A71 viruses separately. Using Bayesian 
phylogeographic methods, two trees incorporating sequence data with the temporal and 
geographic distribution of EV-A71 viruses were created, (Figures 3.3, 3.4 and 3.5). The 
results indicated that viruses obtained from the initial outbreak in Perth, Western 
Australia in 1999 shared a common ancestor with viruses circulating in Sarawak 
Malaysia and Singapore. EV-A71 sequence data from the second stage of the Australian 
outbreak, which occurred in 2000 to 2001 in Sydney, New South Wales on the eastern 
coast of Australia, indicated a common ancestor was shared with viruses identified in 
peninsular Malaysia, (Figures 3.3, 3.4). 
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Figure 3.3 Phylogeographic analysis of enterovirus A71 using Bayesian methods 1997-2003*. Analysis 
of genogroup B and genogroup C EV-A71 sequences during a genogroups shift in Australia from 1997 to 
2003. Coloured branches indicate country of origin. x-axis is time in years. *This graphical representation 
highlights a problem associated with the presentation of phylogenetic data in tree form: data-rich trees can 
be difficult to read. For a more intuitive and visually simpler version of these data, refer to figure 3.4 below. 
 
 
 
Figure 3.4 Phylogeographic analysis of enterovirus A71 using Bayesian methods overlaid on a global 
map. Google Earth representation of EV-A71 transmission during the period 1997 to 2003. The image 
indicates virus transmission patterns over time during a period of genogroup shift in Southeast Asia and 
Australia, from genogroup C (green) to genogroup B (red). Figure data are derived from the same Bayesian 
phylogenetic analysis method as Figure 3.3. For an animation of these data, refer to the electronic 
version
315
. 
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With the implementation of the Enterovirus Reference Laboratory Network of Australia 
in 2009, enterovirus typing data was made available by members from different states of 
Australia. Viruses were identified from a number of different cases presenting with 
various diseases. Genogroup B EV-A71 viruses had been identified up to 2011, with no 
cases associated with AFP. Genogroup C4 EV-A71 was identified in 2011 (Figure 3.5), 
with an ancestral link to viruses circulating in China (Figure 3.6) and exhibiting a high 
sequence identity (99.8%) to viruses identified from an outbreak in Singapore from 2008 
to 2009
164
. 
 
The genogroup C EV-A71 viruses were identified in place of the established genogroup 
B5, which had been introduced during the genogroup shift in 1999 and 2000 originating 
in Western Australia
316
. By late 2012, genogroup C4 EV-A71 appeared to have become 
established, with the first case of AFP being reported to the NERL at the beginning of 
2013. 
 
 
 
Figure 3.5. EV-A71 genogroup shift during the period of 2009 to 2013 from cases reported by the 
Enterovirus Reference Laboratory Network of Australia combined with data from AFP cases identified 
during the period 2012 to 2013 from the Enterovirus Reference Laboratory at VIDRL. Figure legend 
indicates EV-A71 sub-genogroup by colour B5= blue, C1= green, C2= orange, C4= red and unknown 
sub-genogroup= grey. 
 
By mid-2013, twelve AFP cases associated with EV-A71 genogroup C4 had been 
identified through the ERLNA and AFP reporting systems. Samples from patients were 
only available from ten of these cases. One fatal infection was confirmed by the NERL as 
EV-A71 sub-genogroup C4, and a further four deaths were reported from cases exhibiting 
clinical manifestations of pulmonary oedema with a clinical suspicion of EV-A71 
involvement. All cases occurred on the south-eastern seaboard of Australia during 2012 
and 2013. Phylogenetic inference indicated that the viruses shared a common ancestor 
with the exception of a single AFP case in 2012, which was identified as belonging to 
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sub-genogroup C2. The fatal case with a positive EV-A71 sub-genogroup C4 
identification also shared the same common ancestor with EV-A71 viruses circulating in 
China (Figure 3.6). 
 
 
 
 
Figure 3.6. Phylogenetic analysis of enterovirus A71 identified in Australia during the period 2009 to 
2013. Sequence data representing the 5´ aspect of the VP1 genomic region (CODEHOP), derived from 
members of the Enterovirus Reference Laboratory Network of Australia, and the AFP surveillance system 
operating under the auspices of the Enterovirus Reference Laboratory. Maximum likelihood tree calculate 
using an HKY+G+I model with 1000 bootstrap psuedoreplicates. Red arrows indicate cases of AFP, black 
arrows indicate fatal cases. Breakout figure indicates comparative sequence analysis performed on the 3´ 
aspect of the VP1 genomic region.  
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3.4.3 Characterisation of Variants of EV-C96 
During the course of investigations of AFP cases from the PIC and PNG during the 
period 2004-2013, it was noted that a number of newly characterised members of the 
species C Enteroviruses were identified. Partial sequence data derived from the VP1 
genomic region indicated that these viruses were typed as EV-C96. Retrospective 
examination of virus growth patterns in cell culture indicated a variation in tropism 
between different viruses identified (Table 3.7). 
 
 
Identifier Year Country HEL HEP2C RD-A L20B 
107711 2004 PNG + + + - 
110581 2004 PNG - + + - 
124709 2006 KIR + + + - 
009265 2008 PNG - + - - 
009269 2008 PNG - + - - 
124097 2011 PNG + ND + - 
134022 2012 FIJ ND + - - 
173490 2012 PNG ND + - - 
 
Table 3.7 Cell culture results of EV-C96 isolates. Data obtained for culture of enterovirus C96 in 
multiple cell lines. Human embryonic lung (HEL), human epidermoid carcinoma (HEP2C), 
rhabdomyosarcoma (RD-A) and mouse fibroblast expressing the poliovirus receptor is CD 155 (L20B). 
PNG= Papua New Guinea, KIR= Kiribati, FIJ= Fiji. 
 
Partial VP1 sequences derived using the CODEHOP method from the respective viruses 
were analysed using phylogenetic methods. The samples from PNG indicated that they 
belong to a unique and distinct clade, separate from previously described EV-C96 viruses 
with sequences available in the public domain (GenBank). Distinct also from this group 
were two viruses identified from Samoa and Kiribati. Although the phylogenetic analysis 
indicated strong support for the Kiribati, PNG and Samoan EV-C96 viruses as a distinct 
lineage with respect to prototype species C Enteroviruses, there was poor support for 
clustering within the EV-C96 clade (Figure 3.7). 
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Figure 3.7 phylogenetic analysis of the newly described EV-C96 identified from Australia, PIC and PNG 
combined with prototype species C Enteroviruses. Partial VP1 sequence encompassing the BC loop region, 
amplified using the CODEHOP assay. Phylogenetic tree created using DNA distance methods with 1000 
bootstrap replicates. 
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3.4.4 Characterisation of the Novel Virus EV-A120 
An enterovirus of unknown type was identified from PNG as part of AFP surveillance in 
2009. Initial culture results from inoculation of faecal samples onto multiple cell lines 
indicated the presence of toxins, and dilution of samples using standard WHO protocols 
to reduce the effect of toxins on the cell cultures resulted in no growth. Screening using 
the PanEV rRT-PCR indicated the presence of an enterovirus. Subsequent testing using 
semi-nested semi-quantitative EV-SS snrRT-PCR (refer to section 2.3.1), indicated a 
virus titre of approximately 0.9 log CCID50/ mL and estimated at 8 infectious particles per 
millilitre of sample when compared to EV-A71 control virus (Figure 3.8). 
 
 
Figure 3.8. EV-A120 virus titre from original faecal sample. Semiquantitative EV-SS snrRT-PCR 
method incorporating a standard curve derived from serial dilutions (-0.1 to 3.9 log CCID50) of quantitated 
EV-A71 genogroup B5 control material. x- axis = cycle number, y- axis = ΔRn (fluorescence). 
 
In order to identify the enterovirus, sequencing using the CODEHOP method was 
performed and a 297 base pair fragment of the VP1 genomic region was obtained. This 
fragment was used to query the GenBank database online and no significant match was 
found. Full capsid sequencing was performed as described in section 3.3.3. Comparative 
analysis against known prototypes of enterovirus was performed, and indicated less than 
75% nucleic acid and less than 88% amino acid identity against known prototypes (Figure 
3.9) indicating that this virus was a novel type belonging to the species A Enteroviruses 
according to the guidelines examined in section 1.2.5 
112
.   
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Figure 3.9. EV-A120 sequence identity to species A Enterovirus prototypes. Full capsid sequence of 
EVA 120 compared to all available prototype sequences representing species A Enteroviruses. A) nucleic 
acid % identity, B) amino acid % identity. Cut-off values for homologous enterovirus type are 75% for 
nucleic acid and 88% for amino acid identity. x- axis = prototype, y- axis = percent identity (%). 
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Sequence data representative of the complete capsid encoding region of all known species 
A Enteroviruses affecting humans was aligned with the novel virus sequence data using 
the Clustal-W algorithm 
123
. Once aligned, model testing was performed in order to 
determine the most appropriate phylogenetic analysis method using Mega version 5.2.1
50
. 
Two models were determined to be the most suitable for use in phylogenetic inference; 
the generalised time reversible (GTR) and the Hasegawa, Kishino and Yano (HKY) 
models, with a discrete gamma variable incorporating invariant sites (Figure 3.10). 
Phylogenetic inference using Maximum Likelihood methods were performed using both 
models with 1000 bootstrap psuedoreplicates. No significant differences between outputs 
were observed. 
 
 
Figure 3.10. EV-A120 Maximum likelihood phylogenetic tree (HKY+G+I) with 1000 psuedoreplicates 
of Enterovirus species A prototypes with sequence data representing the entire capsid encoding region. 
Scale bar indicates nucleotide substitutions per site.  
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Analysis using phylogenetic inference provided strong support that the novel virus was 
related to a clade incorporating CV-A7, CV-A14, CV-A16 and EV-A71. Simplot analysis 
incorporating bootstrapping methods 
305
 was performed for the entire capsid region using 
nucleic acid sequence data alignments representing the novel virus and available capsid 
encoding sequence data for related prototypic members of the species A Enteroviruses, 
(Figure 3.11). No significant re-combination events were detected, indicating that this 
virus is not a recombinant but given the phylogenetic analysis results, is most likely an 
evolutionary ancestor of CV-A7 and CV-A14. 
 
 
 
Figure 3.11 Simplot and BootScan outputs for EV-A120 and species A Enterovirus prototypes A) 
Simplot output indicating sequence identity below 75% nucleic acid threshold, B) BootScan analysis 
indicating heterogeneous matching that of the capsid region species A Enterovirus prototypes, the most 
significant matches are with CV-A7 (magenta), CV-A14) (brown). Simplot and BootScan performed with a 
200 base pair window in 20 base pair steps using the Kimura-2 parameter method with neighbour joining, 
x- axis = nucleotide number, y- axis = A) similarity B) % bootstrap trees.  
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3.5 Discussion 
The use of bioinformatics methods, incorporating algorithmic sequence matching in the 
form of BLAST searches, sequence alignment and phylogenetic analysis, are critical tools 
in establishing the molecular characterisation and epidemiology of viral pathogens. This 
is particularly evident in the case of serious neurological disease typified by the syndrome 
of AFP and the identification of associated enteroviruses. 
 
The preceding work highlights the usefulness of identifying homologous enterovirus 
types, allowing the determination of viruses in sporadic cases of paralysis or those 
associated with outbreaks. A number of non-polio enteroviruses, including 
coxsackieviruses and echoviruses, have established associations with neurological 
infection that can lead to paralysis through their identification from CSF, a sterile site, 
and repeated detections from such cases
42
. However, a number of non-polio enteroviruses 
have been identified from non-sterile sites, such as stool specimens of AFP cases. More 
stringent analysis is required to establish a connection with severe neurological disease as 
it may be an incidental finding since it is estimated that approximately 90% of enterovirus 
infections are asymptomatic
80
. 
 
Presented in this chapter was the association of a large number of AFP cases with a major 
outbreak of EV-A71 subgenogroup C4, which also included reports of up to 5 fatalities in 
young children
317,318
. The molecular epidemiology of this outbreak follows a similar 
pattern to what had been observed in 1999 and 2000, when the introduction of 
genogroup-B EV-A71 viruses in Western Australia replaced the circulating genogroup C 
viruses
316
. In 2000, a second outbreak of EV-A71 genogroup B was reported in New 
South Wales. Between the years 2000 to 2011, the predominant circulating EV-A71 
belonged to genogroup B
316,319
. The subsequent detection of subgenogroup C4 in 
Australia in 2012 was a significant public health concern, since this strain has caused 
extremely large outbreaks in China and south-east Asia involving a high case fatality rate, 
serious morbidity and mortality
320
. Examination of EV-A71 sequence data from 1997 to 
2003 using Bayesian Phylogeographic methods (section 3.4.2, figures 3.3 and 3.4), 
indicated two separate importation events into Australia. The first was in 1999 to Perth 
from Sarawak Malaysia followed by an importation event in 2000 to Sydney from 
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peninsula Malaysia. The detection and sequence characterisation of the first 
sub-genogroup C4 EV-A71 in Western Australia indicated a genetic similarity to viruses 
identified in outbreaks in Singapore and Malaysia in the preceding years. The chains of 
virus transmission were similar to those observed when examining the previous EV-A71 
outbreaks in 1999 and 2000 in Australia, using Bayesian phylogeographic analysis. 
 
EV-A71 infection is often associated with HFMD, but can also manifest as severe 
neurological illness such as anterior horn cell disease and meningo-encephalitis
134,140
. The 
EV-A71 epidemic in Australia from 2012 to 2013 resulted in multiple cases of paralysis 
as well as deaths. Investigation of the outbreak was complicated by the fact that a number 
of other enteroviruses can cause the same symptoms, specifically coxsackieviruses also 
classified within species A. During the EV-A71 outbreak, coxsackievirus A6 (CV-A6) 
was co-circulating and caused the majority of HFMD cases investigated. In addition, 
echovirus 6 was most frequently associated with viral meningitis during this period 
(Figure 3.2)
317
. This highlights the need to identify the types of enterovirus circulating 
concurrent with any cases being investigated and the clinical manifestations with which 
they are associated. The availability of rapid methods for enterovirus detection and 
identification, are essential to fulfil this need. 
 
With respect to the enteroviruses identified in PNG and the Pacific islands, EV-C96 
viruses were the most frequently associated with AFP. EV-C96 is a newly characterised 
virus first described in 2006 by Oberste et al.,
114
 and although the virus has no established 
causal association with AFP and severe neurological illness, the frequency of 
identification of this virus with AFP cases may indicate such an association. The NERL 
observed that this virus displayed variations in cell line tropism, indicating the potential 
for examining structural variations between viruses to identify a potential receptor 
binding site. The observation of varying cell tropism in EV-C96 isolates has also recently 
been observed by Lu et al., (2014)
321
. 
 
The novel species A Enterovirus identified from a paralysed child in PNG, indicated via 
comparative sequence analysis, that it shared a close identity to CV-A7 and CV-A14. 
Although isolation of the virus in a case of AFP does not constitute a causal association, it 
is of interest to note that in the past, CV-A7 was referred to as poliovirus type 4 during 
large outbreaks of poliomyelitis like illness in Russia and the United States
133
. Sequence 
data incorporating the 5´NTR complete capsid region and partial P2 nonstructural region 
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was sent to the ICTV, who have provisionally assigned the novel species A Enterovirus, 
as EV-A120
322
. 
 
The identification of the novel EV-A120 enterovirus was especially significant, given that 
the virus was not identified using conventional culture methods, but by amplification 
using PanEV snrRT-PCR during parallel testing of samples from AFP cases. The 
examination of virus titre using the newly developed RT-PCR methods in chapter 2, 
estimated the virus titre to be on the borderline of what is detectable using cell culture. 
The low titre of virus, combined with the toxicity of the original sample, complicated the 
identification and sequencing process, as a high titre virus was not available for further 
examination. Whole genome methods, such as those used in deep sequencing, have been 
used to examine novel viruses
323-325
, but the cost involved in using this technology was a 
barrier to the use of such methods. The use of primers designed from consensus data, 
combined with nested RT-PCR and primer walking, allowed the amplification of 
sequence data representing almost the entire 5´ aspect of the genome, which importantly, 
contains the P1 region encoding the virus capsid. The sequencing methods used to derive 
the EV-A120 sequence data proved so effective, that an identical process was used to 
determine the capsid encoding region for multiple EV-C96 viruses identified from AFP 
cases. 
 
In summary, the retrospective analysis of data from 2004 to 2013 identified two viruses 
(EV-A71 and EV-C96) as having a relatively high association with AFP in Australia, the 
Pacific Islands and Papua New Guinea. Further investigation of these viruses was 
considered warranted, and thus, these viruses were selected for 3-dimensional structural 
characterisation. Additionally, the discovery of EV-A120 as a novel pathogen in 
specimens derived from a case of AFP provided the opportunity to test whether a model 
of the capsid structure could be generated purely from sequence data, without the need to 
grow it in culture. The reconstruction and examination of 3-dimensional structures for 
these selected viruses are described in Chapter 5. 
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4.1 Manuscripts Published in Association with this Chapter 
 Roberts, J.A., Kuiper, M.J., Thorley, B.R., Smooker P.M., Hung. A., 2012. 
Investigation of a predicted N-terminal amphipathic α-helix using atomistic molecular 
dynamics simulation of a complete prototype poliovirus virion. Journal of Molecular 
Graphics and Modelling, 38, September: 165-173. [Refer to appendix A8.2.6]. 
 
 
4.2 Introduction 
The examination of the molecular structure of viruses has been an important part of 
understanding processes such as antiviral drug binding or receptor interactions (refer to 
sections 1.4 and 1.5.1). Studies examining molecular interactions typically rely on atomic 
coordinate data derived from experimental methods, but such structural data are not 
always available for viruses that may be of interest. In order to determine the feasibility 
of reconstructing and simulating structural components of viruses for which no structural 
data exist, new processes were required to recreate partial and complete virus structures 
for simulation and comparative analysis. A number of methods incorporating the use of 
comparative protein modelling can be utilised, to produce models of viruses that have not 
had structural data reported
249-255
. The availability of atomic coordinate data derived from 
x-ray diffraction and cryo-EM experiments of closely related viruses can be the basis of 
reconstructing an unknown virus, using software such as Modeller, SwissPDBviewer and 
SwissModel
326,327
. 
 
Model prediction can only be based on structural data that is complete and of reasonable 
quality
328,329
. There are predictive modelling methods that use energy minimization (for 
example Modeller or SWISSmodel) which help to resolve issues related to steric 
clashes
330,331
. Clashes may exist in predicted models where amino acid side chains have 
been incorrectly placed. Rotation of these of side chains may resolve these issues, but not 
necessarily in the case of deeply buried amino acid side chains, where a combination of 
spatial positioning, charge and hydrophobicity may, for example, result in unexpected 
displacement of structures within the immediate vicinity. Furthermore, crystal structures 
and the models on which they are based, even those of very high quality while providing 
a “static” view of a protein, may lack detail on atomic motions (refer to sections 1.3 and 
1.5). 
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Crystal structures provide at best a “snapshot” of the protein under experimental 
crystallisation conditions, which are often far from physiological conditions (refer to 
section 1.3.1). They give no direct information on the stepwise mechanical processes 
affecting conformational transitions as a result of pressure, temperature, ionic 
interactions, or interactions within the context of a biological system. Atomistic MD 
simulations, which model motions of individual atoms at finite (physiological) 
temperature and water and ion solvent, are complementary to experimentally derived 
structures, providing details of protein dynamics of possible functional importance under 
variable conditions. These behaviours are restricted to conditions under which the model 
parameters – force fields - have been derived, and thus are determined to be suitable. 
 
To demonstrate the utility of MD to elucidate biologically-relevant motions of viruses, 
and to demonstrate its appropriateness to model newly described and novel viruses, a 
series of in-silico experiments was required using a virus that has been extensively 
researched, with a large number of available structures. For this purpose, wild-type 
poliovirus 1 was chosen, due to the large body of literature dating back over 100 years, 
and the wealth of research data relating to the investigation of its structure. 
 
The wild poliovirus type 1 (Mahoney strain) capsid was resolved in 1985 to a resolution 
of 2.9 Å, representing one of the first mammalian viruses to be resolved using x-ray 
diffraction methods 
16
. Although the complete structure in the external capsid surface was 
elucidated, certain regions within the interior could not be resolved from the electron 
density data, providing an opportunity for MD to fill this gap. Only partial data existed of 
the N-terminus of VP1, which had been postulated to be in the form of an α-helix332. This 
α-helix is considered a critical component in the uncoating process and extrication of 
RNA across the cell membrane into the cell cytoplasm
89
. Residues 1-7 of the N-terminus 
of VP2 and residues 234-238 of the C-terminus of VP3 were not present in the 1985 
structure, but indications of their placement can be found in related structures such as 
those of the empty capsid form of the virus elucidated in 1994 
68
.  
 
The N-termini of VP1, VP2 and VP4 are each located on the inner surface of poliovirus 
and it was postulated that resolution of these structures was not possible by x-ray 
crystallography, due to the spatial orientation compared to the symmetric icosahedral 
Chapter4: Reconstruction and Atomistic Molecular Dynamics Simulation of Poliovirus 
113 
nature of the virus structure
16
. Prior to assembly into a final capsid structure, biologically 
active protein structures in the form of a pentamer precursor are present, comprising five 
protomers assembled into a pentameric configuration using VP1, VP3 and a single 
combined precursor configuration of the proteins VP2 and VP4, termed VP0 (refer to 
sections 1.2.2 and 1.2.3). VP0 is postulated to undergo cleavage of a scissile bond in the 
presence of RNA during the assembly of the infectious 160S particle from the 70S form 
in the process of creating the separate proteins VP2 and VP4, thereby locking the capsid 
in its final and infectious conformation 
68
. 
 
Since the initial atomic description of the poliovirus and rhinovirus capsids in 1985, more 
than 70 x-ray diffraction or cryoEM derived structures, representing various capsids of 
members of the family Picornaviridae, have been made available on the RCSB protein 
data bank. As of February 2014, 25 atomic coordinate files exist, representing poliovirus 
1, 2 and 3 capsid structures in various states. However, it was noted that the N-terminal 
region of VP1 was not resolved by any of these investigations for species C 
Enteroviruses. This may have been due to spatial disorientation or molecular movement 
of the protein chain. The proximity of the helix to the RNA core within the virus particles 
was not considered to be a contributing factor during the generation of the first crystal 
structure coordinates published in 1985 
333
. The amino acid sequence of the terminal 
sequence of the VP1 protein in many enteroviruses, including poliovirus and rhinovirus, 
indicated a periodicity of hydrophobic residues that may form an amphipathic helix with 
polar residues along one half of the surface and non-polar residues on the opposite 
surface 
89
. The complete VP1 crystal structure of human rhinovirus 16 was resolved in 
1985 at a resolution of 2.15 Å and indicated the formation of an amphipathic helix at the 
N-terminus, supporting the hypothesis that this occurs in a similar manner in other 
enteroviruses 
334
.  
 
The manual inclusion of missing structures, whose positioning can be determined from 
partial data accumulated from a number of different ancestral structures, is a process that 
is easy to perform using current conventional methods with programs like Visual 
Molecular Dynamics (VMD) 
335
, but the manipulation of these data needs to be 
performed with caution and validated against existing known conformations of structure. 
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This chapter describes the reconstruction of wild poliovirus type 1, incorporating 
predicted structures that were missing from the original X-ray diffraction data. The model 
was subjected to MD simulation and analysis against the original capsid structures, to 
validate the method. Previous MD simulation methods of the virus capsid utilised 
symmetry methods, in which the icosahedral rotational symmetry of the capsid were 
exploited to model the entire capsid. Specifically, a single protomer was modelled within 
a periodic cell, creating the effect of the protomer being embedded in a full virus capsid, 
approximated using icosahedral periodic images of the asymmetric unit (refer to section 
1.5)
254
. Exploiting icosahedral symmetry does manage to avoid the high computational 
overheads associated with large atomistic MD simulation by being only thousands of 
atoms in size, but it also fails to emulate any unknown event that may break symmetry 
(such as RNA extrusion)
91,336
, and thus do not adequately represent the biological state of 
the complete virus capsid. 
 
A novel protocol for construction of full poliovirus virions is discussed in this chapter, 
and the simulation and hardware requirements for simulating them at all-atom resolution 
are established. In particular, this chapter describes: construction of missing virion 
structural components and a novel procedure for encapsulating the RNA; the 
establishment of appropriate conditions to simulating virions, including PBC cell 
shape/size and computational architecture; demonstrating the stability of virions under 
simulation conditions and thus the applicability of in-silico modelling to construct 
biologically-realistic virion models which can be used to investigate known external 
factors which influence gross morphological structure. Virion morphology is examined in 
response to variations in temperature conditions, as are the influences of known capsid 
binding compounds (palmitate and Disoxaril, respectively). Finally, a number of 
quantitative and qualitative analyses were performed on the trajectories obtained, to 
demonstrate the range of properties which may be elucidated by MD, including structural 
refinement of a region of the virus unresolved by crystallography.  
 
It is anticipated that the simulation protocol and preliminary analyses established in this 
chapter will form the basis for development of new analysis methodologies, adapted for 
large biological systems, thus enabling more effective quantitative interrogation of MD 
simulation trajectories.  
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4.3 Materials and Methods 
 
4.3.1 In-Silico Reconstruction of Poliovirus Capsids  
The reconstruction of poliovirus capsid and complete virions were based on GenBank 
sequence ID NC002058. Database searches using the SwissModel website determined 
that of the available enterovirus crystal structures, the x-ray co-ordinate data of poliovirus 
type 1 Mahoney strain (PDB file 1HXS) at a 2.2 Å resolution, was the most suitable 
template 
337
. 
 
Poliovirus capsid reconstruction was performed using the Visual Molecular Dynamics 
(VMD) software
335
, incorporating the nVidia GPU-specific Compute Unified Device 
Architecture (CUDA) extensions. A significant element lacking from the original crystal 
data was an α-helix located at the amino terminus of the VP1 protein.  The 19 missing 
residues constitute a region containing an α-helix with an amino acid motif common to 
members of the genus Enterovirus.  PSIpred predictions 
338,339
 derived from amino acid 
sequence data and comparative information determined from available enterovirus crystal 
structures in the Research Collaboratory for Structural Bioinformatics  protein data bank 
(RCSB PDB), assisted in the spatial alignment of the helix, which was reconstructed 
using the molefacture plug-in of VMD.  
 
Icosahedral symmetry data required to reconstruct the 60 virus protomers into a full 
capsid structure were available in the form of metadata within the original crystal 
structure
337
. Using the "mono2poly" Tcl script, a single protomer was positioned 
according to the biological parameters to assemble the 240 proteins and 120 lipids 
required for a full poliovirus capsid
340
. 
 
An additional 3 million atoms were required to replicate a 0.154mM sodium chloride 
suspension, with cell edge padding at 12 Å on each 3-dimensional axis. The final atom 
count for the entire cubic representation of the empty capsid simulation was 
approximately 3.9 million, with cubic cell dimensions of 344.8 Å on each axis. 
Additional model configurations involving complete virions, pentamers and a detached 
helix were constructed in preparation for MD simulation (Table 4.1).  
Chapter4: Reconstruction and Atomistic Molecular Dynamics Simulation of Poliovirus 
116 
 
Simulation Detached helix Pentamer Empty Capsid Complete Virion 
Total Atoms 8,586 388,521 3,938,950 3,301,378 
PBC Cubic Cubic Cubic 
Rhombic- 
dodecahedron 
Water molecules 2,760 106,629 1,038,857 745,287 
Amino acids 20 4,390 52,800 52,822 
Nucleotides (RNA) 0 0 0 7,640 
Fatty Acids 0 10 120 120 
Magesium ions 0 0 0 3,799 
Sodium ions 10 370 3,728 2,785 
Chloride ions 8 309 3,011 2,267 
 
Table 4.1 Table outlining specific details of each simulation. Table indicates the models created for 
simulation, with the periodic boundary conditions (PBC), the type of molecules and the total atoms used.  
 
 
In addition to the wild type Mahoney poliovirus, a homology model was attempted to 
construct the related Sabin vaccine strain. As no crystal structure data existed for the 
Sabin strain of poliovirus type 1, the Mahoney wild poliovirus strain, which shares 98.5% 
capsid amino acid sequence identity with the vaccine strain, was used as a template for 
comparative protein modelling using the SWISS-model server based on the 1HXS 
Mahoney PDB data. 
 
Topology files and CHARMM parameter data for the associated myristate and palmitate 
molecules were determined using the SWISSparam server
341,342
. 
 
4.3.2 Integration of Wild Poliovirus RNA using Steered Molecular Dynamics. 
As there were no structural data available for the reconstruction of the internal core of the 
virus containing genomic RNA and the covalently-linked 22 amino acid VPg protein, a 
simple approach was used, involving 10 RNA fragments created using the "make-na" 
server
343
 and genome fragments compressed (from 2000 Å to 300 Å) using in-vacuo 
steered MD, were arranged in a simple helical structure (Figure 4.1). Each of the 10 RNA 
fragments was 750 bp, and a 20 bp poly-A tail was attached to the 3´NTR of the final 
RNA fragment. The VPg protein was replicated using the PDB file 2BBP and was 
covalently attached to the 5´NTR of the genome. Appropriate angles and partial charges 
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were determined using the NMR data derived from the published work on the VPg 
protein and its association with the 5´NTR of the genome
237,238
. Once constructed, the 
VPg and the first nucleotide of the Wild Poliovirus 5´NTR were uploaded to the 
SwissParam server to obtain appropriate topology and parameter files for simulation 
(refer to appendices 5.6 and 5.7 for topology and parameter files).  
 
 
Figure 4.1 Helical arrangement of complete genome prior to Steered MD.  Simplified “cartoon” 
representation of the supercoiled structure of the Wild Poliovirus RNA genome, prior to compression and 
placement in the core of an empty capsid structure. Colour scale: Red (nucleotide position number 1) to 
Blue (poly-A tail to 7640bp). Image generated using the VMD software package
335
. 
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Steered MD was then used to direct the super coiled RNA into a sphere with of diameter 
of approximately 300 Å, in-vacuo (refer to appendix A5.1 for Tcl scripts). The now 
spherical RNA was then solvated and neutralised in a magnesium chloride solution. 
Using a constant atom number, constant pressure and constant temperature ensemble 
(NPT) with steered MD, the RNA was compressed into a smaller sphere with a 184 Å 
diameter and then transposed into the core of the wild poliovirus capsid, creating a final 
structure totalling 1.05 million atoms. 
 
 
4.3.3 Molecular Dynamics Simulation of a Complete Wild Poliovirus Virion. 
MD simulation was performed using the 64-bit Nanoscale Molecular Dynamics (NAMD) 
software package
344
, which incorporates the CHARMM force fields. A number of 
different in-house computer systems and supercomputers at VIDRL and the Victorian 
Life-Sciences Computation Initiative (VLSCI) were used. Simulations were run on 256 
cores of an SGI Altrix XE supercomputer (Intel x86 architecture) running NAMD version 
2.7, 512 nodes (2048 cores/threads ) of a BlueGene/P running NAMD 2.8 beta 1 with 
memory optimisation extensions and 256 nodes (4096cores, 16,384 threads) and on a 
BlueGene /Q running NAMD 2.9 with memory optimisation extensions. In-house 
simulations were performed on a Dell T3500 workstation incorporating and Nvidia 
Quadro 5000 and Tesla C2070 CUDA-based GPU accelerator, using version 2.8 beta 1 
and a 2.9 of NAMD, which included the GPU-specific CUDA software enhancements.  
 
Initially, 50,000 steps of energy minimisation were performed. This was followed by 
equilibration using an NPT for 0.5 ns at 310 degrees Kelvin with a pressure of 
1013.25 mbar (one atmosphere). Once the process of energy minimisation and 
equilibration had been completed, the virus simulation was moved to a BlueGene/P 
supercomputer running NAMD 2.8 beta 1, with memory optimisation extensions on 2048 
cores (refer to appendix A5.8 for specific parameters). From August 2012 onwards, 
simulations were performed exclusively on a BlueGene /Q supercomputer, using 4096 
cores (16,384 threads). NPT simulations of a detached α-helix (8,586 atoms), pentamer 
(388,521 atoms) and empty capsid (3.94 million atoms), were run for a minimum of 10 ns 
each. Full virion simulations totalling proximally 3.3 million atoms using rhombic 
dodecahedral periodic boundary conditions were run for 0.1 µs. Trajectory data for each 
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simulation were then transferred locally and analysed on site at VIDRL using a Dell 
T3500 workstation. 
Refer to appendix A2 for further details of equipment used. 
 
Once an appropriate workflow was established to create stable full virus simulations, the 
methodology was applied to a series of computational experiments investigating the 
effects of temperature variation on gross virus morphological changes. The complete 
virion experiments performed as above were repeated, but at temperature settings of 4°C, 
37°C, 60°C and 95°C for 10 ns each, in order to observe any structural changes in capsid 
conformation. 
 
 
4.4.4 Examination of trajectory data using VMD 
The wild poliovirus MD simulations (and subsequent simulations presented in chapter 5) 
were performed with atomic position data (trajectories) collected at 0.1 ns time-steps and 
output into the NAMD “DCD trajectory file” format. The Visual Molecular Dynamics 
(VMD) software package was used to analyse these data sets. VMD is capable of not only 
examining static structural data and creating files for simulation, but is also a useful tool 
for the examination of large trajectory data sets, limited in size only by the amount of 
Random Access Memory (RAM) available on the computer system used for the analysis, 
in this instance 24GB for the Dell T3500 computer. VMD is also capable of running 
analysis scripts written in Tcl or the python languages. A number of Tcl scripts were 
created and used in the examination of data derived from the NAMD simulations (refer to 
appendices A5.2, A5.3 and A5.4). 
 
One of the most widely used and accepted methods for the examination of particle 
displacement over time is the Root Mean Square Deviation (RMSD) method
345
. 
Calculated using the formula (4.1): 
 
    (4.1) 
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RMSD is the square-root of the averaged distance (squared) between the two atoms 
(x and y) being compared. This results in a numerical value, usually presented in Å, when 
used for comparative measurement of biological systems. RMSD calculations are used 
frequently in the following chapters of this thesis, as a coarse measurement of movement 
of protein or nucleic acids within an MD simulation, or when comparing x-ray diffraction 
data with MD simulation outputs.  
 
Another method for the examination of structural deviation over time is the Root Mean 
Square Fluctuation (RMSF) method, which examines the fluctuation of a particle around 
a defined average position and is calculated using the following equation (4.2): 
 
    (4.2) 
 
The analysis methods performed in this thesis will focus on RMSD observations. RMSD 
observations over simulation timespan, can be a good indicator of structural stability, as 
shown by Freddolino et al., (2006), in the examination of stable and unstable states of 
STMV
1
. Stable structures were indicated by a modest initial rise in RMSD in the first 100 
ps of the simulation, followed by a plateau phase that resulted in a 1 Å rise in RMSD over 
a 10 ns time-frame. Unstable structures continued on a gradient following the initial 1 Å 
rise in RMSD and continued to between 4 Å and 6 Å depending on the simulation 
temperature (298K or 310K respectively). 
  
In addition to the calculation of RMSD values to examine stability, the external virus 
capsid dimensions were determined over the course of the simulations. This was achieved 
by calculating the distance of the farthest α-carbon at each of the 6 axes (x, -x, y. –y, z and 
–z) from a defined point at the centre of the capsid structure (refer to appendix A5.2.1). 
These values were taken from the trajectory data at 0.1 ns time points over the duration of 
the simulation. The aggregation of these data allowed for the observation of capsid 
geometry over time. Substantial changes to this geometry would indicate an unstable 
structure 
1
. 
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4.4 Results 
 
4.4.1  Optimization of Simulation Cell Morphology and Size. 
A cubic periodic cell, for the simulation of an icosahedral structure, is inefficient. When 
encompassing what is essentially a spherical object in appearance, cubic cells require an 
excessive number of water molecules to fill the cell, resulting in the placement of a large 
number of redundant water molecules. These water molecules would be beyond the 
interaction range of the icosahedral-shaped virion and therefore would exert little direct 
effect on its behaviour. For this reason, rhombic-dodecahedral periodic boundary 
conditions were chosen to reduce the amount of water required to solvate the virus, with 
the advantage of better reproducing the in vitro aggregation of multiple picornavirus 
particles (Figure. 4.2). 
 
 
Figure 4.2 Rhombic-dodecahedral periodic boundary conditions A) Negative-stained transmission 
electron micrograph of a picornavirus sample showing honeycomb-like aggregation of virus particles. 
Image credit: Electron Microscopy Department, VIDRL. B) MD simulation of full wild poliovirus virion 
suspended in saline solution with transparent density representation of water used to show periodic cell 
boundaries. C) Transverse section of periodic cell reflections indicating the similar "honeycomb-like" 
appearance of the MD simulation of a full wild poliovirus virion to electron microscopy data. Figure 
reproduced in Roberts et al., (2012)
2
. 
 
Initial in-silico reconstructions of the solvated wild poliovirus virions were in the order of 
3.94 million atoms using a cubic PBC with 12 Å padding (Table 4.2). The adoption of a 
rhombic-dodecahedral PBC allowed the atom count to be reduced to 3.30 million atoms 
with a 16 Å padding, allowing a greater separation of structures contained within periodic 
cells, thus preventing any potential interactions of the viruses between periodic cells. 
A simulation time of 1.92 days/ns (0.52 ns/day) was achieved when using 1024 cores 
(1024 threads) of a BlueGene/P supercomputer . In 2012, the supercomputer was 
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upgraded to a BlueGene/Q system and simulation times of 0.332 days/ns (3.01 ns/day) 
were achieved when using 4096 cores (16384 threads), with a maximum throughput of 
(0.09 days/ns or 11.1ns/day) using 16,384 cores (32,696 threads). Beyond this point, 
inherent restrictions relating to available memory within the BlueGene hardware 
configuration, prevented an increase in core usage and therefore throughput.  
 
Simulation* Empty Capsid Complete Virion Complete Virion 
Total Atoms 3,938,950 2,754,142 3,301,378 
PBC Cubic Rhombicdodecahedral Rhombicdodecahedral 
PBC Padding 12 Å 12 Å 16 Å 
ns/Day (1024cores)* 0.52 0.66 0.59 
Speed-Up N/A 1.27x 1.13x 
 
Table 4.2 Performance comparison of different periodic boundary conditions. Table outlining specific 
details of each simulation including periodic boundary conditions (PBC) and total atoms used. 
*Statistics for comparison derived using the BlueGene/P supercomputer. 
 
4.4.2 Examination of NAMD on Different Processor Architectures 
During the in-silico reconstruction of the capsid models, it was discovered that the 32-bit 
architecture of the Microsoft Windows XP operating system was unable to process 
simulation data, due to an inherent 4 GB memory restriction. Structures which totalled 
more than four million atoms when solvated in a virtual saline solution exceeded this 
4 GB memory restriction, especially when examining trajectory data greater than 10 ns in 
length. 
 
In order to circumvent the restrictions experienced within the Windows operating system, 
and  also to preserve the established computing environment used in the laboratory, a 
64-bit "live Linux" distribution
 346
 was utilised, in which the operating system (including 
the necessary programs for model construction, atomistic MD simulation and output 
analysis) were able to "boot" on any of the 64-bit capable computer systems tested. In 
order to enhance the portability of the device, the "live" operating environment in the 
form of Ubuntu version 10.04 LTS was installed on a MicroSDHC device. 
 
Concurrent with this issue relating to the operating system environment, three different 
iterations of NAMD were available. Preliminary investigations had been performed using 
the NAMD 2.7 software package on an x86 architecture, but a new version of NAMD 
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became available and incorporated enhanced memory optimisation features for the 
BlueGene architecture as well an increased feature set for the CUDA GPU architecture. 
 
To determine whether there were any statistically relevant impacts of using different 
versions of NAMD, a series of experiments using empty capsids representing wild and 
Sabin-like strains of type 1 poliovirus were performed. Each simulation was run for a 
total of 1 ns and comparisons of each architecture for x86, CUDA and BlueGene were 
made. Gross assessment of capsid stability was performed using RMSD calculations for 
each virus protein, VP1 VP2 VP3 and VP4 (Figure 4.3). Structural motifs for each viral 
protein were assessed using the RMSF method (Figure 4.4). No significant difference was 
observed between different versions of NAMD software or hardware architecture. 
 
At the conclusion of these experiments, the Dell T3500 workstation was converted to a 
dual boot operating system, comprising the original windows environment and 64-bit 
Ubuntu version 10.04 Linux distribution. Refer to appendices A2 and A3 for further 
details of equipment and software used. 
 
 
Figure 4.3 Comparison of Computer Architectures for Simulation Environment. RMSD values for 
proteins VP1 to VP4 (wild and vaccine strains of poliovirus type 1), computer architecture comparisons. 
Mean RMSD value 60 virus protein replicates found within a capsid , error bars indicate standard deviation. 
CUDA = NAMD 2.8b1 CUDA, BG/P = NAMD 2.8b1 "mem-opt" feature enabled, x86 = NAMD 2.7. 
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Figure 4.4 Comparison of Computer Architectures for Simulation Environment (RMSF). RMSF for 
each of the 60 virus capsid protomers calculated in 10ps steps for 0.1ns. y- axis, 60 protomer set for each 
capsid grouped by architecture: x86, BlueGene/P, CUDA. A = wild poliovirus, B = Sabin-like vaccine 
poliovirus. X-axis, amino acid count for a single protomer. Each graph contains a secondary structural index 
header created using the STRIDE algorithm for secondary structural analysis 
347
. x- axis = residue number, 
y- axis = protomer replicate number (n=60). 
 
 
4.4.3 Analysis of model stability  
After 10 ns of simulation, each of the four simulations (α-helix, pentamer, empty capsid 
and full virion) were transferred to the local workstation for on-site analysis. To provide a 
gross measurement of the stability of the simulations, RMSD values for α-carbons were 
calculated for pentamer, empty capsid and the full virion (Figure. 4.5). It is important at 
this point to explain the observed phenomenon of “solvent shock”, which is a result of 
simulation cell size changes due to water molecules (initially in a non-equilibrium state) 
undergoing a sudden reorientation after the minimization step, leading into the 
equilibration phase of the MD simulation. The non-equilibrated water molecules are 
oriented differently to those in an equilibrium fluid state at 310K. Equilibration of the 
water molecules is normally achieved after a short (<20 ps) simulation time, resulting in 
an abrupt but minor change in simulation cell size and associated perturbation of capsid 
structure at the start of the simulation. The “solvent shock” is observed as a sharp 
increase in the first 20 ps of a simulation. This is followed by a modest increase in RMSD 
value as the simulation equilibrates; leading to a plateau phase, indicating that the 
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simulation is stable for the simulation time frame, with no substantial unfolding or 
disruption in capsid integrity (Figure 4.5).  
 
The variation in radius of the empty capsid and the complete virion were calculated for 
the duration of the 10 ns simulations (Figure 4.6). The empty capsid showed an average 
radius of 145.5 Å compared to the full virion at 147.5 Å, representing a 1.4% difference 
in capsid radius between the two structures. These observations are in line with the 
observed diameter of enteroviruses, being in the range of 30 nm (300 Å), refer to section 
1.2.2. 
 
 
 
Figure 4.5 RMSD of poliovirus after 10ns atomistic MD simulation. Wild Poliovirus empty capsid, full 
virion, spherical RNA alone and an individual pentamer over the 10 ns simulation time. Figure reproduced 
in Roberts et al., (2012)
2
. x- axis = time (ns), y- axis = RMSD (Å). 
 
 
 
Chapter4: Reconstruction and Atomistic Molecular Dynamics Simulation of Poliovirus 
126 
 
Figure 4.6 Average capsid radius ( Å) over 10ns simulation time. Change in radius as measured from the 
outermost α-carbons of the capsid for the x, y and z axes over time Empty capsid (grey) and full virion 
(black). Figure reproduced in Roberts et al.,(2012)
2
. x- axis = time (ns), y- axis = Radius (Å). 
 
 
4.4.4 Analysis of Virus Structure after Molecular Dynamics Simulation. 
The flexibility of the structural proteins VP1-4 was performed using the RMSF method 
over the final 2.5 ns of the initial 10 ns simulations, for empty capsid and full virion 
structures (Figure 4.7). Differences were noted on the five-fold axis of symmetry, 
encompassing the five covalently bound myristate molecules of VP4 and the interlocking 
N-termini of the VP3 and VP4 structural proteins. Increased flexibility was observed in 
the empty capsid structure compared to the full virion, indicating that flexibility in this 
region was reduced in the presence of the RNA core.  
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Figure 4.7 RMSF values calculated over 7.5 to 10 ns time period for all protomers in-situ A) empty 
capsid and B) full virion. RMSF values are indicated by the legend blue 0.42 red 1.5. Figure reproduced in 
Roberts et al., (2012)
2
. 
 
Also noted was increased flexibility in the regions that define a pore-like structure which 
appears at the base of the canyon, at the entrance of the hydrophobic pocket. Significant 
positive ion (sodium) movement was observed in this region through the two-fold axis of 
symmetry and the pore-like structure at the base of the canyon (Figure 4.8). This suggests 
that ion permeation may play a role in the biological function of poliovirus. Further 
rigorous identification and quantitative analysis of the free energy of ion permeation and 
selectivity through these channels, will be of interest in future work to fully characterise 
their electrostatic properties and may have implications for virus-host cell interactions, as 
indicated by Smith et al., for rhinovirus
348
. 
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Figure 4.8 Representation of ion movement in a 10 ns equilibration of wild poliovirus virion using 
molecular dynamics. Panel 1 indicates multiple ions traversing the 2 fold axis of symmetry with the 5-fold 
axis of symmetry indicated by an arrow. Panel 2 indicates a single ion traversing the virus capsid via the 
pore-like structure located at the base of the 5 fold axis of symmetry. In each panel the solvent space (A) is 
indicated in the top left of the figure, whilst a coronal section of the virus capsid is presented (B) as a 
3-dimensional surface rendering in white at a resolution of 2Å. Sodium ions are shown traversing the virus 
capsid from the solvent space to the interior of the capsid and interacting with the viral RNA (C), ions are 
coloured according to time point in 0.1ns increments. Scale bar represents ion colouring as time in ns.  
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At the 10 ns time point, each of the 60 individual protomers that comprised the virus 
capsid were transposed to the initial protomer coordinates, as defined by the 1HXS 
template crystal structure. These 60 protomers, which were overlaid to occupy the same 
space, were then averaged to give a single "fit-averaged" structure, Figure 4.9 (A Tcl 
script used for the fit-averaging process is shown in appendix A5.4).  
 
 
 
Figure 4.9 Examination of protomer structural motifs using protomer fit-averaging. A) cutaway 
representation of the full wild poliovirus virion highlighting relative positioning of a protomer in relation to 
the RNA genome (purple). The fit averaged protomer (n=60) is coloured by chain as in previous Figures 
and represented as a backbone structure at the 10 ns time point. B) Overlaid backbone structure of all 60 
fit-averaged protomers, structures missing from original x-ray crystal data, (1HXS), are highlighted in 
white. C) Cartoon representation of the structure derived from the fit averaging procedure. Regions that 
were missing from the original x-ray diffraction data, (1HXS),are highlighted in white. Figure reproduced 
in Roberts et al., (2012)
2
.  
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The individual fit averaged protomer structures for the pentamer, empty capsid and full 
virion were compared to the original 1HXS template PDB file, which incorporates 
B-factor data. RMSD values were calculated for the VP1 protein within the 60 
fit-averaged protomers of the simulated structure, and then compared to the 1HXS 
template B-factors for VP1 (Figure 4.10). The resulting RMSD values ranged from 
0.873 Å to 1.099 Å when compared to the original template structure, 1HXS, and from 
1.125 Å to 1.604 Å for ten other x-ray diffraction-derived structures for poliovirus 
(1AL2, 1AR6, 1AR7, 1AR8, 1AR9, 1ASJ, 1PO1, 1PO2, 1POV, 1VBD) available from 
the RCSB PDB (Figure 4.11). 
 
 
Figure 4.10 Thermal Comparison of VP1 structural proteins.  A) VP1 structural protein of the 1HXS 
template crystal structure coloured by beta value supplied with the original coordinate data. Figures B and 
C are coloured "RMSD by residue" of fit averaged VP1 structural proteins (n=60) at 10 ns time point B) 
empty capsid and C) full virion. Figure reproduced in Roberts et al., (2012)2. 
 
 
 
Figure 4.11 View of fit-averaged VP1 structural protein reconstructed VP1 protein (White) overlayed 
compared with available wild poliovirus type 1 crystal structure coordinates for VP1 (coloured) obtained 
from the RCSB PDB. Position of the reconstructed amphipathic α-helix (black arrow) after 10ns simulation 
of A) Pentamer (fit averaged protomers, n=5), B) Empty capsid (n=60) and C) Full virion (n=60). Figure 
reproduced in Roberts et al., (2012)
2
.  
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Stability of the predicted α-helix of the N-terminus of the VP1 protein was determined in 
isolation from the remainder of the capsid structure. This enabled the determination of 
whether the helix possesses intrinsic structural stability, or whether interaction with 
neighbouring structural components in the full virion is required to maintain helical 
structure. The detached protein, incorporating residues one to twenty of VP1, maintained 
a helical structure for the duration of the 10 ns simulation (Figure. 4.12). Residues 
ARG15-ASP11 and ARG15-GLU16 formed salt bridges, which were significant 
stabilising elements of the α-helix. The cyclic distribution of amino acid residue types is 
indicative of an α-helix that is amphipathic in nature and matching previous descriptions 
for rhinovirus 
334
. 
 
Figure 4.12 N-terminus of VP1 after 10 ns simulation.  Detached α-helix from the N-terminus of VP1 
after 10 ns simulation. A) Conformational indicated at 1 ns time points, (1ns = blue, 10ns = red). B) 
Liquorice representation of amino acid side chains, showing salt bridge between ARG and ASP (centre), 
(hydrophobic = white, polar = green, basic = blue, acidic =red, yellow = Hydrogen-bond. C) Stereo 
representation of side chain charge distribution around the amphipathic helix. Figure reproduced in Roberts 
et al., (2012)
2
.
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4.4.5 Examination of Viral RNA Interactions with the Capsid. 
Individual amino acids of all 60 capsid proteins were analysed, for their proximity to the 
genomic RNA of the virus model. The RNA interactions were predominately confined to 
the N-terminal aspects of the VP1, with the majority of interactions occurring within the 
first 40 amino acids and a second series of interactions occurring between amino acids 64 
and 71. VP4 RNA-to-protein interactions occurred primarily in four regions distributed 
across the entire protein.  Indications of capsid interactions for VP2 occurred primarily 
within the first 10 residues of the N-terminal aspect of VP2, with a second subset of 
interactions occurring between amino acids 35 and 55 (Figure. 4.13). There was limited 
interaction of VP3 with the genomic RNA, with less than 10% of residues found in 
proximity to the RNA for the region between amino acids 29 and 43. 
 
 
 
Figure 4.13 Bar graph depicting the frequency of amino acids occurring within a distance of 5 Å 
relative to the viral RNA for all 60 capsid protomers. Coloured bars at the top of each chart indicate 
available coordinate data by residue for the full virion template files 1HXS (blue) and 1VBD (green) and 
empty capsid 1POV (red). Figure reproduced in Roberts et al., (2012)
2
. x- axis = residue number, y- axis = 
Frequency % (n=60).  
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When comparing the RMSD values of the VP1 protein, particularly with respect to the 
original 1HXS template structure, it was shown that the α-helix displayed marginally 
higher RMSD values in the empty capsid than that of the full virion (Figure. 4.14). This 
would indicate that the α-helix in the empty capsid exhibits increased flexibility when the 
RNA is not in close proximity. 
 
 
 
Figure 4.14 Examination of capsid chain RMSD by residue. RMSD of individual residue for 
fit-averaged protomers (n=60) at the 10 ns time point for empty capsid (grey) and full virion (black). 
Coloured bars at the top of each chart indicate available coordinate data by residue for the full virion 
template files 1HXS (blue) and 1VBD green) and empty capsid 1POV (red) x- axis = residue number, 
y- axis = RMSD (Å). Figure reproduced in Roberts et al., (2012)
2
. 
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4.4.6 Disruption of Virus Capsid Morphology. 
Investigations of the thermal effects of full virus simulations on gross virus morphology 
indicated subtle differences at the four temperatures tested, 37°C, 4°C, 60°C and 95°C. 
Morphological changes can be observed when comparing the 37°C simulation to 
temperature reductions, notably in the reduction in size of the opening of the two-fold 
axis of symmetry at 4°C. At 60°C, the opening of the two-fold axis of symmetry 
maintains prominence and is accompanied by significant size increases for the pore-like 
structures present at the base of the canyon, proximal to the hydrophobic pocket of VP1. 
At 95°C, these two features undergo substantial rearrangements and result in a complete 
destabilisation of the canyon and a significant increase in the size of the opening at the 
two-fold axis of symmetry (Figure 4.15). These results are similar to those indicated in-
vitro for wild poliovirus and coxsackievirus A7 
91,234,336
. 
 
It has been suggested that capsid binding antiviral drugs inhibit the conformational shifts 
in virus structure required for uncoating
349,350
. If this is the case, then it is fair to assume 
that examination of a drug bound in the hydrophobic pocket using MD simulation may 
result in the ability to observe inhibition of large-scale conformational shifts. The use of 
long timescale simulations (in the order of 0.1 µs) to determine the effect of the capsid 
binding compound WIN51711 (Disoxaril) was performed, and movement proximal to the 
centre of the capsid structure was examined. Movement was measured by calculating the 
centre of mass for each of 60 protomers in full virion simulations, and by measuring 
changes in radial distance from the centre of the capsid structure. Simulations 
representing a virion structure with the native lipid (palmitate) occupying the 
hydrophobic pocket (Figure 4.16), a virion with no pocket factor, and a virion bound with 
Disoxaril, were performed. Coordinates for the positioning of Disoxaril were determined 
using the PDB coordinate data for poliovirus (PDB ID 1PIV)
351
. 
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Figure 4.15. 10 ns simulations of wild poliovirus virion at different temperatures. A) 37°C after 10 ns 
relevant landmarks of virus symmetry are indicated by numbers 5– five-fold axis of symmetry, 2– two-fold 
axis symmetry, 3– pseudo three-fold axis of symmetry, Pore-like structure (Yellow arrow). B) 4°C after 10 
ns, C) 60°C after 10 ns, D) 95°C after 10 ns. All representations are shown in the same orientation. Figures 
representing an 8 Å generated using the tachyon renderer in VMD.  
  
Chapter4: Reconstruction and Atomistic Molecular Dynamics Simulation of Poliovirus 
136 
 
 
 
 
 
Figure 4.16 Wild Poliovirus type 1 (Mahoney strain) after 0.1µs of atomistic MD simulation. Total 
simulation size approximately 3.3 million atoms. Water and surrounding ions have been removed from this 
representation. Volumetric (density) map representation is represented (white) with protein backbone 
shown as tubes and coloured by subunit VP1 = Blue, VP2 = Yellow, VP3 = Red, VP4 = Green.  Lipids 
(palmitate and myristate) are represented as Van der Waals models with colouring by name of element. 
RNA is shown using a “liquorice” representation (grey- side chains, tan- backbone) with associated 
magnesium ions (Purple). 
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The MD simulations for the capsid bound with palmitate, Disoxaril and no pocket factor 
over the 0.1 µs timescale, indicated identical RMSD values for the entire simulation 
(Figure 4.17-A). A pattern of virion diameter changes were observed in the simulations 
containing palmitate and no pocket factor (Figure 4.17-B, C), whereas the simulation with 
Disoxaril bound to the hydrophobic pocket indicated less variation in capsid diameter 
(Figure 4.17-D), being particularly evident during the initial recovery from the “solvent 
shock” phase of the MD simulation. The simulations incorporating no anti-viral drug 
required in excess of 50 ns to equilibrate. The simulation involving bound Disoxaril 
showed little evidence of change in the first 30 ns simulation, with a gradual, but slight 
variation in capsid diameter. The final visual representation of the complete virion 
containing palmitate after 0.1 µs atomistic MD simulation appears in Figure 4.16. 
 
 
 
 
Figure 4.17 RMSD and virus capsid diameter variation for simulations incorporating different 
pocket factors. A) RMSD calculated over a 0.1 µs timescale for protein backbone of capsid structures with 
no pocket factor (orange), palmitate (magenta) and Disoxaril (Brown). Percent (%) variation in virus capsid 
diameter for the x, y and z axes calculated in relation to time point 0 of a series of 0.1 µs simulations, B) no 
pocket factor, C) palmitate and D) Disoxaril. x-axis (blue), y-axis (green) and z axis (red). The x- axis for 
graphs A, B, C and D are measured in nanoseconds, the y- axis for graph A is RMSD, and the y- axis in 
graphs B, C and D are in percent (%) variation.  
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4.5 Discussion 
The computational power available from supercomputers now enables MD simulations of 
multi-million atom systems, facilitating the in-silico investigation of macromolecular 
structures including viruses 
2
. Utilising MD software to perform atomistic simulations of 
a complete wild poliovirus including the native RNA sequence, it was possible to 
successfully simulate the virus for a period of up to 0.1 µs and approximately 4.2 million 
atoms. The x-ray crystallographic co-ordinates of wild poliovirus type-1 published in 
1985
16
 and further refined in 2001
337
, were used to reconstruct the molecular structure 
and the missing virus protein polypeptide sequences were reconstituted according to the 
published prototype nucleic acid sequence (GenBank NC002058). 
 
This virus was chosen due to the abundance of x-ray crystallography and biochemical 
analyses published over more than thirty years. It was noted that specific regions of the 
virus internal structure could not be resolved by x-ray crystallography, specifically the 
N-terminus of VP1 and the RNA genome. Although the virus capsid exhibits icosahedral 
symmetry, which allows for the refinement of protomeric subunits, the underlying 
structure of the genomic RNA has not been determined; most likely due to the relatively 
amorphous nature of the virus core. Although initially the intention was to only simulate 
the virus capsid structure, an attempt was made to incorporate the RNA in this structure 
to better reproduce an infectious particle. The resulting complete virus structure 
simulation represents the most complete and published atomistic MD simulation of a viral 
pathogen to date (Figure 4.16) 
2
. 
 
The advantage of full virus simulations, despite the significant increase in the total atom 
count (up to 4.2 million atoms), compared to the simulation of a single protomeric 
subunit (up to 0.2 million atoms), is that an economy of scale comes into play with 60 
protomers available in the full virus (or capsid) simulations as independent entities within 
a biologically relevant assembly. In order to replicate the data obtained from a complete 
virion or capsid simulation, 60 separate protomer simulations would be required and even 
then the molecular interactions from neighbouring protomers and the native RNA would 
not be accounted for in an independent manner. This would be the equivalent of running 
sixty 0.2 million atom simulations, requiring the same computational resources as a single 
12 million atom simulation. Clearly, the simulation of a complete 60 protomer structure is 
an economic proposition, which becomes more compelling when incorporating 
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rhombic-dodecahedral periodic boundary conditions, reducing the total simulation size to 
approximately 3.3 million atoms, representing a saving of over 70% of the computational 
resources required to run 60 simulations of a single protomer. 
 
Validation of the atomistic MD simulation of a complete enterovirus was performed by 
constructing wild poliovirus type 1 (Mahoney strain) and by comparing structural 
elements with published atomic co-ordinate data. An additional advantage of simulating 
the entire virion was the ability to avoid potential artefacts that may have arisen by 
simulating only a portion of the capsid through symmetry. This could be especially 
relevant if there is an event that breaks capsid symmetry such as the gross morphological 
changes observed in the virus capsid prior to RNA release 
91,336
. Inclusion of the 
prototype viral RNA genome may also serve to assist researchers studying RNA-capsid 
interactions, viral uncoating mechanisms and subsequent RNA release. 
 
The computational experiments involving the simulation of full viruses and associated 
individual components (pentamer, empty capsid, spherical RNA) performed in this 
chapter, indicated that protocols so established, had resulted in simulations that were 
stable when assessed using RMSD measurements. Hypotheses exist that indicate an 
N-terminal α-helix located on VP1 of poliovirus type 1; this structure was also 
hypothesised to be amphipathic in nature based on the periodicity of the amino acid 
sequence
89
.  In the MD simulation performed in this chapter, the putative amphipathic 
helical structure was intrinsically stable when the final 20 amino acid residues were 
simulated as an independent entity. When examining the structure using a fit-averaged 
approach, the 60 protomer units indicated an increase in flexibility of the N-terminal 
region of VP1. This was particularly evident when simulated as a part of an empty capsid 
structure compared to the full virion with native RNA.  
 
When using complete capsid or virion structures for MD simulation, the individual 
hydrophobic pockets represent 60 independent drug binding sites, incorporated in a single 
simulation. In terms of statistical and biological relevance, this is important for future 
experiments that examine antiviral drug-binding. The core of the five-fold axis of 
symmetry proximal to the RNA indicated variations in flexibility when compared to 
empty capsids, as shown in Figures 4.7 and 4.10.  
 
With respect to the observed interactions of the genomic RNA with the inner surface of 
the virus capsid, the N-terminal aspects of VP1 and VP2 showed significant instances of 
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contact with the genomic RNA (Figure 4.13). Observations involving the interaction of 
the N-terminal aspect of VP2 with genomic RNA have been previously observed
91
, but 
the significance of these interactions is unknown. With respect to the interactions of the 
N-terminal aspect of VP1 with the genomic RNA, it is not surprising that a large internal 
structure such as an amphipathic helix would make contact with the RNA. This structure 
has not been observed in poliovirus using in-vitro experimentation, most likely due to 
mobile nature of the helix moving within the core of the virus, or exposed on the external 
surface of the capsid during virus breathing. It can be assumed that such mobility is 
critical to virus function. 
 
The N-terminus of VP1 is reversibly displayed on the exterior of the virus capsid through 
virus breathing, a feat that would necessitate molecular flexibility as indicated in the 
simulations performed in this chapter. It is hypothesised that binding of poliovirus to the 
cellular receptor, CD155, results in the irreversible externalization of the N-terminus of 
VP1. This is thought to occur during the process of cell membrane penetration, involving 
the formation of a pore-like complex, thus facilitating egress of the genomic RNA 
89,90
.  
 
The orientation of the N-terminus of VP1 on the internal surface of the capsid prior to 
receptor binding, has been the subject of much speculation
89,234,334
. The amphipathic helix 
of the N-terminus of VP1 of human rhinovirus 16 has been reported to be located on the 
interior surface of the capsid along the icosahedral five-fold axis, the orientation used in 
simulations in this chapter 
334
. Recent published data of EV-A71 indicate the positioning 
of the VP1 α-helix as being oriented toward the 2 fold axis of symmetry 215. Experiments 
involving the use of antibodies directed to the N-terminus of the VP1 in poliovirus were 
performed using cryo-EM analysis and found to be orientated towards the two-fold axis 
of symmetry 
352
. An advantage of the atomistic models is that components, such as the 
VP1 N-terminal helix, can be repositioned to account for new data, or to investigate 
alternative theories and compared as new MD simulations. 
 
Enteroviruses, in particular polioviruses, are relatively stable under a number of 
conditions that would result in inactivation of other viruses; an example is exposure to 
ethanol which does not denature or destroy the proteinaceous virus capsid as it does with 
the lipid containing envelope of other viruses, such as influenza. One way that 
polioviruses can be inactivated is by exposure to elevated temperatures. Exposure to 
increases in temperature has been observed to result in the expulsion of RNA across the 
2-fold axis of symmetry
91,336
. The in-silico experimentation described in this chapter 
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involved the gradual increase of simulated temperature on poliovirus virions which 
yielded evidence of significant morphological changes. Gross morphological distortion 
occurred in the canyon of the virus at 60°C and 95°C (Figure 4.17) and an opening of the 
2-fold axis of symmetry was observed. 
 
As a result of these observations, it was hypothesised that subtle conformational shifts 
may be observed during the initial “solvent shock” and equilibration phase of a virion 
structure undergoing MD simulation. To examine if this effect was observable, and 
affected by the binding of an antiviral drug, a series of experiments were performed 
involving the presence or absence of a native lipid compound or antiviral drug WIN51711 
(Disoxaril). Observations of capsid deformation in the form of expansion and contraction 
during “solvent shock” and equilibration, were observed in simulations that contained 
either native lipid or no small molecule in the hydrophobic pocket. No significant 
alteration in capsid dimensions in response to “solvent shock” was observed in the 
in-silico experiment that contained the antiviral drug WIN51711, indicating that the 
bound state of the drug may interfere with the rigidity of the capsid, affecting the viruses’ 
ability to respond to changes in environmental conditions.  
 
A number of preliminary semi-quantitative and qualitative analyses and observations 
were performed on the simulation trajectories obtained, including the overall “shape” of 
poliovirus capsids, by monitoring the time-series evolution of its radius, averaged 
conformations of protomers, capsid-RNA contacts, and secondary structure of previously 
unresolved N-terminus helix. Further examination of the specific interactions of the RNA 
with the internal surface of the capsid is warranted. In addition to the examination of the 
virion structure itself, it is worth noting that MD trajectories derived from these 
simulations also produce vital information on the interactions between the virus, solvent 
and ions. Of particular interest is the potential existence of ion channels throughout the 
capsid, which may serve important functions relating to virion-host cell interactions. 
These pores have been described previously in rhinovirus capsid structures determined by 
x-ray diffraction methods, but not poliovirus
15,348,353
. While the work presented in this 
thesis identified that the pores may be cation-selective (sodium-ions), future work could 
focus on extracting quantitative free-energy profiles of ion permeation through these 
pores. 
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This chapter has demonstrated a range of preliminary, simple analyses on virion MD 
trajectories, forming a platform for further work with poliovirus and other members of the 
genus Enterovirus (refer to chapter 5). It is anticipated that new analysis methods and 
protocols will be developed to keep pace with the increasing sizes of biological systems 
which may be simulated. Below, three potential properties of virions which merit further 
investigation are listed. 
1. Identify solvent/ion permeable pores around virus capsid and examine their activity 
using methods involving the extraction of potentials of mean force (PMF) profiles for 
cations and anions (including complex ions). Such methods have been used in the past 
to examine potassium, calcium and chloride ion movement through ion 
channels.
354,355
 
2. Employ statistical techniques to quantify and identify concerted virion motions. Such 
motions are analogous to vibration motions of small molecules, and low- or high-pass 
filtering techniques could be used to extract large-scale (slow) motions and 
small-scale (localised, rapid) motions, both of which may have implications for virus 
function. 
3. Analyse capsid structural activity in a manner that characterises the concerted motions 
of large segments (“plates”, representing protomers or pentamers) of the capsid, 
analogous to the study of planetary tectonic plate motions. Studies of these 
phenomena in viruses have been performed in the past using experimentally derived 
data
356,357
. Examination of MD trajectory data in a similar manner would prove useful 
in the elucidation of the underlying molecular mechanics of these motions.  
MD trajectory data collected at an appropriate time-frame resolution (1 ns per frame or 
less) would allow the investigation of these properties, although a side effect of this 
process is a larger data set for analysis, beginning at ~40GB of trajectory data for a 0.1 µs 
simulation collected at 1 ns time points. Given the sheer size and complexity of virions 
and the associated data files generated by MD simulation, it will be necessary to develop 
novel methods to enable efficient use of supercomputing architectures, to fully “mine” the 
wealth of biophysical information embedded within all-atom MD simulation trajectories. 
In this chapter, an initial approach to these complex problems is proposed via a protocol 
for the production and preliminary analysis of stable all-atom MD simulations of 
poliovirus. These protocols were developed and validated against crystallographic data, 
laying the foundation for the modelling of other viruses exhibiting icosahedral symmetry, 
as discussed in the following chapter. 
 143 
 
Chapter Five 
 
 
Comparative Protein Modelling of 
Enteroviruses 
 
 
Chapter5: Comparative Protein Modelling of Enteroviruses 
144 
5.1 Manuscripts Published in Association with this Chapter 
 
 Roberts, J.A., Bowden, D.S., Thorley, B. R., Revill, P.A., 2014. Chapter: New 
Technologies for Viral Diagnosis and Detection, Foodborne Viral Pathogens, 
Hansman, G., White, P., (Eds.), CRC Press, 1st Ed. ISBN-10: 1466579501. [In-
press]. 
 
5.2 Introduction 
The methodologies developed for successful in-silico reconstruction and atomistic MD 
simulation of poliovirus type 1, as described in the preceding chapter, would be amenable 
to other members of the genus Enterovirus that share fundamental structural 
characteristics. In order to take advantage of comparative protein modelling methods in 
conjunction with MD simulation of novel virus structures, adequate atomic coordinates 
must be available to be used as suitable templates for the homologous virus sequence. 
Given that unknown structural components will be modelled on known structural 
templates, it is important that the coordinate data are derived by reliable methods such as 
X-ray crystallography, nuclear magnetic resonance or high resolution cryo-EM. 
 
If there are no coordinate data available to exactly match the sequence of the virus under 
investigation, then the use of comparative modelling methods using structures that match 
with a high enough degree of sequence identity will be required. This assumes that there 
are proteins structures available in the Protein Data Bank with a suitable degree of amino 
acid sequence similarity. But what is an acceptable limit for sequence similarity, which 
may permit the accurate reconstruction of virus components?  The answer is dependent 
on the type of protein to be modelled, and whether they are structural proteins, such as 
those found in the enteroviruses with known highly conserved extended-beta structures, 
or globular non-structural proteins such as proteases and polymerases, where the 
requirement for a high degree of sequence identity may vary. 
 
As a general rule, an amino acid sequence identity of greater than 30% is considered 
acceptable when selecting structural templates for comparative protein modelling 
358
, 
although others have stated that a minimum of 50% sequence identity is required with 
less than 1 Å deviation from backbone atoms
359
. There have also been indications that the 
minimum percentage identity acceptable for some models can be as low as 20% 
360
. 
Chapter5: Comparative Protein Modelling of Enteroviruses 
145 
Either way, it appears that through common usage, the figure of 30% identity has been 
considered by many as representative of the lower limit for the successful reconstruction 
of structural models using comparative modelling methods. Whilst these guidelines for 
sequence identity may be appropriate for the modelling of small structures, no substantial 
work has been performed to determine if these limits are appropriate for the in-silico 
prediction of extremely large macromolecular structures such as viruses. 
 
As described in chapter 1 sections 1.4 and 1.5, a significant proportion of the molecular 
modelling of virus structures is devoted to the study of antiviral interactions with specific 
virus features, with a large focus being the development or examination of antivirals for 
the treatment of influenza infection and HIV.  
 
It is important to understand the limits associated with sequence identity and model 
accuracy. Assumptions based on a flawed model can lead to a significant waste of 
resources. This is especially true, when considering that modelling a full virion through a 
0.1 microsecond simulation, can from personal experience, take in excess of two million 
supercomputer hours to perform and a week in “hands-on” time to construct and analyse 
the simulation. 
 
This chapter investigates issues associated with the reconstruction of structural proteins 
representing enterovirus capsids, using comparative protein modelling methods with 
templates of varying degrees of sequence identity. This was achieved by selecting 
prototype species C and species A Enteroviruses that have structural co-ordinate data 
derived using x-ray diffraction methods. Comparative protein models were created using 
two commonly used modelling software packages: Modeller
326,361
 and Swiss-PDB 
viewer
327,362
. Both packages were selected due to their ease of use and for their capability 
to allow manual input during the threading process enabling combination of query 
sequence data with template structural data. 
 
Once the most accurate and precise modelling method was established using manual 
threading methods, the reconstruction of the species C, EV-C96 and the species A, 
EV-A120 capsids, were performed. All capsids constructed were examined for stability, 
using the methods described in chapter 4. The stability of the model virions during the 
simulation time frames, strongly support the validity of the comparative modelling 
approach employed.  
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5.3 Materials and Methods 
Sequences used in the reconstruction of prototype, newly described and novel enterovirus 
capsids were derived from GenBank, while novel species A and newly described species 
C Enterovirus sequences, were derived in-house. The species C Enterovirus prototype 
selected for reconstruction was coxsackievirus A21 (GenBank sequence accession 
number AF546702)
363
. The species A Enterovirus prototype selected for reconstruction 
was enterovirus A71 (GenBank sequence accession number FJ461781)
164
.  
 
Comparative protein modelling methods for the reconstruction of a single protomer used 
in the reconstruction of a complete capsid, were performed using manual threading 
methods in the programs Modeller and Swiss-PDB viewer. The models were constructed 
using the recommended protocols for each program, with five protomer homology 
models generated by default using Modeller
361
,  and a single protomer model generated 
by Swiss-PDB viewer
362
. In the case of the Swiss-PDB viewer generated homology 
model, the final step involved uploading the predicted protomer to the SWISS-MODEL 
website for refinement. 
 
After generation of the final protomer structures, virus capsids were reconstructed, 
accessory lipids added and a final structure solvated and ionised, using the methods 
described in chapter 4. Scripts used for the extraction and compilation of data for analysis 
were the same as those used for the examination of wild poliovirus as described in 
chapter 4 and as set out in appendix A5. 
 
Capsid structures were solvated and ionised, then subjected to atomistic MD simulation 
using NAMD on a BlueGene/Q supercomputer housed at the VLSCI. Simulations were 
performed using a constant number, pressure and temperature (NPT) environment 
maintained at 37°C and one atmosphere for 10ns each, as described in chapter 4 (refer to 
appendix A5.8). These simulation parameters were selected in order to allow the 
predicted structures to equilibrate, providing opportunity for any incorrectly placed 
side-chains to rotate into a more energetically favourable position. Once equilibrated, the 
virus capsids were deconstructed using a Tcl script (appendix A8.4), which placed all 
protomers in the same 3-dimensional space aligned by their structural motifs, specifically 
the residues representing the beta-strand formations comprising the Swiss roll motifs. 
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Model quality assessment was performed using RMSD comparison of backbone (C, Cα, 
and N atoms) or all atoms (not including hydrogen “NoH”) for the original template, 
compared with the predicted model where indicated. Additional model assessment was 
performed using the web-based “Protein Quality Prediction” ProQ364 method and two 
values obtained: LGscore, which determines the longest non-contiguous segment and 
measures the similarity using the structural P-value and MaxSub, which calculates the 
largest number of residues found with distances between structures shorter than 3.5 Å 
328,329
. Ranking of LGscore is divided into the following qualitative interpretations: 
>1 =  fairly good model, >2.5 = very good model, >4 = extremely good model. Max Sub 
values are ranked as follows: >0.1 = fairly good model, >0.5 = very good model, 
>0.8 = extremely good model. 
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5.4 Results 
 
5.4.1 Comparative Modelling of Complete Virus Capsid Structures 
In order to examine the limitations of comparative modelling methods for the 
reconstruction of novel or newly described virus capsids, a series of experiments were 
performed to determine the amount of variation compared to a predetermined series of 
structures elucidated using x-ray crystallographic methods. The aim of these experiments 
was to determine the most appropriate methodology to accurately and precisely 
reconstruct prototype virus capsids, and then to apply these methods to the reconstruction 
of the newly described EV-C96 and the novel enterovirus EV-A120. 
 
5.4.1.1 Coxsackievirus A21 
To validate a methodology for the reconstruction of EV-C96 using comparative protein 
modelling, first CV-A21 was reconstructed based on wild poliovirus crystal co-ordinates 
and then compared to actual CV-A21 crystallography data. The reconstruction of CV-
A21 was performed using automated methods via the SWISS-Model website, with a 
manual template selection method forcing the use of PDB file 1HXS (the Mahoney strain 
of poliovirus 1HXS at 2.2 Å). This template was used previously in chapter 4 and 
contains the most complete x-ray crystallographic data of poliovirus. Amino acid 
sequence identity between CV-A21 and poliovirus capsid proteins ranged from 57.4% to 
76.8%, with an overall identity of 68.1% for the entire protomer structure (Table 5.1). 
Manual threading methods were attempted using the Swiss-PDB viewer program version 
4.04 and the command-line interface-based program Modeller. 
 
CV-A21 VP1 VP2 VP3 VP4 Protomer 
PV1-Wild 57.4% 73.1% 73.9% 76.8% 68.1% 
 
Table 5.1 CV-A21 protomer amino acid percentage identity to wild poliovirus type 1 template 
structure. Comparison of CV-A21 prototype sequence AF546702 to sequence data derived from the PDB 
structure file 1HXS for wild poliovirus. 
 
The use of the program Modeller involved the alignment of the query CV-A21 sequence 
data with the PDB file data for wild poliovirus. The output consisted of five structures 
(PDB coordinate files representing the homology models), were all five structures bore 
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little resemblance to the x-ray diffraction-derived structure for CV-A21 with RMSD 
values approaching 5 Å (Figure 5.1A and Table 5.2). Using the protomer averaging 
method based on the five models, resulted in a greatly improved structure that was within 
4 Å of the known coordinates for the CV-A21 virus capsid (Figure 5.1B and Table 5.2). 
Methods using manual threading via the Swiss-PDB viewer program proved to be 
relatively straightforward and required a manual alignment process followed by 
uploading of the data to the SWISS-model server for completion. Resultant data were 
within 2.1 Å of the experimentally derived VP1 structural data (PDB file 1Z7S)
365
 for 
CV-A21 using x-ray diffraction methods (Figure 5.1C and Table 5.2). 
 
 
 
Figure 5.1 Predicted models of coxsackievirus A21 VP1 protein. VP1 protein predictions for CV-A21 
overlaid on the original x-ray crystal structure 1Z7S (white), A) five outputs from the Modeller program 
(coloured green, cyan, violet, yellow and grey), B) fit averaged outputs from Modeller (blue), C) output 
from Swiss-PDB viewer in manual threading mode (purple). RMSD values, compared to original crystal 
structure are given in table 5.1 below. 
 
 
Modeller 
No. 1 
Modeller 
No. 2 
Modeller 
No. 3 
Modeller 
No. 4 
Modeller 
No. 5 
Modeller 
Averaged 
SWISS-PDB 
viewer 
RMSD 3.382 3.983 4.658 3.281 3.382 2.593 2.097 
 
Table 5.2 Backbone RMSD values for predicted models of VP1 for CA21 using comparative 
modelling methods. Values given for five outputs from the modeller program, protomer fit averaged 
output from modeller, protomer fit averaged model from Swiss PDB viewer project. 
 
The model from SWISS-MODEL was used for subsequent MD simulation. After 20 ns of 
atomistic MD simulation using NAMD (Figure 5.2) with a constant number of atoms, 
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pressure and temperature (NPT), the stability of the capsid structures were examined 
using RMSD calculations for the entire protein (Figure 5.3). Virus expansion and 
contraction was determined using measurements of the virus capsid across the x, y and z 
axes for the α-carbons, representing the furthest loop structures which are subjected to 
variability in the solvent accessible space. Virus diameter measurements were also made 
to the extended beta sheets located towards the centre of mass of each protomer on the x, 
y and z axes. The β-sheets represent the major structural components of the virus capsid 
and are therefore not expected to undergo substantial variations in 3-dimensional space 
when compared to the solvent accessible α-carbons of the external surface of the capsid 
(Figure 5.4). 
 
 
 
 
Figure 5.2 Final structure output after 20 ns of atomistic MD simulation for CV-A21. A) Radial depth 
shaded Van der Waals representation of the CV-A21 capsid measured from the origin (blue = 133 Å to Red 
166 Å), B) cutaway density model calculated at 3.0A, the +x and –z axes. –x and +y axes are represented in 
new cartoon format and shaded by protein chain VP1 (blue), VP2 (yellow), VP3 (red) and VP4 (not visible 
in this representation). 
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Figure 5.3 RMSD values for whole capsid simulation of CV-A21 homology model after atomistic MD 
simulation for 20 ns after 50,000 steps of minimisation. x- axis = time (ns), y- axis = RMSD (Å). 
 
 
Figure 5.4 Virus diameter measurements for the CV-A21 capsid over the x, y and z axes in Å 
measured for the α- carbons (Cα) of the protein backbone and the extended-beta sheets comprising the 
primary structural regions of the Swiss jellyrolls (β). x- axis = time (ns), y- axis = diameter (Å). 
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After the initial “solvent shock”, the capsid structure remained stable as indicated in 
Figures 5.3 and 5.4. Upon completion of the simulation, all 60 protomers were positioned 
in the same space as protomer number one and an averaged structure was obtained from 
the overlay (Figure 5.5). 
 
 
 
Figure 5.5 Protomer fit-averaged structure output after 20 ns of MD simulation. A) spatial overlay of 
60 protomers comprising the virus capsid (grey), B) spatial overlay of the 60 protomers with fit averaged 
protomer coloured by chain VP1 (blue), VP2 (yellow), VP3 (red) and VP4 (green), C) fit averaged 
protomer coloured by chain with spatial overlay of 60 protomers removed, D) fit averaged protomer 
coloured by chain overlaid on original crystal structure for CV-A21 1Z7S, indicating areas of mismatch 
between in-vitro and in-silico experimental data.  
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Examination of the averaged virus proteins VP1, VP2, VP3 and VP4 that comprise the 
CV-A21 protomer, indicated backbone RMSD values ranging from 1.8 Å to 3.6 Å for the 
minimised structure and an overall RMSD for the protomer of 2.6 Å when compared to 
the original crystal structure. Subsequent to the 20 ns of atomistic MD simulation, the 
RMSD values dropped to a range of 1.6 Å to 3.8 Å for the viral capsid proteins and 2.5 Å 
for the protomer (table 5.3). The experimental error for the original x-ray data for 
CV-A21 was 3.2 Å
365
. 
 
  VP1 VP2 VP3 VP4 Protomer 
Minimized 2.707 1.816 2.578 3.850 2.609 
20ns MD 
simulation 
2.737 1.614 2.231 3.807 2.524 
 
Table 5.3 RMSD values for individual proteins and protomer for CV-A21 post minimisation and post 
atomistic MD simulation. 
 
ProQ quality assessment indicated that the original crystal structure for CV-A21 was 
ranked as an “extremely good model” (LGscore) and “fairly good model” (MaxSub). The 
models created using threading methods ranked initially as “Very good” for the LGscore 
but increased marginally and crossed the threshold to “extremely good”, once the 
fit-averaging method was utilised. MaxSub scores indicated a similar phenomenon (Table 
5.4). 
 
LG Score MaxSub 
1Z7S 
Template 
Protomer 
No. 1 
Averaged 
Protomer 
1Z7S 
Template 
Protomer 
No. 1 
Averaged 
Protomer 
5.902 3.945 4.055 0.423 0.342 0.362 
 
Table 5.4 Quality assessment of CV-A21 predicted model using the ProQ Protein quality prediction 
website. LGscore and MaxSub values obtained for the original crystal structure, a single protomer derived 
from position 1 of the predicted capsid structure after 20ns of atomistic MD simulation and the fit-averaged 
protomer structure derived from all 60 protomers of the capsid after 20ns of MD simulation. For 
information regarding LGscore and MaxSub ranking see section 5.3. 
 
Based on an RMSD variation of 2.524 Å from the experimentally derived structure and 
ProQ values that indicated that the predicted model was a “good model”, manual 
threading methods using SwissPDBviewer were seen to be an appropriate technique. 
Subsequent models were generated using the SwissPDBviewer program and the validated 
methods described above were used to examine the quality of the final structures.  
Chapter5: Comparative Protein Modelling of Enteroviruses 
154 
5.4.1.2 Enterovirus A71 
Enterovirus A71 (EV-A71), which is considered an emerging pathogen, has gained a 
significant amount of attention from the scientific community
134,152,164,165,317,366
. During 
the initial reconstruction attempts made during the PhD candidature period, no x-ray 
crystal structure data existed. As a result, three sub-genogroups of EV-A71 were 
reconstructed using manual methods via the SWISS-PDBviewer program, with sequence 
identity as low as 32.1% for individual virus capsid proteins and overall identity of 43.0% 
for the protomer structure (table 5.5). The three sub-genogroups constructed where EV-71 
A, B5 and C4, as these represented the types most likely to be of scientific interest, with 
serotypes B5 and C4 co-circulating in the Asia Pacific region. A protomer was 
constructed using the 1HXS PDB template structure of wild poliovirus. The virus capsid 
structure for EV-A71 C4 was constructed as per the methods used for wild poliovirus and 
equilibrated for 1 ns using a live installation of Ubuntu Linux on a microSD card running 
on a Dell T3500 workstation using VMD and NAMD with CUDA GPU extensions. 
 
EV-A71 VP1 VP2 VP3 VP4 Protomer 
PV1-Wild 32.1% 50.9% 41.3% 57.9% 43.0% 
 
Table 5.5 EV-A71 protomer amino acid percentage identity to wild poliovirus type 1 template 
structure. Comparison of EV-A71 prototype sequence AB550338 to sequence data derived from the PDB 
structure file 1HXS for wild poliovirus. 
 
After the simulation of the EV-A71 comparative model was determined to be stable for 
1 ns using Dell T3500 workstation, it was transferred to the BlueGene Q supercomputer 
and run on 4096 cores (65,536 threads) for 3 days, (3.3ns per day), resulting in a stable 
10 ns atomistic MD simulation of a complete EV-A71 capsid structure (Figure 5.6). The 
simulation parameters used a constant number of atoms, pressure and temperature (NPT) 
ensemble as described in appendix A5.8. The stability of the capsid structures were 
examined using RMSD calculations for the entire protein over the 10 ns simulation time 
(Figure 5.7). As described for the examination of CV-A21 (section 5.4.1.1), virus 
expansion and contraction were determined using measurements of the virus capsid 
across the x, y and z axes for the α- carbons and extended beta sheets located towards the 
centre of mass of each protomer (Figure 5.8). 
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Figure 5.6 Final structure output after 10 ns of atomistic MD simulation for EV-A71. A) Radial depth 
shaded Van der Waals representation of the capsid measured from the origin (blue = 133 Å to Red 166 Å), 
B) cutaway density model calculated at 3.0A, the +x and –z axes. –x and +y axes are represented in new 
cartoon format and shaded by protein chain VP1 (blue), VP2 (yellow), VP3 (red) and VP4 (not visible in 
this representation). 
 
 
 
Figure 5.7 RMSD values for capsid simulation of EV-A71 homology model after atomistic MD 
simulation for 10 ns after 50,000 steps of minimisation. x- axis = time (ns), y- axis = RMSD (Å). 
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Figure 5.8 Virus diameter measurements for EV-A71 over the x, y and z axes in Å measured for the 
α- carbons (Cα) of the protein backbone and the extended beta sheets comprising the primary structural 
regions of the Swiss jellyrolls (β). x- axis = time (ns), y- axis = diameter (Å). 
 
After the completion of the reconstruction and simulation process for the EV-A71 capsid 
structure, experimentally derived coordinate data for the virus in differing states using 
x-ray diffraction methods were released into the public domain, allowing the comparison 
of the model to a number of x-ray diffraction-derived EV-A71 structures (Figure 5.9, 
Table 5.6 and 5.7).  
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Chain 3VBF 3VBH 3VBO 3VBR 3VBS 3VBU 4AED 
VP1 2.338 2.368 3.076 3.055 2.327 3.075 2.379 
VP2 2.163 2.162 2.374 2.342 2.171 2.343 2.149 
VP3 1.558 1.556 3.469 3.437 1.564 3.506 1.471 
 
Table 5.6 “Backbone” RMSD values calculated for predicted models compared to available EV-A71 
structures. Predicted model reconstructed using comparative modelling methods, simulated and then 
compared to all available reference structures, RCSB protein data bank (PDB ID codes indicated in header 
row). 
 
 
 
 
 
Predicted 3VBF 3VBH 3VBO 3VBR 3VBS 3VBU 4AED 
Predicted 0 2.156 2.164 3.255 3.248 2.153 3.277 2.120 
3VBF 2.156 0 0.147 2.326 2.313 0.121 2.343 0.506 
3VBH 2.164 0.147 0 2.322 2.311 0.180 2.341 0.505 
3VBO 3.255 2.326 2.322 0 0.266 2.324 0.301 2.423 
3VBR 3.248 2.313 2.311 0.266 0 2.312 0.232 2.411 
3VBS 2.153 0.121 0.180 2.324 2.312 0 2.341 0.507 
3VBU 3.277 2.343 2.341 0.301 0.232 2.341 0 2.440 
4AED 2.120 0.506 0.505 2.423 2.411 0.507 2.440 0 
  
Table 5.7 Pairwise comparison of “Backbone” RMSD values calculated for predicted models 
compared to available EV-A71 structures. Pairwise comparison of reference protomer structures, chains 
VP1, VP2, and VP3. VP4 has not been included in this analysis as only 3VBF, 3VBH, 3VBS and 4AED 
contain coordinate data for VP4. RCSB protein data bank (PDB ID codes indicated in header row). 
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Figure 5.9 Structural comparisons of enterovirus 71 homology models with X-ray crystal data. A) 
EV-A71 protomer fit-averaged structure coloured by chain VP1 (blue), VP2 (yellow), VP3 (red) and VP4 
(green), B) EV-A71 predicted VP1 structure (white) overlaid on the seven available crystal structures for 
EV-A71 C) EV-A71 predicted VP2 structure (white) overlaid on all available crystal structures for EV-A71 
D) EV-A71 predicted VP3 structure (white) overlaid on all available crystal structures for EV-A71 and E) 
EV-A71 predicted VP4 structure (white) overlaid on all available crystal structures for EV-A71. Reference 
structure colours are as follows: Red – 3VBF, Yellow – 3VBH, Orange – 3VBO, Green – 3VBR, Blue – 
3VBS, Purple – 3VBU, Cyan – 4AED. 
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Quality assessment using the ProQ website, ranked the experimentally derived structure 
for EV-A71 (PDB ID 4AED) as an “extremely good model” (LGscore) and “fairly good 
model” (MaxSub). The models created using threading methods ranked initially as “Very 
good” for the LGscore, with a score approaching 5 for the fit-averaged protomer. As 
indicated in section 5.4.1.1, the MaxSub scores indicated that all models were “fairly 
good” with values within the 0.1 to 0.5 range (Table 5.8). 
 
LG Score MaxSub 
4AED 
Template 
Protomer  
No. 1 
Averaged 
Protomer 
4AED 
Template 
Protomer 
No. 1 
Averaged 
Protomer 
6.110 4.113 4.819 0.392 0.302 0.375 
 
Table 5.8 Quality assessment of EV71 predicted model using the ProQ Protein quality prediction 
website. LGscore and MaxSub values obtained for the original crystal structure, a single protomer derived 
from position 1 of the predicted capsid structure after 10ns of atomistic MD simulation and the protomer-fit 
averaged structure derived from all 60 protomers after 10ns of MD simulation. For LGscore and MaxSub 
ranking see section 5.3. 
 
Using the most complete experimentally derived EV-A71 structure (4AED) with the 
lowest resolution (3.8 Å) as a reference
367
, the protomer-fit average model was evaluated 
and RMSD figures obtained for all viral capsid proteins for the backbone atoms and all 
atoms (excluding hydrogen) compared to the reference (Table 5.9). 
 
  VP1 VP2 VP3 VP4* Protomer 
Not Hydrogen 3.903 3.761 3.358 4.357 3.716 
Backbone 2.433 2.319 1.538 2.746 2.120 
 
Table 5.9 RMSD values for predicted models compared to the reference structure 4AED. Values 
calculated for the backbone, and all atoms excluding hydrogen, of the capsid proteins for the predicted 
EV-A71 model after 10ns MD Simulation compared to the experimentally derived structure (PDB 
accession number 4AED). 
 
Results indicated that the comparative model, although only sharing an overall identity of 
43% with the wild poliovirus template model (1HXS), was within 3.716 Å of the 
experimentally derived structure when comparing all atoms except hydrogen. This closely 
mirrors the resolution of the x-ray diffraction data for EV-A71 at 3.8 Å (PDB ID 4AED). 
It should be noted that the N-terminal α-helix of VP1 was excluded from this analysis, 
given the uncertainty of the appropriate positioning of this particular motif, as was noted 
for wild poliovirus in chapter 4.  
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In order to further assess the quality of the predicted model and its potential utility in the 
examination of antiviral drug binding, the amino acid residues lining the hydrophobic 
pocket were examined. Amino acids within 4 Å of the native laurate molecule in PDB file 
4AED were selected for comparison with the EV-A71 model generated using 
comparative protein methods (Figure 5.10). 
 
 
 
Figure 5.10 Comparison of hydrophobic pocket x-ray diffraction data and the predicted structure for 
EV-A71. showing residues lining the hydrophobic pocket and within 4 Å of the native lauric acid molecule. 
Left (white) a single protomer derived from the crystal structure of EV-A71 C4 (PDB file accession number 
4AED). Break-out figure shows the amino acid residues (“liquorice” representation) coloured by beta value 
from the crystal structure of EV-A71 C4 (PDB file accession number 4AED) within 4 Å of lauric acid 
(white) in the hydrophobic pocket. Corresponding individual amino acid residues derived from 60 
protomers after 10ns of MD simulation of the predicted EV-A71 model are identified as a grey “line” 
representations and numbered by position within the VP1 amino acid sequence and three-letter amino acid 
abbreviation. Scale-bar = B-factor range 0 (blue) to >100 (red).  
 
 
Observation of the interior lining of the hydrophobic pocket showed a good correlation 
between the predicted model and the experimentally derived structure. Where significant 
deviation occurred between the two structures, a corresponding increase in B-factor value 
was also observed, indicating that significant thermal fluctuation was present. This was 
reflected in the predicted model by a corresponding increase in spatial disorder (Figure 
5.10).  
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 60 protomers Fit-averaged 
RMSD (Backbone) 1.410 (SD 0.259) 1.089 
RMSD (Not Hydrogen) 3.513 (SD 0.114) 3.292 
 
Table 5.10 RMSD values calculated for hydrophobic pocket x-ray diffraction data and the predicted 
structure for EV-A71. Values calculated for the backbone structure and all atoms excluding hydrogen 
between the experimentally derived structure (PDB accession number 4AED) and the predicted structure 
for residues lining the hydrophobic pocket and within 4 Å of the native lauric acid molecule, for all 
protomers of the capsid after 10ns of MD simulation and the fit-averaged protomer structure. 
 
 
Comparison of the hydrophobic pocket indicated that there was approximately 1 Å 
variation from the experimentally derived structure when calculating RMSD for the 
backbone coordinates of the fit-averaged structure. When calculating the variation of 
individual protomers, this difference increased to 1.4 Å (Table 5.10). The exterior of the 
predicted structure when compared to PDB file 4AED showed a deviation (RMSD) as 
low as 2.1 Å for the backbone structure and 3.7 Å for all atoms excluding hydrogen, 
when compared to x-ray crystallographic data (Table 5.9). The interior aspects of the 
capsid deviated significantly due to the rearrangement of the VP4 protein chain, which 
differs to structures observed in wild poliovirus. This observation is discussed further in 
section 5.5. 
 
 
5.4.2 Comparative Modelling of Novel and Newly Described Viruses 
In order to reconstruct the newly described and novel enteroviruses, EV-C96 and 
EV-A120 respectively, the manual methods determined in section 5.4.1.1 were applied. 
Sequences representing the capsid region for each virus were obtained using a 
combination of primer walking and primer design by alignment of homologous serotypes. 
A combination of the SwissPDBviewer manual threading method and the web-based 
SWISS-Model was a simple and accurate method for the prediction of protomeric 
structures for capsid construction, and was used for the subsequent experimental 
reconstruction of newly-described and novel enteroviruses.  
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5.4.2.1 Enterovirus C96 
The template selection for the reconstruction of the EV-C96 structures was based on 
homologous structures available as x-ray diffraction data on the RCSB. In this case, two 
templates of species C Enteroviruses were deemed suitable for reconstruction according 
to phylogenetic inference using maximum-likelihood methods, namely coxsackievirus 
A21 and wild poliovirus. Given that the wild poliovirus coordinates for 1HXS 
represented the most complete structures at the best resolution, comparative modelling 
was performed using these coordinates. The percentage amino acid identity for the 
template structures ranged from 59.7% to 84.0% with an overall protomer sequence 
identity of 68.5% (Table 5.11). 
 
EV-C96 VP1 VP2 VP3 VP4 Protomer 
PV1-Wild 59.7% 72.4% 70.9% 84.0% 68.5% 
 
Table 5.11 EV-C96 protomer amino acid percentage identity to wild poliovirus type 1 template 
structure. Comparison of EV-C96 sequence 118030-PNG-05 to sequence data derived from the PDB 
structure file 1HXS for wild poliovirus. 
 
Reconstruction and atomistic method dynamics simulation was performed using the 
methods described previously in chapter 4 and chapter 5. Simulations were performed as 
previously described (section 5.4.1.1) and the stability of the capsid structures were 
examined using RMSD calculations for the entire protein over a 10 ns simulation time 
(Figure 5.11). As described for the examination of CV-A21 (section 5.4.1.1), virus 
expansion and contraction was determined using measurements of the virus capsid across 
the x, y and z axes (Figure 5.12). Observations over the course of the 10ns simulation 
indicated subtle changes in virus diameter and plateau of RMSD values, indicating that 
the virus capsid had stabilised relatively quickly compared to the previous EV-A71 
model. The final capsid structure is shown in figure 5.13. 
 
Quality assessment using the ProQ website ranked the predicted model as a “very good 
model” using the LGscore, with the protomer-fit average structure falling just short of the 
“extremely good model” ranking at 3.914. MaxSub values were similar to those values 
for the experimentally derived and predicted models for CV-A21 and EV-A71, all of 
which fell within the “fairly good model” range of 0.1 to 0.5 (Table 5.12).  
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Figure 5.11 RMSD values for capsid simulation of EV-C96 homology model after atomistic MD 
simulation for 10 ns after 50,000 steps of minimisation. x- axis = time (ns), y- axis = RMSD (Å). 
 
 
Figure 5.12 Virus diameter measurements for EV-C96 over the x, y and z axes in Å measured for the 
α- carbons (Cα) of the protein backbone and the extended beta sheets comprising the primary structural 
regions of the Swiss jellyrolls (β). x- axis = time (ns), y- axis = diameter (Å).  
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Figure 5.13 Final structure output after 10 ns of atomistic MD simulation for EV-C96. A) radial depth 
shaded Van der Waals representation of the capsid measured from the origin (blue = 133 Å to Red 166 Å), 
B) cutaway density model calculated at 3.0A on the +x and –z axes. –x and +y axes are represented in new 
cartoon format and shaded by protein chain VP1 (blue), VP2 (yellow), VP3 (red) and VP4 (not visible in 
this representation). Refer to section 5.4.3 for topological comparison of the EV-C96 predicted model to 
other representatives of the family Picornaviridae. 
 
 
 
LG Score MaxSub 
Protomer  
No. 1 
Averaged 
Protomer 
Protomer 
No. 1 
Averaged 
Protomer 
3.593 3.914 0.319 0.359 
 
Table 5.12 Quality assessment of EV-C96 predicted model using the ProQ Protein quality prediction 
website. LGscore and MaxSub values obtained for a single protomer derived from position 1 of the 
predicted capsid structure after 10ns of atomistic MD simulation and the protomer-fit averaged structure 
derived from all 60 protomers after 10ns of MD simulation. For LGscore and MaxSub ranking see section 
5.3. 
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5.4.2.2 Enterovirus EV-A120 
Given that the complete capsid region was now sequenced as described in chapter 3, it 
was possible to use the above described comparative protein modelling methods to 
reconstruct the capsid structure of the newly discovered enterovirus EV-A120. In order to 
do so, appropriate templates were selected from homologous structures determined using 
x-ray diffraction methods, which represented a high degree of amino acid sequence 
identity. The capsid region sequence was queried against available data using the 
SwissModel website in order to determine suitable templates. 
 
This method indicated that X-ray crystallography data were available for EV-A71 (amino 
acid identity of 72.1%, Table 5.13), CV-A16 (amino acid identity of 71.6%) and cryo-EM 
data for CV-A7 (amino acid identity 80.0%), Figure 5.14. The x-ray diffraction data for 
EV-A71 was more complete in terms of chain data for VP1, VP2, VP3 and VP4. The 
x-ray diffraction data for CV-A7 (PDB file 4AGY, 4AGX) contained only partial chain 
data. The experimental error of 3.8 Å for EV-A71 and 6.09 Å for CV-A7 indicated that 
although CV-A7 showed a higher amino acid sequence identity with EV-A120, the 
completeness and high resolution of the x-ray diffraction data for EV-A71 (PDB file 
4AED) was a better choice for modelling the novel virus EV-A120. 
 
 
EV-A120 VP1 VP2 VP3 VP4 Protomer 
EV-A71 64.6% 82.6% 71.4% 69.5% 72.1% 
 
Table 5.13 EV-A120 protomer amino acid percentage identity to EV-A71 template structure. 
Comparison of EV-A120 to sequence data derived from the PDB structure file 4AED for EV-A71 
genogroup C4. 
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Figure 5.14 Ancestral relationships from the available crystal structures for EV-A120. Radial 
phylogenetic tree calculated using maximum likelihood method using the HKY+G+I model for the 
complete capsid encoding region. Amino acid percent identity given in parentheses. 
 
After 10 ns of atomistic MD simulation using NAMD with a constant number of atoms, 
pressure and temperature (NPT), the stability of the capsid structures were examined 
using RMSD calculations for the entire protein over the 10 ns simulation time (Figure 
5.15). Virus expansion and contraction was determined using measurements of the virus 
capsid across the x, y and z axes for the α- carbons and extended beta sheets located 
towards the centre of mass of each protomer (Figure 5.16). It was noted that the RMSD 
values calculated over the duration of the simulation showed evidence of stabilisation 
after the initial “solvent shock”, but the assessment of the capsid expansion indicated that 
although the extended β-sheets remained at a constant radius from the origin, the 
outermost α-carbons contracted by almost 5 Å. Examination of the simulation indicated 
that the outermost loop structures of the BC loop and the C-terminal end of VP1 settled 
toward the capsid surface. The final capsid structure after 10 ns is indicated in Figure 
5.17. 
 
Quality assessment using the ProQ website ranked the predicted model as a “extremely 
good model” using the LGscore for both the single protomer and protomer-fit averaged 
structures. MaxSub values were once again within the 0.1 to 0.5 range corresponding to 
the “fairly good model” ranking, as seen for all experimentally derived and predicted 
structures examined in this body of work. Table 5.14.  
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Figure 5.15 RMSD values for capsid simulation of EV-A120 homology model after atomistic MD 
simulation for 10 ns after 50,000 steps of minimisation. x- axis = time (ns), y- axis = RMSD (Å). 
 
 
Figure 5.16 Virus diameter measurements for EV-A120 over the x, y and z axes in Å measured for the 
α- carbons (Cα) of the protein backbone and the extended beta sheets comprising the primary structural 
regions of the Swiss jellyrolls (β). x- axis = time (ns), y- axis = diameter (Å).  
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Figure 5.17 Final structure output after 10 ns of atomistic MD simulation for EV-A120. A) Radial 
depth shaded Van der Waals representation of the capsid measured from the origin (blue = 133 Å to Red 
166 Å), B) cutaway density model calculated at 3.0A, the +x and –z axes. –x and +y axes are represented in 
new cartoon format and shaded by protein chain VP1 (blue), VP2 (yellow), VP3 (red) and VP4 (not visible 
in this representation). Refer to section 5.4.3 for topological comparison of the EV-A120 predicted model 
to other representatives of the family Picornaviridae. 
 
LG Score MaxSub 
Protomer  
No. 1 
Averaged 
Protomer 
Protomer 
No. 1 
Averaged 
Protomer 
4.257 4.437 0.305 0.350 
 
Table 5.14 Quality assessment of EV-A120 predicted model using the ProQ Protein quality prediction 
website. LGscore and MaxSub values obtained a single protomer derived from position 1 of the predicted 
capsid structure after 10ns of atomistic MD simulation and the protomer-fit averaged structure derived from 
all 60 protomers after 10ns of MD simulation. For LGscore and MaxSub ranking see section 5.3. 
 
Given the issues surrounding the lack of success cultivating the virus, it was decided to 
concentrate on the identification of a potential receptor binding site in order to help select 
a more appropriate cell line for cultivation. A review of the literature indicated that 
members of the clade shared by EV-A120, specifically CV-A7, CV-A14, CV-A16 and 
EV-A71 show evidence of the utilisation of the SCARB2 receptor for binding. A binding 
motif has been described that indicated a series of mutations that affected SCARB2 
binding affinity368,369. An amnio acid alignment of the clade members, CV-A7 and 
EV-A71, with EV-A120 was performed to indicate whether this motif was present, 
Figure 5.18  
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Figure 5.18 Multiple amino acid sequence alignment for CV-A7, CV-A14, CV-A16, EV-A71 and 
EV-A120. A fragment of the VP1 encoding region of the genome indicating the residues (blue shading) 
comprising an area in the “canyon” wall considered significant to binding of the cellular receptor 
SCARB2
368,369
. 
 
 
The alignment of CV-A7, EV-A71 and EV-A120 indicated that the hypothesised binding 
motif was present. CV-A7 and EV-A71 were selected for the alignment based on the 
availability of x-ray diffraction derived coordinate data that could be used to compare the 
3-dimension presentation of the binding motif that lies on the canyon wall (Figure 5.19). 
Structurally, the motif present in CV-A7 and EV-A71 was present in EV-A120. 
 
Figure 5.19 3-Dimensional reconstruction of EV-A120 after 10ns MD simulation indicating residues 
considered significant to SCARB2 binding. A) Surface representation of EV-A120 capsid at 5 Å 
resolution, break-out figure indicates residues flanking the EF loop of VP1 as described 
368,369
, B) 
hypothesised SCARB2 amino acid motif indicated for EV-A71, C) CV-A7 and D) EV-A120 represented in 
a “liquorice” format with colouring by residue type, Basic (Blue), Hydrophobic (White) and polar 
uncharged (Green).  
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5.4.3 Comparison of Picornavirus Capsid Topography. 
Comparing the topological features of the newly described enterovirus EV-C96 and the 
novel enterovirus EV-A120 with other members of the family Piconaviridae, (Figure 
5.20), indicated a number of structural variations worthy of discussion. One feature of 
prominence common to all viruses represented in figure 5.20 was the 2-fold axis of 
symmetry, which was represented by a deep depression in the surface of all viruses 
depicted. 
 
With regard to the models presented in this chapter, firstly, EV-C96 bore a striking 
resemblance to the related species C Enterovirus (wild poliovirus, PDB 1HXS), with 
prominent “mesa” representing the five-fold axis of symmetry, punctuated by BC-loop 
structures that extended into the solvent accessible space to a radial distance of 166 Å 
(Figure 5.20). The puff of the EF loop of VP2 on the tips of the pseudo three-fold axis of 
symmetry, extended to 160 Å. Also of note were the deep well-defined canyons, 
reminiscent of poliovirus. These canyons were not as wide as those found in poliovirus 
and were partially obscured by the C-terminal aspect of the VP1 protein, indicating a 
tendency to make contact with the canyon wall. These features were in stark contrast to 
that of the aphthoviruses- Foot and Mouth Disease virus and Equine Rhinitis A virus, 
which showed a relatively modest prominence of the 5-fold axis of symmetry, but a 
significantly well-defined pseudo 3-fold axis of symmetry. This observation was also 
made for the species F Enterovirus, Bovine Enterovirus 2.  
 
Secondly, the EV-A120 virus although modelled on the EV-A71 coordinate data, showed 
a substantially different morphological presentation in comparison to the marked 
similarity of the predicted model for EV-C96 to poliovirus. The most significant feature 
missing from EV-A120 when compared to the EV-A71 structure was that of the 
prominent canyon feature (though not as prominent as poliovirus). The pseudo 3-fold axis 
of symmetry was similar in height and features but the puff representing the EF loop of 
VP2 was more prominent extending out to the solvent accessible space. As with EV-C96, 
the fivefold axis of symmetry was highlighted by a VP1 BC-loop that extended further 
into the solvent accessible space than EV-A71. 
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Figure 5.20 Picornavirus phylogeny compared with capsid topography. Amino acid 
maximum-likelihood polar phylogram, indicating genetic relationships of the capsid encoding region 
between representative members of the family Picornaviridae. Each representative displays a capsid 
reconstruction created using the VMD software package
335
 with a “Surface” representation calculated at a 
1 Å radius from x-ray diffraction data obtained from the RCSB Protein Data Bank, Exceptions are 
EV-A120 and EV-C96 which were reconstructed using comparative protein modelling methods, 
equilibrated for 10ns using atomistic MD simulation (section 5.4.2). Capsids are coloured by radial distance 
from the point of origin, Blue- 133 Å to Red- 166 Å. Picornavirus representatives used: SENECA (Seneca 
valley virus, GenBank Accession No. DQ641257, PDB Accession No.3CJI), FMDV (Foot and mouth disease virus-A, 
AY593803, 1ZBE), ERAV (Equine rhinitis A virus, DQ272127, 2WFF), RV-B (Rhinovirus-B3, DQ473485, 1RHI), 
RV-A (Rhinovirus-A1, FJ445111, 1R1A), EV-C96 (sections 3.4.3 and 5.4.2.1), EV-C (Wild Poliovirus-1, NC002058, 
1HXS), SVDV (Swine Vesicular Disease Virus, EU151448, 1OOP), EV-B (Echovirus-1, AF029859, 1EV1), BEV 
(Bovine Enterovirus-2, NC021220), EV-A120 (sections 3.4.4 and 5.4.2.2), EV-A (Enterovirus-A71, ETU22521, 
4AED). Scale bar indicates amino acid substitutions per site. Alignment performed using the ClustalW 
algorithm using the BioEdit software package version 7.1.20
370
. Branch lengths calculated using the Phylip 
Protein Distance model
371
.   
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5.5 Discussion 
This chapter investigated the use of comparative protein modelling methods to 
reconstruct enterovirus capsid structures. Examination of two manual threading methods 
for the VP1 of CV-A21, using prototype sequence and freely available software 
packages, indicated that SwissPDBviewer was easier to use than Modeller and yielded the 
most accurate and precise outputs when compared to experimentally derived x-ray 
diffraction data. As a result, SWISSPDBviewer was used to model the predicted capsid 
structures for EV-A71 (sub-genogroup C4), EV-C96 and EV-A120 using a manual 
threading method. 
 
A quality assessment for all models was determined for the predicted structures. The 
capsid structures were examined for any indication of instability using an RMSD 
calculation and observation of capsid expansion or contraction using diameter 
measurements of the whole capsid over the course of the complete MD simulation. In all 
instances, the observations indicated that the predicted capsid structures were stable. In 
the case of the EV-A71 simulation, a significant increase in RMSD was observed after 
the initial minimisation and “solvent shock”. This can be attributed to a number of steric 
clashes that existed within the initial reconstruction stage. Resolution of these clashes in 
the first stages of simulation resulted in relatively large increase in RMSD followed by a 
plateau phase.  
 
The characteristics of the RMSD increases over time could also be indicative of 
mechanical characteristics inherent in each viral capsid. CV-A21 showed a gradual and 
smooth approach to plateau, with a significant RMSD gradient still present after 10 ns 
simulation time. This may be indicative of greater structural elasticity present in CV-A21 
capsids when compared to other virus capsids. In contrast, EV-A71 showed an abrupt 
RMSD jump to ~4 Å in the first 100 ps, where it remained for the rest of the simulation 
(reaching a true plateau). This may be due to the lower sequence identity of the query 
sequence to template structure, resulting in an increased initial rearrangement of side 
chains in comparison to the CV-A21 model. The RMSD observations for EV-A71 may 
also indicate that this capsid is structurally less malleable, with a propensity for stepwise, 
rigid motions. EV-C96 and EV-A120, on the other hand, are likely to possess mechanical 
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properties intermediate between those of CV-A21 and A71. The functional and biological 
implications of the mechanical properties of different capsids deserve further study.  
 
During the simulation of EV-A71, no significant changes in capsid diameter were 
observed, indicating that overall the capsid was structurally sound. Predicted structures 
for CV-A21, EV-C96 and EV-A120 were derived from templates with a closer match to 
template data, with protomer amino acid sequence percentage identity values of 68.1% 
for CV-A21, 68.5% for EV-C96 and 72.% for EV-A120, compared to a sequence identity 
of 43% for the EV-A71 predicted model, a value that lies between the 30% lower limit 
and the 50% cut-off described by Chothia and Lesk
359
. 
 
Model assessment was performed using ProQ on the original x-ray diffraction data, on 
the individual protomer assemblies, and on the data derived using the protomer 
fit-averaging method. In most instances, the LGscore was above 4, indicating an excellent 
model. In the case of EV-C96, this value was 3.593 for the single protomer, but increased 
to 3.914 when using the protomer fit-average model. The MaxSub score was below 0.5 
for all models examined, including those derived using x-ray diffraction methods. Values 
for predicted models ranged from 0.305 for EV-A120 (single protomer) to 0.375 for 
EV-A71 (protomer fit-averaged). These values were comparable to those of 
experimentally derived structures, indicating that the predicted models were of a quality 
comparable to those derived using x-ray diffraction methods. 
 
For the prediction of EV-A71, significant differences were observed in the N-terminal 
region of VP4 and the N-terminal α-helix structure positioning of VP1. With respect to 
the variation in the conformation of VP4 in EV-A71, this phenomenon has been 
described previously and resulted in difficulty during the reconstruction of cryo-EM data 
for CV-A7. As a result, the authors elected to exclude the entire protein chain from the 
final structure
234
. The significant variation in structure is indicative of the problems 
associated with the prediction of protein chain configuration in 3-dimensional space. 
Given that the N-terminal helix of VP4 plays a critical role in the replication of 
enteroviruses, and is known to transition from the interior surface of the capsid to the 
exterior in the replication of poliovirus
89
, then the data for the N-terminal aspect of VP4 
for EV-A71 may be correct and representative of a transitional state of the protein (Figure 
5.21). 
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Figure 5.21 Structural variation of poliovirus and EV-A71 VP4 crystal structures. Left) poliovirus 
type I 1HXS and Right) EV-A71 4AED. Single protomer reconstructed to form a pentamer using the matrix 
data contained within the respective PDB files. The initial protomer (position one) is coloured in solid green 
and subsequent mapping of the remaining four protomers are ghosted to allow visualisation of the 
differences in the N-terminal aspect of the VP4. 
 
As for the placement of the N-terminal α-helix of the VP1 protein, the clockwise rotation 
of the motif is not surprising given the different conditions used in the derivation of the 
experimental data. X-ray diffraction data were derived from the poliovirus crystal at 
pH 7.0 and pH 8.0 for EV-A71. Temperature values at which the x-ray diffraction data 
were obtained are known for poliovirus (277°K) but unknown for EV-A71. Both 
temperature and pH are significant variables implicated in the uncoating process in 
members of the genus Enterovirus
39,52,89,372
 and may explain the differing spatial 
alignments of not only the VP1, but also possibly the VP4. Substantial mobility of the 
N-terminal α-helix was observed in the long time-scale simulations performed for 
poliovirus in chapter 4 and these observations were published in 2012 
2
.  
 
Taking into account the observation of the spatial variation of the internal structures of 
the capsid, it is prudent to investigate whether these variations impact the structures 
associated with receptor binding, neutralising antibody binding sites or antiviral 
interaction sites. Specific sites of interest for receptor or neutralising antibody binding are 
the canyon and flanking regions defined by the BC and EF loops of VP1, and the EF loop 
of VP2
75,76
. Investigation of pentamers, empty capsids and complete virion forms of 
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poliovirus were undertaken in chapter 4, and no obvious deviation from crystal structure 
was observed, with the exception of movement in the solvent accessible aspects of the BC 
and EF loops. This observation is expected as part of the normal movement of these 
structures in an aqueous environment. Importantly, the hydrophobic pocket representing 
the binding site of a number of antiviral drugs which inhibit virus entry into cells and the 
uncoating process, were observed to maintain their integrity during the MD simulation 
process when compared to crystal structures as described in section 5.4.1.2 (Figures 5.9 
and 5.10). The examination of this site in EV-A71 indicated a correlation between amino 
acid side-chain placement for the predicted model and B-factors obtained during x-ray 
diffraction, indicating that the protein comparative modelling methods combined with 
MD simulation are appropriate for the examination of this structure. 
 
Quality assessments for the predicted models for EV-C96 and EV-A120 capsids indicated 
that the predicted models were of good quality and that the simulations of these capsid 
structures were stable, supporting the use of the models for future research to examine the 
contribution of structural motifs to receptor binding, neutralising antibody binding, or 
antiviral-drug interactions.  
 
For EV-A120, significant difficulty was experienced deriving the genetic sequence, due 
to the virus not growing in culture. The specimen in question was extraordinarily toxic to 
any cells used in cell culture and molecular detection methods proved to be the only 
possible method to identify this virus. It is of interest to investigate the possibility of 
cultivating this virus for further research, and given the relatively small amount of 
inoculum available, it is critical to select a cell line that best suits the tropism of the virus. 
Examination of a motif found on the canyon wall common to members of the species A 
Enteroviruses for which the cellular receptor SCARB2 is suspected to bind, was found to 
be conserved in EV-A120, indicating that cell lines expressing SCARB2 may be 
appropriate to the cultivation of EV-A120. Research efforts into this line of investigation 
are ongoing. 
 
With respect to the topographical differences observed between predicted virus models 
for EV-C96 and EV-A120, it was expected that they would be virtually identical to the 
viruses on which they had been modelled. This was for the most part the case for 
EV-C96, with only modest variation in structures defining the canyon and a more 
punctuated BC-loop when compared to the poliovirus crystal structure used for threading. 
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EV-A120 exhibited a significant and unexpected morphological difference to EV-A71, 
even though it shared a higher amino acid percentage identity when compared to the 
predicted EV-C96 model (68.5% for EV-C96 versus 72.1% for EV-A120). These 
variations may be due to artefacts as a result of interactions of the solvent accessible loop 
structures encountered during the crystallisation process, or possibly the observed 
differences in available chain data representing the C-terminal aspect of VP1. Also of 
note, is that (with the exception of the EV-C96 and EV-A120 predicted models) the 
structures depicted in Figure 5.20 are derived exclusively from x-ray diffraction data, 
which represents data collected from crystals that are not representative of a biological 
environment. The simulation data from which the predicted EV-C96 and EV-A120 
models were derived were designed to emulate an aqueous 37°C saline environment, 
which may have allowed a freedom of movement not necessarily experienced in the 
crystalline lattice used for x-ray diffraction.  
 
In summary, this chapter has investigated the use of comparative protein modelling 
methods incorporating manual threading of amino acid sequences on template structures, 
with amino acid identities as low as 43% for protomers (EV-A71) and 32.1% for single 
amino acid chains (VP1 of EV-A71). These values can be considered to be approaching 
the minimum sequence identity acceptable for effective comparative modelling methods. 
The outcome of the investigation showed that even when reconstructing models with such 
low amino acid identities, accurate and precise models were produced for further 
research. Accordingly, the methods were applied to newly-described and novel viruses 
for which no experimentally derived structures exist. This will allow the use of these 
models in the investigation of receptor binding motifs, neutralising antibody binding sites 
and the examination of antiviral drug binding
373
. Importantly, these models represent a 
starting point for integration with experimentally derived data such as cryo-EM density 
data using methods such as the MD flexible fitting process
241,374,375
. 
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6.1 Manuscripts Published in Association with this Chapter 
 Liu, H., Roberts J. A., Moore, D., Anderson, B., Pallansch, M. A., Pevear, D. C., 
Collett M. S., Oberste, M. S., 2012. Characterization of Poliovirus Variants Selected 
for Resistance to the Antiviral Compound V-073 Antimicrobial Agents and 
Chemotherapy, 56 (11): 5568-5574. [Refer to appendix A8.2.7]. 
 
 
6.2 Concluding Remarks 
The primary aim of the research for this thesis was to examine ways to integrate a range 
of statistical, bioinformatics and computational biophysical approaches, and to exploit the 
massive increase in computational power available to researchers and public health 
professionals for the detection, surveillance and study of disease causing agents, 
specifically viruses of the genus Enterovirus.  
 
The approaches taken to incorporate computational methods included sequence database 
searching and retrieval, multiple sequence alignment, and phylogenetic analysis using a 
number of different algorithms to analyse viruses at the nucleic acid and amino acid level. 
Additional to the incorporation of bioinformatics approaches was the inclusion of 
3-dimensional structure prediction and analysis, using comparative protein modelling and 
atomistic MD simulation to reconstruct viruses of interest. In essence, this body of work 
examines the utility of taking data retrieved from clinical samples in a 2-dimensional 
format (sequences) and using computational biophysics, to convert them to a 
3-dimensional structure, then to incorporate a 4
th
 dimension, time, using MD methods. 
 
These approaches were only possible as a result of (i) the exponential increase in 
computational capacity both at the institutional level (supercomputer) and locally 
(personal computer), combined with (ii) easy access to data in the form of thousands of 
sequences via GenBank and (iii) the increase in freely available software packages 
designed specifically for bioinformatics applications, MD simulation and structure 
visualisation. The software packages allowed a pragmatic approach to the research 
questions to be undertaken, resulting in a stepwise methodology with practical 
applications to any disease surveillance laboratory environment (Appendices A5.9, 
A5.10).  
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In summary, the research incorporated leading-edge computational methodologies and 
resulted in the following outcomes: 
 
i.) Utilised bioinformatics methods to improve the detection of enteroviruses in clinical 
samples, by examining hundreds of available sequences to refine the detection of 
human enteroviruses, as distinct from human rhinoviruses. This resulted in a novel 
real-time reverse-transcription PCR method which streamlined the detection and 
differentiation of Enterovirus species C including poliovirus, from Enterovirus 
species A and B, which is applicable to the WHO polio eradication initiative. 
ii.) Used simple phylogenetic methods and more complex, computationally intensive 
algorithms which incorporated temporal and geographic variables, to examine the 
chains of transmission for specific enteroviruses within Australia and the Western 
Pacific region. 
iii.) Analysed enterovirus serotypes identified within Australia and the Western Pacific 
region that represent a significant or potential threat to public health; specifically 
EV-A71 and EV-C96. 
iv.) Discovered a novel enterovirus, EV-A120, from a patient suffering AFP. The virus is 
closely related to CV-A7 and was detected and sequenced direct from faecal extract 
as it was unable to be grown in culture. More than 2,500 base pairs of sequence were 
determined by primer walking. 
v.) Developed an atomistic MD simulation approach to the reconstruction of a complete 
poliovirus virion, including RNA, utilising x-ray diffraction data of the capsid. The 
methodology was used to reconstruct CV-A21 and EV-A71 models of the capsids 
from atomic coordinate data. 
vi.) Validated the use of comparative protein modelling methods combined with atomistic 
MD simulation methods to predict enterovirus structure, using prototype sequences 
and 3-dimensional threading methods. The use of these methods indicated that 
comparative protein modelling methods are an accurate and precise way of 
reproducing 3-dimensional structures from 2-dimensional sequence data. 
vii.) Applied bioinformatics and computational biophysics approaches to the detection, 
characterization and in-silico reconstruction of EV-A71, EV-C96 and novel virus 
EV-A120. The methodologies developed in this thesis enabled atomistic MD 
simulations to be performed of EV-C96 and EV-A120, by using atomic coordinate 
data derived from related virus structures.  
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6.3 Future Research 
The workflows established in this thesis can enable information derived from clinical 
samples to be used to create a functional in-silico virus model for further research. 
Examination of anti-viral drug binding events, receptor binding sites, and major 
conformational shifts in virus structure can be assessed using these models. 
 
As the technologies advance, it will become faster and easier to obtain genetic sequence 
data from pathogens, and rapid dissemination of these data will allow real-time 
observation of disease emergence. Theoretically, the combination of increased 
computational power and more advanced simulation methods would allow reconstruction 
of pathogens, using comparative protein modelling techniques to “build” an in-silico copy 
of the pathogen or possibly even a component that is a known target for existing 
therapeutics. This process could in the future be done locally on a personal computer, as 
shown by the simulation of EV-A71 on a MicroSD card running a virtual operating 
system on a desktop workstation (section 5.4.1.2). 
 
These experiments could allow the examination of the drug binding site and any known 
mutations, by performing in-silico experiments using advanced MD methods, to 
determine the effectiveness of a range of therapeutic options for specific viruses and any 
mutants that may arise over time. The examination of drug resistance mechanisms in 
viruses, specifically influenza, have recently been examined using free energy 
perturbation methods, exploring the mechanism that confers resistance to Oseltamivir but 
not Relenza
376
. This particular method may be useful when applied to enteroviruses and 
the examination of the hydrophobic pocket with existing capsid binding anti-virals such 
as V-073, BTA-798 or other WIN compound derivatives.  
 
An example of the application of atomistic MD simulation to the examination of this 
hydrophobic pocket, can be found in work examining anti-viral drug resistance in vaccine 
derived polioviruses
373
 (Appendix A8.2.7). In this work, fourteen simulations 
representing V-073 resistant and sensitive vaccine derived polioviruses were constructed 
representing pentamer configurations of the virus proteins, VP1 VP2 and VP3 and VP4. 
Positioning of the anti-viral compound within each protomer was performed in 
comparison with the known crystal structure of V-073 complexed with poliovirus type 2. 
After 10 ns of simulation time the pentamers underwent the protomer fit methodology to 
examine the positioning of point mutants that confer resistance. 
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Figure 6.1 Vaccine Derived Poliovirus type 2 with Myristate as the pocket factor. Simulations 
performed in the absence of drug, substituted with a single myristate molecule occupying a hydrophobic 
pocket in order to examine conformational distortion. The figure indicates the location in the poliovirus 
type 2 structure of predominant amino acids substitutions that confer resistance to V-073, based on the 
crystallographic structure of V-073 bound to poliovirus type 2 (Lentz et al.,1997)
377
, PDB file 1EAH. 
Superolateral cut-away view of electron density maps showing V073 bound within the hydrophobic pocket 
of VP1. Density mapping at 1 Å resolution and 2 Å radius representing the original parental strain (cyan) 
with a wireframe overlay (yellow) of the resistant virus. A) and B) original results for VDPV2 as presented 
by Liu et al., (2012)
373
, amino acid differences are shown as a liquorice representation with parental 
(magenta) and variant (yellow), C) and D). repeat of the VDPV2 simulation experiments with myristate in 
the hydrophobic pocket, amino acid point mutations are shown as liquorice representations with parental 
(magenta) and variant (yellow), the original simulation results with V-073 in-situ are indicated in Green. 
Note the differences in yellow wireframe configurations between figures A and C, and between figures B 
and D. 
 
 
In order to further examine the potential for free energy perturbation methods to predict 
anti-viral drug resistance, preliminary experiments involving atomistic MD simulations 
were performed based on the previous work described above, but instead of using the 
drug bound in the hydrophobic pocket, myristic acid was used in place of the drug. This 
lipid is a common element found within members of the genus Enterovirus, and allowed 
the examination of pocket deformation in the presence of a hydrophobic small molecule. 
Given that this thesis has examined the binding effect of small anti-viral (capsid binding) 
molecule and established that there is an observable effect on the plasticity of the capsid 
(section 4.4.6), it stands to reason that the placement of a hydrophobic non-binding small 
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molecule would elucidate any pocket deformation more effectively than any bound 
anti-viral which inhibits structural deformation (Figure 6.1). 
 
The observed distortion of the hydrophobic pocket described in figure 6.1 indicates that 
free energy perturbation methods, specifically alchemical approaches, would be suitable 
to examine the potential for binding capacity of existing enterovirus capsid binding 
anti-virals. Free energy perturbation approaches and normal-modes analysis methods 
have historically been used to examine anti-viral drug binding in members of the genus 
Enterovirus, as described in section 1.5.1 of this thesis. The difference now is that 
experiments of this type no longer require the use of institutional supercomputers. 
Multiple experiment instances can now be performed on a relatively modest personal 
computer. 
 
An exciting potential for the advancements revealed by the research performed in this 
thesis, indicates that virus models created using comparative protein modelling methods 
combined with atomistic MD simulation are both accurate and precise. This allows the 
application of molecular dynamics flexible fitting methods (MDFF) to be used in the 
application and refinement of experimentally derived cryo-EM density data. An MDFF 
approach has been used to examine the capsid structure of the HIV capsid in one of the 
largest atomistic MD simulations ever performed to date at 64 million atoms 
241
. This 
advance is particularly relevant in the context of examining emerging pathogens at the 
atomic scale, using workflows such as those established in this thesis.  
 
Given the above, it is further theoretically possible to monitor an outbreak in real time, to 
generate relevant virus structures, and to determine anti-viral resistance in order to 
enhance the clinical approach and the use of the correct anti-viral drug. In the event that 
anti-viral resistance occurs during the course of the outbreak, molecular modelling can be 
performed in response to amino acid sequence changes and the underlying antiviral 
mechanisms can be determined, enabling the potential to recommend alternative anti-viral 
drug therapies to combat the emergence of resistant phenotypes. This would revolutionise 
the clinical approach to the emergence of disease in humans with a broader applicability 
to agriculture.  
 
This thesis has successfully demonstrated the use of comparative modelling and all-atom 
MD to model full virions under simulated physiological conditions. Additionally, this 
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thesis has demonstrated a range of preliminary, simple analyses on virion MD 
trajectories, forming a platform for the development of new analysis methods and 
protocols. The sheer size of whole virions means that analysis methodologies must be 
developed which ensure efficient use of emerging supercomputing capabilities. One 
obvious future direction has been described above - the study of drug-virion interactions. 
But more subtle, yet possibly important, behaviours of the virion could potentially be 
brought to light. These include (i) the examination of tectonic movement across virus 
capsids, (ii) the derivation of potential of mean force profiles for putative ion channels 
traversing virus capsids and (iii) the examination of vibrational states of virus capsids via 
the extraction of large-scale (slow) motions and small-scale (localised, rapid) motions for 
native virions, empty capsids in concert with bound antivirals or receptor even molecules. 
The scope for the examination of the trajectory data derived from the in-silico 
experiments performed in this research work is vast and will require a pragmatic 
approach and significant computational resources. Given the rate at which computer 
power is evolving, this is an exciting proposition. 
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Appendices  
A1. Material and Reagents listing 
 
Item Company Cat # 
0.22 μm filter units Sartorius 17597K 
50mL Falcon Tubes Becton Dickinson 352070 
Big Dye Terminator with 5 x buffer University of Melbourne, Australia BDT v3.1 
Bioanalyzer DNA 7500 series II kit Pacific Laboratory Products 5067-1506 
Chloroform Sigma Aldrich Fine Chemicals 496189 
dNTP Mix 40mM (10mM each) Promega U1511 
EMEM, w/ Hanks Salts and L-Glutamine, Sigma Aldrich Fine Chemicals M4780-500mL 
Ethanol Sigma Aldrich Fine Chemicals E-7023-500ML 
FastStart PCR Master mix Roche 04710444001 
HEPES Buffer Sigma Aldrich Fine Chemicals H0887-100mL 
High pure PCR product purification kit Roche 11 732 668 001 
MagMax -96 Viral RNA isolation kit Applied Biosystems AM1836 
MagMax 96 well plates Applied Biosystems 4388474 
MagMax combs Applied Biosystems 4388452 
MicroAmp 96-well optical FAST plates Applied Biosystems 4346906 
MicroAmp Optical 8-well Strip caps Applied Biosystems 4323032 
MicroAmp Optical 8-well Strip tubes Applied Biosystems 4358293 
Nuclease free water Promega P1193 
Nunc plates (96 flat well microtitre) Thermo Fisher Scientific 167008 
Nunc TC flasks 80cm2 Thermo Fisher Scientific 153732 
Oligonucleotide probes Biosearch NA 
Oligonucleotide probes, primers  and 
calibrator dye 
Geneworks NA 
Optical adhesive film Applied Biosystems 4311971 
Penicillin-Streptomycin Sigma Aldrich Fine Chemicals P0781-100mL 
Protector RNase inhibitor Roche 03 335 402 001 
Sarsted plastic Tissue Culture tubes Sarstedt 83.9923.953 
Superscript III Reverse Transcriptase Life Technologies 18080-044 
Superscript III Reverse Transcriptase and 
Platinum Taq 
Life Technologies 12574-026 
Taq DNA Polymerase Roche 11418432001 
TaqMan Fast Universal PCR master mix  Applied Biosystems 4352042 
Transcriptor Roche 03 531 287 001 
Trypan Blue 0.4% (250mL) Fluka 93595-250ML 
Trypsin-EDTA (1x solution) Sigma Aldrich Fine Chemicals 59430C-500ML 
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A2  Equipment. 
 
Item Manufacturer Serial Number Asset Number 
7500FAST Real-time 
machine 
Applied Biosystems 275011364 MH11617 
Veriti thermalcycler Applied Biosystems 299020589 MH14731 
Bioanalyser 
Agilent 
Technologies 
DE54704689 MH11618 
Precision T3500, Tesla 
C2070, Quadro 5000 
Dell 4BQT22S MH15107 
Freezer, -30°C Sanyo 60814358 MH12067 
Freezer -70°C 
Thermo Scientific 814876-2110 MH14656 
Blue Gene/P 
supercomputer, 
IBM Grant number VR0069 Grant number VR0069 
Blue Gene/Q 
supercomputer 
IBM 
Gant numbers 
VR0069, VR0262 
Grant numbers 
VR0069, VR0262 
Incubator with roller 
drums 
LEEC P33 MH12070 
MagMax extraction robot 
Applied Biosystems 700-450 rs-232c MH18095 
Microscope Olympus CK2 MH45028 
Shaker 
Ratek 80597342 MH13265 
Refrigerator, 4°C Westinghouse 63252923 MH11413 
Centrifuge, refrigerated Beckman Coulter ALP07H02 MH11600 
Altix XE supercomputer 
SGI 
Grant numbers 
VR0069, VR0262 
Grant numbers 
VR0069, VR0262 
Nitro G25, 4x Tesla 
M2090, compute node 
Xenon N/A MH23069 
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A3 Specific Software Package Details 
 
 ABI 7500 software version 2.0.5 
 Agilent Bioanalyser 2100 expert version B.02.04.SI356 
 Bioedit version 7.1.3.0 
 BEAST 1.7.4 
 BEAGLE 1.0 
 Blender version 2.63 
 ChromasPro version 1.5 
 Chromas 2.24 
 FigTree version 1.4 
 GIMP 
 Libre Office 3 
 Linux Mint 14 
 MakeNA 
 MEGA 5.1 
 Microsoft Office 2003, 2010 
 Modeller version 9.10 
 Nanoscale Molecular Dynamics (NAMD) version 2.7, 2.8, 2.9 
 NCBI (GenBank portal) 
 PSIpred 
 RCSB (PDB portal) 
 SwissPDBviewer (aka DeepView) version 4.04 
 SWISSmodel 
 TreeView 
 Ubuntu 10.04 LTS 
 Visual Molecular Dynamics (VMD) 1.9.2  
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A4 Sequencing Primers 
 
 
Table A4.1. Generic. Primers
1
 used in sequencing of both EV-C96 and EV-A120. Primer locations based on 
the prototype sequence for Poliovirus type 1, GenBank accession number V01150. 
 
 
Table A4.2. EV-C96. Primers
1
 used in sequencing of EV-C96. Primer locations based on the prototype 
sequence Enterovirus C96 BAN-00, GenBank accession number EF015886. 
 
 
Table A4.3. EV-A120. Primers
1
 used in sequencing of the novel virus EV-A120. Primer locations based on the 
prototype sequence for Coxsackievirus A16 GenBank accession number U05876. 
 
1
Abbreviations Used: 
For=Sense, Rev=Anti-sense, A=Adenine, C=Cytosine, G=Guanine, T=Thymine, I=Inosine, 
B=C,G,T, D=A,G,T, H=A,C,T, K=G,T, M=A,C, N=A,C,G,T, R=A,G, S=C,G, V=A,C,G, W=A,T, Y=C,T.  
 
Primer Sequence5´ to 3´ Position 
(PV-1 Sabin V01150) 
1 PanEV1_OS CAAGCACTTCTGTTTCCCCGG 164-184 
2 PanEV2_IS TCCTCCGGCCCCTGAATGCG 446-465 
3 PanEV3_IaS ATTGTCACCATAAGCAGCCA 581-600 
 
Primer Sequence5´ to 3´ 
Position 
(EV-C96 EF015886) 
1 12134022_VP1_for TACACTGATACTGTCCAACTCAG 2841-2863 
2 12134022_VP1_rev CTGAGTTGGACAGTATCAGTGTA 2863-2841 
3 12173491_VP1_for TATACAGACACAGTACAACTCAG 2841-2863 
4 12173491_VP1_rev CTGAGTTCTACTGTGTCTGTATA 2863-2841 
5 04107711_VP1_for TACACAGACACAGTTCAACTCAG 2841-2863 
6 04107711_VP1_rev CTGAGTTGAACTGTGTCTGTGTA 2863-2841 
7 05118030_VP1_for TACACAGACACAGTGCAACTTAG 2841-2863 
8 05118030_VP1_rev CTAAGTTGCACTGTGTCTGTGTA 2863-2841 
9 EV-C_2C_rev TCTTGAACTGTATGTARTTGTTG 4478-4492 
10 EV96_2A_3657_rev TCRTTRGSYTCCATSYAYTG 3657-3676 
11 EV96_VP1_3288_for ATGAARCCYAARCAYATYAGAG 3288-3309 
12 EV96_VP1_2877_rev AARCGYGARTAKGTRAASAT 2877-2896 
13 EV96_VP1_2508_for GARWCMGTRGCYCADAATGC 2508-2527 
14 EV96_VP3_2037_rev TGYARYCTYTGRTCACTWGC 2037-2056 
15 EV96_VP3_1950_rev TACATRTCCTAKGTRTTHGC 1950-1969 
16 EV96_VP3_1818_for AAYTTYCARTCRCCRTGTGC 1818-1837 
17 EV96_VP2_1370_rev ACATARCTRGTGTARTTKGTC 1370-1390 
18 EV96_VP2_1090_for ARGCHAACCCMGTTGATGC 1090-1108 
19 EV96_VP4_846_rev GCATTRCTRGCRCTATCYTT 846-866 
 Primer Sequence5´ to 3´ Position  
(CV-A16 U05876) 
1 Novel_EVA_VP1rev TCCCCATTTGGAGTAGTAGC 2863-2882 
2 Novel_EVA_VP1for GGGCTTGTGGGAGTTATAGA 2707-2726 
3 Novel_EVA_2Crev GTGTTTGCTCTTGAACTGCATGTA 4414-4437 
4 EV-A120_4235for AAATTATACCAGCAGCCAAAGA 4235-4256 
5 EV-A120_3540rev GTGCTTCCTTTTAGAATTGCAG 3519-3540 
6 EV-A120_3450for AGTTTCCTCTACCACTGCTCAA 3450-3471 
7 EV-A120_2040rev GTAATAACGGCACAATTGACCT 2019-2040 
8 EV-A120_1930for ATACCGGTTAAAGTGCAAACAT 1930-1951 
9 EV-A120_1360rev ATACAGTGCCCAGCACATATTC 1339-1360 
10 EV-A120_1265for ATTTTGCATCCACGTTCAGT 1265-1284 
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A5 Computational Biology Scripts 
 
A5.1 TCL scripts written for atom selection for application of constraints and virus 
substructure positioning 
 
A5.1.1 File Name: Beta_select.tcl 
 
#select and changes beta values for alpha carbon for constraints 
 
  set sel0 [atomselect 0 "protein and type C"]  
   
  $sel0 set beta 1 
   
 
 
A5.1.2 File Name: RNA_supercoil_betaselect_step1 
 
# selects and changes beta values for Mahoney RNA coordinates 
# 10 strands moves the centre 10 residues 1000A y axis 
# step 1 of 2 step in triangulation of RNA strands 
# in preparation for joining and supercoiling 
 
 set N1 [atomselect top "segname N1 and resid 370 to 380"]  
   
 $N1 set beta 1 
 $N1 set x 0 
 $N1 set y 1000 
 $N1 set z 1260 
 
 set N2 [atomselect top "segname N2 and resid 370 to 380"]  
   
 $N2 set beta 1 
 $N2 set x 40 
 $N2 set y 1000 
 $N2 set z 1260 
 
 set N3 [atomselect top "segname N3 and resid 370 to 380"]  
   
 $N3 set beta 1 
 $N3 set x 80 
 $N3 set y 1000 
 $N3 set z 1260 
 
 set N4 [atomselect top "segname N4 and resid 370 to 380"]  
   
 $N4 set beta 1 
 $N4 set x 120 
 $N4 set y 1000 
 $N4 set z 1260 
 
 set N5 [atomselect top "segname N5 and resid 370 to 380"]  
   
 $N5 set beta 1 
 $N5 set x 160 
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 $N5 set y 1000 
 $N5 set z 1260 
 
 set N6 [atomselect top "segname N6 and resid 370 to 380"]  
   
 $N6 set beta 1 
 $N6 set x 200 
 $N6 set y 1000 
 $N6 set z 1260 
 
 set N7 [atomselect top "segname N7 and resid 370 to 380"]  
   
 $N7 set beta 1 
 $N7 set x 240 
 $N7 set y 1000 
 $N7 set z 1260 
 
 set N8 [atomselect top "segname N8 and resid 370 to 380"]  
   
 $N8 set beta 1 
 $N8 set x 280 
 $N8 set y 1000 
 $N8 set z 1260 
 
 set N9 [atomselect top "segname N9 and resid 370 to 380"]  
   
 $N9 set beta 1 
 $N9 set x 320 
 $N9 set y 1000 
 $N9 set z 1260 
 
 set N10 [atomselect top "segname N10 and resid 370 to 380"]  
   
 $N10 set beta 1 
 $N10 set x 360 
 $N10 set y 1000 
 $N10 set z 1260 
 
 
A5.1.3 File Name: Origin_contraints.tcl 
 
#select and changes beta values for alpha carbon for contraints 
 
  set sel0 [atomselect top all]  
   
  $sel0 set beta 1 
  $sel0 set x 1 
  $sel0 set y 1 
  $sel0 set z 1 
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A5.2 TCL scripts written for the calculation of virus diameter, RMSD and RMSF. 
 
A5.2.1 File Name: diameterCA 
 
set outfile [open viriondiameterCA.dat w] 
set nf  [molinfo top get numframes] 
set sel [atomselect top "protein and type CA"] 
for { set i 1 } { $i < $nf } { incr i} { 
 $sel frame $i 
puts $outfile "[measure minmax $sel]" 
} 
close $outfile 
 
 
A5.2.2  File Name: RMSD_segments 
 
# Script to calculate RMSD's for last frame of trajectory 
# Calculates each RMSD for a given number of segments 
 
 
# Create output file 
 
set output [open "RMSD_segments_PV1W.dat" w] 
 
 
#calculate VP1 RMSD's 
 
 
for {set VP1 1} {$VP1 <= 240} {incr VP1} { 
puts $VP1 
  
 set frame_ref [atomselect top " segname P$VP1 and backbone " frame 0] 
 set frame_calc [atomselect top " segname P$VP1 and backbone " frame last] 
 
 set fit [measure fit $frame_calc $frame_ref] 
 set frame_move [atomselect top " segname P$VP1 and backbone " frame last] 
 $frame_move move $fit 
 
 set RMSD [measure rmsd $frame_move $frame_ref] 
 puts $output $VP1,$RMSD 
  
  
 } 
 
close $output 
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A5.2.3  File Name: VirusCapsidRMSD 
 
################################################################################# 
#                                                                               # 
#  Calculates the RMSD for a given number of segments in a multimeric assembly  # 
#  May 8th 2011 by Jason A. Roberts, VIDRL/RMIT University Australia            # 
#                                                                               # 
################################################################################# 
 
 
# Create prefix for output file 
# Enter the virus name after the "set virus" variable 
 
set virus PV1WBG 
 
 
# Calculate VP1 RMSD's 
 
# Create VP1 output file 
 
set VP1chains [open "$virus.VP1_RMSD.dat" w] 
 
# Start looping for x number of times with start point 1 "sega" 
for {set sega 1} {$sega <= 240} {incr sega} { 
 
# Print out a screen count for visual feedback 
puts $sega 
  
 # Select the first and last frames for RMSD calculation 
 set frame_ref [atomselect top " segname P$sega and backbone " frame first] 
 set frame_calc [atomselect top " segname P$sega and backbone " frame last] 
  
 # Fit last frame to reference frame and move molecule 
 set fit [measure fit $frame_calc $frame_ref] 
 set frame_move [atomselect top " segname P$sega and backbone " frame last] 
 $frame_move move $fit 
  
 # Calculate the RMSD 
 set RMSD [measure rmsd $frame_move $frame_ref] 
 puts $VP1chains $sega,$RMSD 
  
 #Skip 3 molecules ahead according to previous chain IDs in usage 
 set sega [expr 3 + $sega] 
 
 
 } 
 
# Close the output file 
close $VP1chains 
 
# End of script for VP1, the remaining VPs are the same 
# but have a new start point "segb" starts at 2, "segc" starts at 3 etc. 
 
 
#calculate VP2 RMSD's 
 
set VP2chains [open "$virus.VP2_RMSD.dat" w] 
 
for {set segb 2} {$segb <= 240} {incr segb} { 
puts $segb 
  
 set frame_ref [atomselect top " segname P$segb and backbone " frame first] 
 set frame_calc [atomselect top " segname P$segb and backbone " frame last] 
 
 set fit [measure fit $frame_calc $frame_ref] 
 set frame_move [atomselect top " segname P$segb and backbone " frame last] 
 $frame_move move $fit 
 
 set RMSD [measure rmsd $frame_move $frame_ref] 
 puts $VP2chains $segb,$RMSD 
  
 set segb [expr 3 + $segb] 
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 } 
 
close $VP2chains 
 
 
#calculate VP3 RMSD's 
 
set VP3chains [open "$virus.VP3_RMSD.dat" w] 
 
for {set segc 3} {$segc <= 240} {incr segc} { 
puts $segc 
  
 set frame_ref [atomselect top " segname P$segc and backbone " frame first] 
 set frame_calc [atomselect top " segname P$segc and backbone " frame last] 
 
 set fit [measure fit $frame_calc $frame_ref] 
 set frame_move [atomselect top " segname P$segc and backbone " frame last] 
 $frame_move move $fit 
 
 set RMSD [measure rmsd $frame_move $frame_ref] 
 puts $VP3chains $segc,$RMSD 
  
 set segc [expr 3 + $segc] 
 
 } 
 
close $VP3chains 
 
 
#calculate VP4 RMSD's 
 
set VP4chains [open "$virus.VP4_RMSD.dat" w] 
 
for {set segd 4} {$segd <= 240} {incr segd} { 
puts $segd 
  
 set frame_ref [atomselect top " segname P$segd and backbone " frame first] 
 set frame_calc [atomselect top " segname P$segd and backbone " frame last] 
 
 set fit [measure fit $frame_calc $frame_ref] 
 set frame_move [atomselect top " segname P$segd and backbone " frame last] 
 $frame_move move $fit 
 
 set RMSD [measure rmsd $frame_move $frame_ref] 
 puts $VP4chains $segd,$RMSD 
  
 set segd [expr 3 + $segd] 
 
 } 
 
close $VP4chains 
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A5.2.4  File Name: RMSF_Capsidv2 
 
############################################################ 
#                                                          # 
#    RMSF script for cuboidal PV1W and PV1SL protomers     # 
#                                                          # 
############################################################ 
 
# create output file 
 
set output [open "RMSF_protomers.dat" w] 
 
#calculate RMSF 
 
for {set segA 1} {$segA <=240} {incr segA} { 
 
puts $segA 
 
  
 set segB [expr 1 + $segA] 
 set segC [expr 2 + $segA] 
 set segD [expr 3 + $segA] 
 
 set segment [atomselect top "segname P$segA P$segB P$segC P$segD and name CA"] 
 set result [measure rmsf $segment first 0 last 9 step 1] 
  
 puts $output "Protomer_Starting$segA" 
 puts $output $result 
 
 
 set segA [expr 3 +$segA] 
  
 
 } 
 
close $output 
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A5.3 TCL script written for the renaming of virus protein chains. 
 
File Name: VirusCapsidChainRename.tcl 
 
################################################################################# 
#                                                                               # 
#  Renames the chains for a given number of segments in a multimeric assembly   # 
#                                                                               # 
#  May 8th 2011 by Jason A. Roberts, VIDRL/RMIT University Australia            # 
#                                                                               # 
################################################################################# 
 
 
# Start looping for x number of times with start point 1 "sega" 
for {set sega 1} {$sega <= 240} {incr sega} { 
 
# Print out a screen count for visual feedback 
puts $sega 
  
 # Select the first and last frames for RMSD calculation 
 set chain1 [atomselect top " segname P$sega"] 
 $chain1 set chain 1 
  
 #Skip 3 molecules ahead according to previous chain IDs in usage 
 set sega [expr 3 + $sega] 
 
 
 } 
 
# End of script for VP1, the remaining VPs are the same 
# but have a new start point "segb" starts at 2, "segc" starts at 3 etc. 
 
# Start looping for x number of times with start point 2 "segb" 
for {set segb 2} {$segb <= 240} {incr segb} { 
 
# Print out a screen count for visual feedback 
puts $segb 
  
 # Select the first and last frames for RMSD calculation 
 set chain2 [atomselect top " segname P$segb"] 
 $chain2 set chain 2 
  
 #Skip 3 molecules ahead according to previous chain IDs in usage 
 set segb [expr 3 + $segb] 
 
 
 } 
 
# End of script for VP2 
 
# Start looping for x number of times with start point 3 "segc" 
for {set segc 3} {$segc <= 240} {incr segc} { 
 
# Print out a screen count for visual feedback 
puts $segc 
  
 # Select the first and last frames for RMSD calculation 
 set chain3 [atomselect top " segname P$segc"] 
 $chain3 set chain 3 
  
 #Skip 3 molecules ahead according to previous chain IDs in usage 
 set segc [expr 3 + $segc] 
 
 
 } 
 
# End of script for VP3 
 
# Start looping for x number of times with start point 4 "segd" 
for {set segd 4} {$segd <= 240} {incr segd} { 
 
# Print out a screen count for visual feedback 
puts $segd 
  
 # Select the first and last frames for RMSD calculation 
 set chain4 [atomselect top " segname P$segd"] 
 $chain4 set chain 4 
  
 #Skip 3 molecules ahead according to previous chain IDs in usage 
 set segd [expr 3 + $segd] 
 
 
 } 
 
# End of script for VP4 
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A5.4 TCL script written postion all 60 virus protomers in the same space as protomer 
No. 1. 
 
File Name: ProtomerFit_capsidalternate.tcl 
 
############################################################# 
#                                                           # 
#    Script for translating protomer positions relative     # 
#    to protomer reference 1 coordinates for analysis    # 
# Jason A. Roberts 2011 VIDRL RMIT  # 
#                                                           # 
############################################################# 
 
# Enter the number of protomers after "set protomer" 
# Enter the name of the output file after "set name" 
# The rest just resets all variables to 0 
 
set protomer  60 
set name  PV1W5ns 
set counter  0 
set loop  0 
set segA 0 
set segB  0 
set segC 0 
set segD 0 
set segE 0 
set segF 0 
set reference [atomselect top "segname P1 P2 P3 P4 and resid 30 to 60"]  
 
# This procedure lifted from John Stones “animatepdbs” 
 
proc animatepdbs {start end fileformat} { 
  set filename [format $fileformat [expr $start]] 
  incr start 
  puts "Reading initial frame in PDB sequence $filename" 
  mol load pdb $filename 
 
  puts "Reading PDB files as an animation..." 
  for {set i $start} {$i <= $end} {incr i 1} { 
    set filename [format $fileformat [expr $i]] 
    animate read pdb $filename 
  } 
} 
 
 
# This part loops the selections for each protein and lipid/drug 
# Then remaps them to the new coordinates and updates the new pdb 
 
for {set counter 1} {$counter <=$protomer} {incr counter} { 
 
 
 set segA [expr 1 + $loop] 
 set segB [expr 2 + $loop] 
 set segC [expr 3 + $loop] 
 set segD [expr 4 + $loop] 
  
 set segF [expr $segD / 2] 
 set segE [expr $segF - 1] 
 
 set segment [atomselect top "segname P$segA P$segB P$segC P$segD O$segE O$segF"] 
 set query [atomselect top "segname P$segA P$segB P$segC P$segD and resid"] 
 set fit [measure fit $query $reference] 
 $segment move $fit 
  
 $segment writepdb "$counter.pdb" 
 
  puts "protomer $counter" 
  puts "loop number $loop" 
  puts "P$segA" 
  puts "P$segB" 
  puts "P$segC" 
  puts "P$segD" 
  puts "O$segE" 
  puts "O$segF" 
 
 set loop [expr 1 + $segC] 
  
 } 
 
animatepdbs 1 $loop %d.pdb 
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A5.5 Selection parameters for the selection and comparison of multiple poliovirus 
capsid proteins with standard naming convention. 
 
File Name: 1HXS_crystal_selection.txt 
 
1HXS.pdb specific selection data 
 
(chain 1 and resid 20 to 302) or (chain 2 and resid 6 to 272) or (chain 3 and resid 1 to 235) 
or (chain 4 and resid 2 to 69) 
 
Matches across the range of available type 1 crystal structures 
 
(chain 1 and resid 70 to 302) or (chain 2 and resid 6 to 272) or (chain 3 and resid 1 to 235) 
or (chain 4 and resid 2 to 13) or (chain 4 and resid 25 to 69) 
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A5.6. Small molecule parameterization, customised topology data file for 
virus construction in VMD. 
 
File Name: Picornavirus_small_molecules_rev2.top 
 
*>Small molecule topology for picornavirus simulations< 
*>>>>>>>> JA Roberts, MJ Kuiper and A Hung 2012 <<<<<<<< 
 
 
!The following residue PLM (PALM) derived from original 
CHARMM file.   
!partial charges derived from (PALM) in original CHARMM 
!file and renamed to suit virus reconstructions 
!Jason Roberts 2012 VIDRL/RMIT University 2012 
 
MASS   201 CO2M  12.011000 
MASS   202 O2CM  15.999400 
MASS   203 CR    12.011000 
MASS   204 HCMM   1.007940 
 
AUTOGENERATE ANGLES DIHE 
DEFA FIRS NONE LAST NONE 
 
RESI PLM  -1.000  
GROUP 
ATOM C1   CO2M  0.62 
ATOM O1   O2CM -0.76 
ATOM O2   O2CM -0.76 
ATOM C2   CR   -0.28 
ATOM C3   CR   -0.18 
ATOM C4   CR   -0.18 
ATOM C5   CR   -0.18 
ATOM C6   CR   -0.18 
ATOM C7   CR   -0.18 
ATOM C8   CR   -0.18 
ATOM C9   CR   -0.18 
ATOM CA   CR   -0.18 
ATOM CB   CR   -0.18 
ATOM CC   CR   -0.18 
ATOM CD   CR   -0.18 
ATOM CE   CR   -0.18 
ATOM CF   CR   -0.18 
ATOM CG   CR   -0.27 
ATOM H22  HCMM  0.09 
ATOM H23  HCMM  0.09 
ATOM H32  HCMM  0.09 
ATOM H33  HCMM  0.09 
ATOM H42  HCMM  0.09 
ATOM H43  HCMM  0.09 
ATOM H52  HCMM  0.09 
ATOM H53  HCMM  0.09 
ATOM H62  HCMM  0.09 
ATOM H63  HCMM  0.09 
ATOM H72  HCMM  0.09 
ATOM H73  HCMM  0.09 
ATOM H82  HCMM  0.09 
ATOM H83  HCMM  0.09 
ATOM H92  HCMM  0.09 
ATOM H93  HCMM  0.09 
ATOM HA2  HCMM  0.09 
ATOM HA3  HCMM  0.09 
ATOM HB2  HCMM  0.09 
ATOM HB3  HCMM  0.09 
ATOM HC2  HCMM  0.09 
ATOM HC3  HCMM  0.09 
ATOM HD2  HCMM  0.09 
ATOM HD3  HCMM  0.09 
ATOM HE2  HCMM  0.09 
ATOM HE3  HCMM  0.09 
ATOM HF2  HCMM  0.09 
ATOM HF3  HCMM  0.09 
ATOM HG1  HCMM  0.09 
ATOM HG2  HCMM  0.09 
ATOM HG3  HCMM  0.09 
BOND C1   O1   
BOND C1   O2   
BOND C1   C2   
BOND C2   C3   
BOND C3   C4   
BOND C4   C5   
BOND C5   C6   
BOND C6   C7   
BOND C7   C8   
BOND C8   C9   
BOND C9   CA   
BOND CA   CB   
BOND CB   CC   
BOND CC   CD   
BOND CD   CE   
BOND CE   CF   
BOND CF   CG   
BOND HG2  CG   
BOND HG1  CG   
BOND HG3  CG   
BOND HF2  CF   
BOND HF3  CF   
BOND HE3  CE   
BOND HE2  CE   
BOND HD3  CD   
BOND HD2  CD   
BOND HC2  CC   
BOND HC3  CC   
BOND HB3  CB   
BOND HB2  CB   
BOND HA2  CA   
BOND HA3  CA   
BOND H93  C9   
BOND H92  C9   
BOND H83  C8   
BOND H82  C8   
BOND H73  C7   
BOND H72  C7   
BOND H63  C6   
BOND H62  C6   
BOND H53  C5   
BOND H52  C5   
BOND H43  C4   
BOND H42  C4   
BOND H33  C3   
BOND H32  C3   
BOND H23  C2   
BOND H22  C2   
IMPH C1   O1   C2   O2    
IMPH C2   C3   C1   H23   
IMPH C2   C3   C1   H22   
IMPH C3   C4   C2   H33   
IMPH C3   C4   C2   H32   
IMPH C4   C5   C3   H43   
IMPH C4   C5   C3   H42   
IMPH C5   C6   C4   H53   
IMPH C5   C6   C4   H52   
IMPH C6   C7   C5   H63   
IMPH C6   C7   C5   H62   
IMPH C7   C8   C6   H73   
IMPH C7   C8   C6   H72   
IMPH C8   C9   C7   H83   
IMPH C8   C9   C7   H82   
IMPH C9   CA   C8   H93   
IMPH C9   CA   C8   H92   
IMPH CA   CB   C9   HA2   
IMPH CA   CB   C9   HA3   
IMPH CB   CC   CA   HB3   
IMPH CB   CC   CA   HB2   
IMPH CC   CD   CB   HC2   
IMPH CC   CD   CB   HC3   
IMPH CD   CE   CC   HD3   
IMPH CD   CE   CC   HD2   
IMPH CE   CF   CD   HE3   
IMPH CE   CF   CD   HE2   
IMPH CF   CG   CE   HF2   
IMPH CF   CG   CE   HF3   
IMPH CG   HG2  CF   HG1   
IMPH CG   HG2  CF   HG3   
IC C1   C2    C3   C4    1.55   119.16 -175.79  110.92  
1.57   
IC C1   C2    C3   H32   1.55   119.16  -55.61  109.08  
1.09   
IC C1   C2    C3   H33   1.55   119.16   63.78  109.25  
1.09   
IC O1   C1    C2   C3    1.26   120.56 -103.84  119.16  
1.55   
IC O1   C1    C2   H22   1.26   120.56   17.52  107.00  
1.09   
IC O1   C1    C2   H23   1.26   120.56  133.11  107.73  
1.09   
IC O2   C1    C2   C3    1.25   118.42   79.75  119.16  
1.55   
IC O2   C1    C2   H22   1.25   118.42 -158.89  107.00  
1.09   
IC O2   C1    C2   H23   1.25   118.42  -43.30  107.73  
1.09   
IC C2   C3    C4   C5    1.55   110.92   62.15  109.64  
1.53   
IC C2   C3    C4   H42   1.55   110.92  -57.86  109.41  
1.09   
IC C2   C3    C4   H43   1.55   110.92 -177.79  109.43  
1.09   
IC C3   C4    C5   C6    1.57   109.64 -176.79  114.94  
1.54   
IC C3   C4    C5   H52   1.57   109.64   62.41  108.09  
1.09   
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IC C3   C4    C5   H53   1.57   109.64  -55.11  108.52  
1.09   
IC C4   C3    C2   H22   1.57   110.92   62.83  106.99  
1.09   
IC C4   C3    C2   H23   1.57   110.92  -52.76  107.77  
1.09   
IC C4   C5    C6   C7    1.53   114.94 -167.63  107.67  
1.56   
IC C4   C5    C6   H62   1.53   114.94  -47.91  109.90  
1.09   
IC C4   C5    C6   H63   1.53   114.94   72.91  109.78  
1.09   
IC C5   C4    C3   H32   1.53   109.64  -58.03  109.10  
1.09   
IC C5   C4    C3   H33   1.53   109.64 -177.40  109.21  
1.09   
IC C5   C6    C7   C8    1.54   107.67 -161.51  109.67  
1.54   
IC C5   C6    C7   H72   1.54   107.67  -41.48  109.41  
1.09   
IC C5   C6    C7   H73   1.54   107.67   78.40  109.47  
1.09   
IC C6   C5    C4   H42   1.54   114.94  -56.80  109.43  
1.09   
IC C6   C5    C4   H43   1.54   114.94   63.16  109.46  
1.09   
IC C6   C7    C8   C9    1.56   109.67 -161.40  113.63  
1.53   
IC C6   C7    C8   H82   1.56   109.67   77.99  108.41  
1.09   
IC C6   C7    C8   H83   1.56   109.67  -40.09  108.75  
1.09   
IC C7   C6    C5   H52   1.56   107.67  -46.83  108.08  
1.09   
IC C7   C6    C5   H53   1.56   107.67   70.69  108.52  
1.09   
IC C7   C8    C9   CA    1.54   113.63  177.94  113.11  
1.55   
IC C7   C8    C9   H92   1.54   113.63  -61.54  108.53  
1.09   
IC C7   C8    C9   H93   1.54   113.63   56.79  108.87  
1.09   
IC C8   C7    C6   H62   1.54   109.67   78.79  109.93  
1.09   
IC C8   C7    C6   H63   1.54   109.67  -42.05  109.77  
1.09   
IC C8   C9    CA   CB    1.53   113.11  -67.56  119.48  
1.54   
IC C8   C9    CA   HA2   1.53   113.11  171.07  106.90  
1.09   
IC C8   C9    CA   HA3   1.53   113.11   55.52  107.68  
1.09   
IC C9   C8    C7   H72   1.53   113.63   78.58  109.42  
1.09   
IC C9   C8    C7   H73   1.53   113.63  -41.30  109.44  
1.09   
IC C9   CA    CB   CC    1.55   119.48 -167.44  109.12  
1.53   
IC C9   CA    CB   HB2   1.55   119.48  -47.50  109.56  
1.09   
IC C9   CA    CB   HB3   1.55   119.48   72.66  109.56  
1.09   
IC CA   C9    C8   H82   1.55   113.11  -61.46  108.43  
1.09   
IC CA   C9    C8   H83   1.55   113.11   56.65  108.78  
1.09   
IC CA   CB    CC   CD    1.54   109.12 -168.50  116.66  
1.53   
IC CA   CB    CC   HC2   1.54   109.12  -47.49  107.62  
1.09   
IC CA   CB    CC   HC3   1.54   109.12   69.28  108.22  
1.09   
IC CB   CA    C9   H92   1.54   119.48  171.93  108.55  
1.09   
IC CB   CA    C9   H93   1.54   119.48   53.59  108.85  
1.09   
IC CB   CC    CD   CE    1.53   116.66 -168.77  110.30  
1.54   
IC CB   CC    CD   HD2   1.53   116.66  -48.63  109.26  
1.09   
IC CB   CC    CD   HD3   1.53   116.66   70.99  109.32  
1.09   
IC CC   CB    CA   HA2   1.53   109.12  -46.06  106.89  
1.09   
IC CC   CB    CA   HA3   1.53   109.12   69.46  107.66  
1.09   
IC CC   CD    CE   CF    1.53   110.30 -167.93  114.49  
1.53   
IC CC   CD    CE   HE2   1.53   110.30   71.35  108.18  
1.09   
IC CC   CD    CE   HE3   1.53   110.30  -46.37  108.61  
1.09   
IC CD   CC    CB   HB2   1.53   116.66   71.56  109.55  
1.09   
IC CD   CC    CB   HB3   1.53   116.66  -48.58  109.53  
1.09   
IC CD   CE    CF   CG    1.54   114.49  178.82  114.17  
1.57   
IC CD   CE    CF   HF2   1.54   114.49   58.13  108.25  
1.09   
IC CD   CE    CF   HF3   1.54   114.49  -59.73  108.67  
1.09   
IC CE   CD    CC   HC2   1.54   110.30   70.23  107.64  
1.09   
IC CE   CD    CC   HC3   1.54   110.30  -46.53  108.20  
1.09   
IC CE   CF    CG   HG1   1.53   114.17 -179.99  109.51  
1.09   
IC CE   CF    CG   HG2   1.53   114.17   60.01  109.44  
1.09   
IC CE   CF    CG   HG3   1.53   114.17  -59.97  109.50  
1.09   
IC CF   CE    CD   HD2   1.53   114.49   71.94  109.27  
1.09   
IC CF   CE    CD   HD3   1.53   114.49  -47.70  109.33  
1.09   
IC CG   CF    CE   HE2   1.57   114.17  -60.47  108.20  
1.09   
IC CG   CF    CE   HE3   1.57   114.17   57.26  108.61  
1.09   
IC H22  C2    C3   H32   1.09   106.99 -176.98  109.08  
1.09   
IC H22  C2    C3   H33   1.09   106.99  -57.60  109.25  
1.09   
IC H23  C2    C3   H32   1.09   107.77   67.43  109.08  
1.09   
IC H23  C2    C3   H33   1.09   107.77 -173.19  109.25  
1.09   
IC H32  C3    C4   H42   1.09   109.10 -178.04  109.41  
1.09   
IC H32  C3    C4   H43   1.09   109.10   62.04  109.43  
1.09   
IC H33  C3    C4   H42   1.09   109.21   62.59  109.41  
1.09   
IC H33  C3    C4   H43   1.09   109.21  -57.33  109.43  
1.09   
IC H42  C4    C5   H52   1.09   109.43 -177.59  108.09  
1.09   
IC H42  C4    C5   H53   1.09   109.43   64.89  108.52  
1.09   
IC H43  C4    C5   H52   1.09   109.46  -57.64  108.09  
1.09   
IC H43  C4    C5   H53   1.09   109.46 -175.16  108.52  
1.09   
IC H52  C5    C6   H62   1.09   108.08   72.88  109.90  
1.09   
IC H52  C5    C6   H63   1.09   108.08 -166.29  109.78  
1.09   
IC H53  C5    C6   H62   1.09   108.52 -169.60  109.90  
1.09   
IC H53  C5    C6   H63   1.09   108.52  -48.77  109.78  
1.09   
IC H62  C6    C7   H72   1.09   109.93 -161.18  109.41  
1.09   
IC H62  C6    C7   H73   1.09   109.93  -41.29  109.47  
1.09   
IC H63  C6    C7   H72   1.09   109.77   77.98  109.41  
1.09   
IC H63  C6    C7   H73   1.09   109.77 -162.13  109.47  
1.09   
IC H72  C7    C8   H82   1.09   109.42  -42.04  108.41  
1.09   
IC H72  C7    C8   H83   1.09   109.42 -160.11  108.75  
1.09   
IC H73  C7    C8   H82   1.09   109.44 -161.92  108.41  
1.09   
IC H73  C7    C8   H83   1.09   109.44   80.01  108.75  
1.09   
IC H82  C8    C9   H92   1.09   108.43   59.07  108.53  
1.09   
IC H82  C8    C9   H93   1.09   108.43  177.40  108.87  
1.09   
IC H83  C8    C9   H92   1.09   108.78  177.17  108.53  
1.09   
IC H83  C8    C9   H93   1.09   108.78  -64.50  108.87  
1.09   
IC H92  C9    CA   HA2   1.09   108.55   50.56  106.90  
1.09   
IC H92  C9    CA   HA3   1.09   108.55  -64.99  107.68  
1.09   
IC H93  C9    CA   HA2   1.09   108.85  -67.78  106.90  
1.09   
IC H93  C9    CA   HA3   1.09   108.85  176.68  107.68  
1.09   
IC HA2  CA    CB   HB2   1.09   106.89   73.87  109.56  
1.09   
IC HA2  CA    CB   HB3   1.09   106.89 -165.97  109.56  
1.09   
IC HA3  CA    CB   HB2   1.09   107.66 -170.60  109.56  
1.09   
IC HA3  CA    CB   HB3   1.09   107.66  -50.44  109.56  
1.09   
IC HB2  CB    CC   HC2   1.09   109.55 -167.43  107.62  
1.09   
IC HB2  CB    CC   HC3   1.09   109.55  -50.66  108.22  
1.09   
IC HB3  CB    CC   HC2   1.09   109.53   72.43  107.62  
1.09   
IC HB3  CB    CC   HC3   1.09   109.53 -170.80  108.22  
1.09   
IC HC2  CC    CD   HD2   1.09   107.64 -169.63  109.26  
1.09   
IC HC2  CC    CD   HD3   1.09   107.64  -50.01  109.32  
1.09   
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IC HC3  CC    CD   HD2   1.09   108.20   73.61  109.26  
1.09   
IC HC3  CC    CD   HD3   1.09   108.20 -166.77  109.32  
1.09   
IC HD2  CD    CE   HE2   1.09   109.27  -48.79  108.18  
1.09   
IC HD2  CD    CE   HE3   1.09   109.27 -166.50  108.61  
1.09   
IC HD3  CD    CE   HE2   1.09   109.33 -168.42  108.18  
1.09   
IC HD3  CD    CE   HE3   1.09   109.33   73.86  108.61  
1.09   
IC HE2  CE    CF   HF2   1.09   108.20  178.84  108.25  
1.09   
IC HE2  CE    CF   HF3   1.09   108.20   60.98  108.67  
1.09   
IC HE3  CE    CF   HF2   1.09   108.61  -63.43  108.25  
1.09   
IC HE3  CE    CF   HF3   1.09   108.61  178.71  108.67  
1.09   
IC HF2  CF    CG   HG1   1.09   108.30  -59.32  109.51  
1.09   
IC HF2  CF    CG   HG2   1.09   108.30 -179.33  109.44  
1.09   
IC HF2  CF    CG   HG3   1.09   108.30   60.69  109.50  
1.09   
IC HF3  CF    CG   HG1   1.09   108.66   58.56  109.51  
1.09   
IC HF3  CF    CG   HG2   1.09   108.66  -61.45  109.44  
1.09   
IC HF3  CF    CG   HG3   1.09   108.66  178.57  109.50  
1.09   
IC O1   C2   *C1   O2    0.00     0.00  180.00    0.00  
0.00   
IC C3   C1   *C2   H23   0.00     0.00  120.00    0.00  
0.00   
IC C3   C1   *C2   H22   0.00     0.00 -120.00    0.00  
0.00   
IC C4   C2   *C3   H33   0.00     0.00  120.00    0.00  
0.00   
IC C4   C2   *C3   H32   0.00     0.00 -120.00    0.00  
0.00   
IC C5   C3   *C4   H43   0.00     0.00  120.00    0.00  
0.00   
IC C5   C3   *C4   H42   0.00     0.00 -120.00    0.00  
0.00   
IC C6   C4   *C5   H53   0.00     0.00  120.00    0.00  
0.00   
IC C6   C4   *C5   H52   0.00     0.00 -120.00    0.00  
0.00   
IC C7   C5   *C6   H63   0.00     0.00  120.00    0.00  
0.00   
IC C7   C5   *C6   H62   0.00     0.00 -120.00    0.00  
0.00   
IC C8   C6   *C7   H73   0.00     0.00  120.00    0.00  
0.00   
IC C8   C6   *C7   H72   0.00     0.00 -120.00    0.00  
0.00   
IC C9   C7   *C8   H83   0.00     0.00  120.00    0.00  
0.00   
IC C9   C7   *C8   H82   0.00     0.00 -120.00    0.00  
0.00   
IC CA   C8   *C9   H93   0.00     0.00  120.00    0.00  
0.00   
IC CA   C8   *C9   H92   0.00     0.00 -120.00    0.00  
0.00   
IC CB   C9   *CA   HA2   0.00     0.00  120.00    0.00  
0.00   
IC CB   C9   *CA   HA3   0.00     0.00 -120.00    0.00  
0.00   
IC CC   CA   *CB   HB3   0.00     0.00  120.00    0.00  
0.00   
IC CC   CA   *CB   HB2   0.00     0.00 -120.00    0.00  
0.00   
IC CD   CB   *CC   HC2   0.00     0.00  120.00    0.00  
0.00   
IC CD   CB   *CC   HC3   0.00     0.00 -120.00    0.00  
0.00   
IC CE   CC   *CD   HD3   0.00     0.00  120.00    0.00  
0.00   
IC CE   CC   *CD   HD2   0.00     0.00 -120.00    0.00  
0.00   
IC CF   CD   *CE   HE3   0.00     0.00  120.00    0.00  
0.00   
IC CF   CD   *CE   HE2   0.00     0.00 -120.00    0.00  
0.00   
IC CG   CE   *CF   HF2   0.00     0.00  120.00    0.00  
0.00   
IC CG   CE   *CF   HF3   0.00     0.00 -120.00    0.00  
0.00   
IC HG2  CF   *CG   HG1   0.00     0.00  120.00    0.00  
0.00   
IC HG2  CF   *CG   HG3   0.00     0.00 -120.00    0.00  
0.00   
 
 
!The following residue MYR derived from SWISSparam 
output, 
!partial charges derived from (PALM) in original CHARMM 
!file and renamed to suit virus reconstructions 
!Jason Roberts 2012 VIDRL/RMIT University 2012 
 
RESI MYR  -1.000  
GROUP 
ATOM C1   CO2M  0.62 
ATOM O1   O2CM -0.76 
ATOM O2   O2CM -0.76 
ATOM C2   CR   -0.28 
ATOM C3   CR   -0.18 
ATOM C4   CR   -0.18 
ATOM C5   CR   -0.18 
ATOM C6   CR   -0.18 
ATOM C7   CR   -0.18 
ATOM C8   CR   -0.18 
ATOM C9   CR   -0.18 
ATOM C10  CR   -0.18 
ATOM C11  CR   -0.18 
ATOM C12  CR   -0.18 
ATOM C13  CR   -0.18 
ATOM C14  CR   -0.27 
ATOM H22  HCMM  0.09 
ATOM H23  HCMM  0.09 
ATOM H32  HCMM  0.09 
ATOM H33  HCMM  0.09 
ATOM H42  HCMM  0.09 
ATOM H43  HCMM  0.09 
ATOM H52  HCMM  0.09 
ATOM H53  HCMM  0.09 
ATOM H62  HCMM  0.09 
ATOM H63  HCMM  0.09 
ATOM H72  HCMM  0.09 
ATOM H73  HCMM  0.09 
ATOM H82  HCMM  0.09 
ATOM H83  HCMM  0.09 
ATOM H92  HCMM  0.09 
ATOM H93  HCMM  0.09 
ATOM H102 HCMM  0.09 
ATOM H103 HCMM  0.09 
ATOM H112 HCMM  0.09 
ATOM H113 HCMM  0.09 
ATOM H122 HCMM  0.09 
ATOM H123 HCMM  0.09 
ATOM H132 HCMM  0.09 
ATOM H133 HCMM  0.09 
ATOM H141 HCMM  0.09 
ATOM H142 HCMM  0.09 
ATOM H143 HCMM  0.09 
BOND C1   O1   
BOND C1   O2   
BOND C1   C2   
BOND H23  C2   
BOND H22  C2   
BOND C2   C3   
BOND H33  C3   
BOND H32  C3   
BOND C3   C4   
BOND H43  C4   
BOND H42  C4   
BOND C4   C5   
BOND H53  C5   
BOND H52  C5   
BOND C5   C6   
BOND H63  C6   
BOND H62  C6   
BOND C6   C7   
BOND H73  C7   
BOND H72  C7   
BOND C7   C8   
BOND H83  C8   
BOND H82  C8   
BOND C8   C9   
BOND H93  C9   
BOND H92  C9   
BOND C10  C9   
BOND H103 C10  
BOND H102 C10  
BOND C10  C11  
BOND H113 C11  
BOND H112 C11  
BOND C11  C12  
BOND H123 C12  
BOND H122 C12  
BOND C12  C13  
BOND H133 C13  
BOND H132 C13  
BOND C13  C14  
BOND H142 C14  
BOND H143 C14  
BOND H141 C14  
IMPH C1   O1   C2   O2    
IMPH C2   C3   C1   H23   
IMPH C2   H23  C1   H22   
IMPH C3   C4   C2   H33   
IMPH C3   H33  C2   H32   
IMPH C4   C5   C3   H43   
IMPH C4   H43  C3   H42   
IMPH C5   C6   C4   H53   
IMPH C5   H53  C4   H52   
IMPH C6   C7   C5   H63   
IMPH C6   H63  C5   H62   
IMPH C7   C8   C6   H73   
IMPH C7   H73  C6   H72   
IMPH C8   C9   C7   H83   
IMPH C8   H83  C7   H82   
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IMPH C9   C10  C8   H93   
IMPH C9   H93  C8   H92   
IMPH C10  C11  C9   H103  
IMPH C10  H103 C9   H102  
IMPH C11  C12  C10  H113  
IMPH C11  H113 C10  H112  
IMPH C12  C13  C11  H123  
IMPH C12  H123 C11  H122  
IMPH C13  C14  C12  H133  
IMPH C13  H133 C12  H132  
IMPH C14  H142 C13  H143  
IMPH C14  H142 C13  H141  
IC C1   C2    C3   C4    1.49   112.94  -95.18  113.33  
1.54   
IC C1   C2    C3   H32   1.49   112.94  144.25  108.49  
1.09   
IC C1   C2    C3   H33   1.49   112.94   26.02  108.80  
1.09   
IC O1   C1    C2   C3    1.25   119.21 -110.39  112.94  
1.53   
IC O1   C1    C2   H22   1.25   119.21   10.12  108.61  
1.09   
IC O1   C1    C2   H23   1.25   119.21  128.53  108.91  
1.09   
IC O2   C1    C2   C3    1.24   117.28   69.06  112.94  
1.53   
IC O2   C1    C2   H22   1.24   117.28 -170.42  108.61  
1.09   
IC O2   C1    C2   H23   1.24   117.28  -52.02  108.91  
1.09   
IC C2   C3    C4   C5    1.53   113.33 -159.93  110.88  
1.56   
IC C2   C3    C4   H42   1.53   113.33   79.84  109.13  
1.09   
IC C2   C3    C4   H43   1.53   113.33  -39.47  109.20  
1.09   
IC C3   C4    C5   C6    1.54   110.88 -169.60  114.90  
1.56   
IC C3   C4    C5   H52   1.54   110.88  -48.82  108.08  
1.09   
IC C3   C4    C5   H53   1.54   110.88   68.69  108.51  
1.09   
IC C4   C3    C2   H22   1.54   113.33  144.29  108.59  
1.09   
IC C4   C3    C2   H23   1.54   113.33   25.92  108.87  
1.09   
IC C4   C5    C6   C7    1.56   114.90  167.21  111.24  
1.54   
IC C4   C5    C6   H62   1.56   114.90   46.97  109.03  
1.09   
IC C4   C5    C6   H63   1.56   114.90  -72.25  109.18  
1.09   
IC C5   C4    C3   H32   1.56   110.88  -39.36  108.50  
1.09   
IC C5   C4    C3   H33   1.56   110.88   78.88  108.83  
1.09   
IC C5   C6    C7   C8    1.56   111.24 -164.51  113.20  
1.54   
IC C5   C6    C7   H72   1.56   111.24  -43.97  108.50  
1.09   
IC C5   C6    C7   H73   1.56   111.24   74.36  108.83  
1.09   
IC C6   C5    C4   H42   1.56   114.90  -49.37  109.13  
1.09   
IC C6   C5    C4   H43   1.56   114.90   69.98  109.27  
1.09   
IC C6   C7    C8   C9    1.54   113.20  153.65  115.43  
1.54   
IC C6   C7    C8   H82   1.54   113.20  -85.49  107.97  
1.09   
IC C6   C7    C8   H83   1.54   113.20   31.79  108.45  
1.09   
IC C7   C6    C5   H52   1.54   111.24   46.43  108.09  
1.09   
IC C7   C6    C5   H53   1.54   111.24  -71.11  108.57  
1.09   
IC C7   C8    C9   C10   1.54   115.43 -176.66  107.86  
1.52   
IC C7   C8    C9   H92   1.54   115.43  -56.93  109.87  
1.09   
IC C7   C8    C9   H93   1.54   115.43   63.83  109.76  
1.09   
IC C8   C7    C6   H62   1.54   113.20  -44.26  109.00  
1.09   
IC C8   C7    C6   H63   1.54   113.20   74.95  109.16  
1.09   
IC C8   C9    C10  C11   1.54   107.86 -178.34  119.71  
1.53   
IC C8   C9    C10  H102  1.54   107.86   60.22  106.84  
1.09   
IC C8   C9    C10  H103  1.54   107.86  -55.16  107.66  
1.09   
IC C9   C8    C7   H72   1.54   115.43   33.13  108.53  
1.09   
IC C9   C8    C7   H73   1.54   115.43  -85.21  108.82  
1.09   
IC C9   C10   C11  C12   1.52   119.71  164.10  106.11  
1.56   
IC C9   C10   C11  H112  1.52   119.71  -76.44  110.28  
1.09   
IC C9   C10   C11  H113  1.52   119.71   45.13  110.03  
1.09   
IC C10  C9    C8   H82   1.52   107.86   62.47  107.95  
1.09   
IC C10  C9    C8   H83   1.52   107.86  -54.80  108.44  
1.09   
IC C10  C11   C12  C13   1.53   106.11  150.56  117.23  
1.54   
IC C10  C11   C12  H122  1.53   106.11  -88.31  107.49  
1.09   
IC C10  C11   C12  H123  1.53   106.11   28.13  108.12  
1.09   
IC C11  C10   C9   H92   1.53   119.71   61.92  109.86  
1.09   
IC C11  C10   C9   H93   1.53   119.71  -58.80  109.73  
1.09   
IC C11  C12   C13  C14   1.56   117.23 -167.93  110.27  
1.57   
IC C11  C12   C13  H132  1.56   117.23  -47.80  109.28  
1.09   
IC C11  C12   C13  H133  1.56   117.23   71.84  109.36  
1.09   
IC C12  C11   C10  H102  1.56   106.11  -74.47  106.86  
1.09   
IC C12  C11   C10  H103  1.56   106.11   40.90  107.61  
1.09   
IC C12  C13   C14  H141  1.54   110.27 -180.00  109.53  
1.09   
IC C12  C13   C14  H142  1.54   110.27  -59.98  109.48  
1.09   
IC C12  C13   C14  H143  1.54   110.27   60.00  109.46  
1.09   
IC C13  C12   C11  H112  1.54   117.23   31.11  110.31  
1.09   
IC C13  C12   C11  H113  1.54   117.23  -90.46  110.01  
1.09   
IC C14  C13   C12  H122  1.57   110.27   70.95  107.51  
1.09   
IC C14  C13   C12  H123  1.57   110.27  -45.49  108.11  
1.09   
IC H22  C2    C3   H32   1.09   108.59   23.73  108.49  
1.09   
IC H22  C2    C3   H33   1.09   108.59  -94.50  108.80  
1.09   
IC H23  C2    C3   H32   1.09   108.87  -94.64  108.49  
1.09   
IC H23  C2    C3   H33   1.09   108.87  147.13  108.80  
1.09   
IC H32  C3    C4   H42   1.09   108.50 -159.60  109.13  
1.09   
IC H32  C3    C4   H43   1.09   108.50   81.09  109.20  
1.09   
IC H33  C3    C4   H42   1.09   108.83  -41.35  109.13  
1.09   
IC H33  C3    C4   H43   1.09   108.83 -160.66  109.20  
1.09   
IC H42  C4    C5   H52   1.09   109.13   71.41  108.08  
1.09   
IC H42  C4    C5   H53   1.09   109.13 -171.08  108.51  
1.09   
IC H43  C4    C5   H52   1.09   109.27 -169.24  108.08  
1.09   
IC H43  C4    C5   H53   1.09   109.27  -51.73  108.51  
1.09   
IC H52  C5    C6   H62   1.09   108.09  -73.80  109.03  
1.09   
IC H52  C5    C6   H63   1.09   108.09  166.97  109.18  
1.09   
IC H53  C5    C6   H62   1.09   108.57  168.65  109.03  
1.09   
IC H53  C5    C6   H63   1.09   108.57   49.43  109.18  
1.09   
IC H62  C6    C7   H72   1.09   109.00   76.28  108.50  
1.09   
IC H62  C6    C7   H73   1.09   109.00 -165.39  108.83  
1.09   
IC H63  C6    C7   H72   1.09   109.16 -164.52  108.50  
1.09   
IC H63  C6    C7   H73   1.09   109.16  -46.18  108.83  
1.09   
IC H72  C7    C8   H82   1.09   108.53  154.00  107.97  
1.09   
IC H72  C7    C8   H83   1.09   108.53  -88.72  108.45  
1.09   
IC H73  C7    C8   H82   1.09   108.82   35.65  107.97  
1.09   
IC H73  C7    C8   H83   1.09   108.82  152.93  108.45  
1.09   
IC H82  C8    C9   H92   1.09   107.95 -177.80  109.87  
1.09   
IC H82  C8    C9   H93   1.09   107.95  -57.04  109.76  
1.09   
IC H83  C8    C9   H92   1.09   108.44   64.93  109.87  
1.09   
IC H83  C8    C9   H93   1.09   108.44 -174.31  109.76  
1.09   
IC H92  C9    C10  H102  1.09   109.86  -59.52  106.84  
1.09   
IC H92  C9    C10  H103  1.09   109.86 -174.90  107.66  
1.09   
IC H93  C9    C10  H102  1.09   109.73  179.76  106.84  
1.09   
IC H93  C9    C10  H103  1.09   109.73   64.37  107.66  
1.09   
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IC H102 C10   C11  H112  1.09   106.86   44.99  110.28  
1.09   
IC H102 C10   C11  H113  1.09   106.86  166.55  110.03  
1.09   
IC H103 C10   C11  H112  1.09   107.61  160.37  110.28  
1.09   
IC H103 C10   C11  H113  1.09   107.61  -78.07  110.03  
1.09   
IC H112 C11   C12  H122  1.09   110.31  152.25  107.49  
1.09   
IC H112 C11   C12  H123  1.09   110.31  -91.32  108.12  
1.09   
IC H113 C11   C12  H122  1.09   110.01   30.68  107.49  
1.09   
IC H113 C11   C12  H123  1.09   110.01  147.11  108.12  
1.09   
IC H122 C12   C13  H132  1.09   107.51 -168.92  109.28  
1.09   
IC H122 C12   C13  H133  1.09   107.51  -49.28  109.36  
1.09   
IC H123 C12   C13  H132  1.09   108.11   74.64  109.28  
1.09   
IC H123 C12   C13  H133  1.09   108.11 -165.72  109.36  
1.09   
IC H132 C13   C14  H141  1.09   109.28   59.87  109.53  
1.09   
IC H132 C13   C14  H142  1.09   109.28  179.89  109.48  
1.09   
IC H132 C13   C14  H143  1.09   109.28  -60.13  109.46  
1.09   
IC H133 C13   C14  H141  1.09   109.31  -59.75  109.53  
1.09   
IC H133 C13   C14  H142  1.09   109.31   60.27  109.48  
1.09   
IC H133 C13   C14  H143  1.09   109.31 -179.74  109.46  
1.09   
IC O1   C2   *C1   O2    0.00     0.00  180.00    0.00  
0.00   
IC C3   C1   *C2   H23   0.00     0.00  120.00    0.00  
0.00   
IC H23  C1   *C2   H22   0.00     0.00 -120.00    0.00  
0.00   
IC C4   C2   *C3   H33   0.00     0.00  120.00    0.00  
0.00   
IC H33  C2   *C3   H32   0.00     0.00 -120.00    0.00  
0.00   
IC C5   C3   *C4   H43   0.00     0.00  120.00    0.00  
0.00   
IC H43  C3   *C4   H42   0.00     0.00 -120.00    0.00  
0.00   
IC C6   C4   *C5   H53   0.00     0.00  120.00    0.00  
0.00   
IC H53  C4   *C5   H52   0.00     0.00 -120.00    0.00  
0.00   
IC C7   C5   *C6   H63   0.00     0.00  120.00    0.00  
0.00   
IC H63  C5   *C6   H62   0.00     0.00 -120.00    0.00  
0.00   
IC C8   C6   *C7   H73   0.00     0.00  120.00    0.00  
0.00   
IC H73  C6   *C7   H72   0.00     0.00 -120.00    0.00  
0.00   
IC C9   C7   *C8   H83   0.00     0.00  120.00    0.00  
0.00   
IC H83  C7   *C8   H82   0.00     0.00 -120.00    0.00  
0.00   
IC C10  C8   *C9   H93   0.00     0.00  120.00    0.00  
0.00   
IC H93  C8   *C9   H92   0.00     0.00 -120.00    0.00  
0.00   
IC C11  C9   *C10  H103  0.00     0.00  120.00    0.00  
0.00   
IC H103 C9   *C10  H102  0.00     0.00 -120.00    0.00  
0.00   
IC C12  C10  *C11  H113  0.00     0.00  120.00    0.00  
0.00   
IC H113 C10  *C11  H112  0.00     0.00 -120.00    0.00  
0.00   
IC C13  C11  *C12  H123  0.00     0.00  120.00    0.00  
0.00   
IC H123 C11  *C12  H122  0.00     0.00 -120.00    0.00  
0.00   
IC C14  C12  *C13  H133  0.00     0.00  120.00    0.00  
0.00   
IC H133 C12  *C13  H132  0.00     0.00 -120.00    0.00  
0.00   
IC H142 C13  *C14  H143  0.00     0.00  120.00    0.00  
0.00   
IC H142 C13  *C14  H141  0.00     0.00 -120.00    0.00  
0.00   
 
 
! Jason A Roberts and Mike Kuiper 21/2/12 
PRES MYRI       0.00 ! myristoyl patch     
GROUP                !  
ATOM 1C1  CO2M  0.63 !  myri 
ATOM 1C2  CR   -0.29 ! 
ATOM 1O1  O    -0.52 !                2HT1    2HA1
  
ATOM 2HT1 H     0.31 !                  |      | 
ATOM 2N   NH1  -0.47 !  1C2---1C1------2N-----2CA- 
ATOM 2CA  CT2  -0.02 !        ||               | 
ATOM 2HA1 HB    0.09 !        1O1             2HA2 
ATOM 2HA2 HB    0.09 !                  gly 
 
DELETE ATOM 1O2 
DELETE ATOM 2HT2 
DELETE ATOM 2HT3 
 
BOND 1C1  2N    
AUTO ANGLES DIHE  
ANGLE  1O1 1C1 2N 2HT1 2N 1C1  
DIHE   1O1 1C1 2N  2HT1 
IMPR 2N 1C1 2CA 2HT1 1C1 1C2 2N 1O1 
 
PATCHING FIRS NONE LAST NONE 
 
 
! >>>>>>>>>>>>>> Tyrosine to Uracil patch 
<<<<<<<<<<<<<<<<< 
! >>>>>>>>>>>>>> Jason A. Roberts VIDRL 2012 
<<<<<<<<<<<<<< 
 
 
PRES TYRU       0.00 !  Tyrosine-Uracil Patch 
GROUP                ! --1CE1           2O1P          
2H5' 
ATOM 1CZ  CA    0.08 !       \           |           / 
ATOM 1OH  OH1  -0.57 ! TYR    -1CZ--1OH-2P-2O5'-2C5'-  
URACIL 
ATOM 2P   P     1.50 !       /           |           \ 
ATOM 2O1P ON3  -0.78 ! --1CE2           2O2P          
2H5'' 
ATOM 2O2P ON3  -0.78 ! 
ATOM 2O5' ON2  -0.57 
 
DELETE ATOM 1HH 
DELETE ATOM 2H5T 
BOND 1OH 2P 2P 2O5' 
BOND 2P 2O1P 
BOND 2P 2O2P 
 
PATCHING FIRS NONE LAST NONE 
 
END
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A5.7 Small molecule parameterization, customised simulation structure 
data file 
 
A8.7.1 File Name: Picornavirus_small_molecules.par 
 
*>>> Myristate and Myristate to Glycine Patch parameters 
<<< 
*>>>>>>>>>> Used for Picornavirus simulations 
<<<<<<<<<<<<<< 
*> Derived from a combination of existing CHARMM 
parameters< 
*>>>>>>>>>>>>> and the SWISSparam server 
<<<<<<<<<<<<<<<<<<< 
*>>>>> Created by Jason A. Roberts and Mike J. Kuiper. 
<<<<< 
*>>>>>>>>>>>>>>>>>>>>> 2011 to 
2013<<<<<<<<<<<<<<<<<<<<<<<<< 
*>>>>>>>>>>>>>>>>> 
jason.roberts@mh.org.au<<<<<<<<<<<<<<<<<< 
* 
 
 
BONDS 
CO2M O2CM  702.103     1.2610  
CO2M CR    275.631     1.5100  
HCMM CR    342.991     1.0930  
CR   CR    306.432     1.5080  
CO2M NH1   419.491     1.3690 ! 
        ! for myristoyl patch jr 21FEB2012 
CO2M O     931.963     1.2220 ! 
    ! for myristoyl patch jr 21FEB2012 
OH1  P     270.0       1.60   ! 
    ! for tyru patch jr 10APR2012 
 
 
ANGLES 
O2CM CO2M O2CM   84.991    130.6000  
O2CM CO2M CR     87.007    114.6890  
CO2M CR   CR     23.749    98.4220  
CO2M CR   HCMM   37.782    108.9040  
CR   CR   HCMM   45.770    110.5490  
HCMM CR   HCMM   37.134    108.8360  
CR   CR   CR     61.243    109.6080  
CO2M NH1  H      41.380    120.2770 ! 
 ! for myristoyl patch jr 21FEB2012 
CR   CO2M O      67.504    124.4100 ! 
 ! for myristoyl patch jr 21FEB2012 
NH1  CO2M O      65.273    127.1520 ! 
 ! for myristoyl patch jr 21FEB2012 
CR   CO2M NH1    80.000    116.5000 ! 
 ! for myristoyl patch jr 21FEB2012 
CO2M NH1  CT2    50.000    120.0000 ! 
 ! for myristoyl patch jr 21FEB2012 
OH1  P    ON3      98.9    111.6  ! 
    ! for tyru patch jr 10APR2012 
OH1  P    ON2     80.0     104.3  ! 
    ! for tyru patch jr 10APR2012 
CA  OH1  P        20.0    120.0   35.00   2.33 ! 
    ! for tyru patch jr 10APR2012 
 
 
DIHEDRALS 
CO2M CR   CR   CR       0.150  3     0.00  
CO2M CR   CR   HCMM    -0.070  3     0.00  
O2CM CO2M CR   CR       0.631  2   180.00  
O2CM CO2M CR   HCMM    -0.053  3     0.00  
CR   CR   CR   CR       0.051  1     0.00  
CR   CR   CR   CR       0.341  2   180.00  
CR   CR   CR   CR       0.166  3     0.00  
CR   CR   CR   HCMM     0.320  1     0.00  
CR   CR   CR   HCMM    -0.315  2   180.00  
CR   CR   CR   HCMM     0.132  3     0.00  
HCMM CR   CR   HCMM     0.142  1     0.00  
HCMM CR   CR   HCMM    -0.693  2   180.00  
HCMM CR   CR   HCMM     0.157  3     0.00  
O    CO2M CR   CR       0.4000 2   180.00 ! 
 ! for myristoyl patch jr 21FEB2012   
O    CO2M CR   HCMM     0.6000 2     0.00 ! 
 ! for myristoyl patch jr 21FEB2012 
O    CO2M NH1  H        1.4000 2   180.00 ! 
 ! for myristoyl patch jr 21FEB2012 
H    NH1  CO2M CR      2.5000  2   180.00 ! 
 ! for myristoyl patch jr 21FEB2012 
NH1  CO2M CR   HCMM    0.0000  3     0.00 ! 
 ! for myristoyl patch jr 21FEB2012 
NH1  CO2M CR   CR      0.0000  3     0.00 ! 
 ! for myristoyl patch jr 21FEB2012 
CO2M  NH1 CT2  C       0.2000  1   180.00 ! 
 ! for myristoyl patch jr 21FEB2012 
CO2M  NH1 CT2  HB      0.0000  3     0.00 ! 
 ! for myristoyl patch jr 21FEB2012 
CR   CO2M NH1  CT2     1.6000  1     0.00 ! 
 ! for myristoyl patch jr 21FEB2012 
P    OH1  CA  CA      0.000   3     0.0  ! 
    ! for tyru patch jr 10APR2012 
ON3  P    OH1  CA       0.10    3     0.0  ! 
    ! for tyru patch jr 10APR2012 
ON2  P    OH1  CA       1.20    1   180.0  ! 
ON2  P    OH1  CA       0.10    2   180.0  ! 
ON2  P    OH1  CA       0.10    3   180.0  ! 
ON2  P    OH1  CA       0.00    6     0.0  ! 
    ! for tyru patch jr 10APR2012 
CN8B ON2 P OH1     1.20    1   180.0  ! 
CN8B ON2 P OH1     0.10    2   180.0  ! 
CN8B ON2 P OH1     0.10    3   180.0  ! 
CN8B ON2 P OH1     0.00    6     0.0  ! 
    ! for tyru patch jr 10APR2012 
 
IMPROPER 
CO2M O2CM CR   O2CM    12.810  0     0.00  
CR   CR   CO2M HCMM     0.000  0     0.00  
CR   HCMM CO2M HCMM     0.000  0     0.00  
CR   CR   CR   HCMM     0.000  0     0.00  
CR   HCMM CR   HCMM     0.000  0     0.00  
O CR NH1 CO2M 9.284  0     
0.00 ! 
  ! for myristoyl patch jr 15Apr2011 
CO2M  CR  NH1 O 120.000   0     0.00 ! 
  ! for myristoyl patch jr 15Apr2011 
 
 
NONBONDED nbxmod  5 atom cdiel shift vatom vdistance 
vswitch -  
cutnb 14.0 ctofnb 12.0 ctonnb 10.0 eps 1.0 e14fac 1.0 
wmin 1.5  
CO2M    0.000000  -0.070000     2.000000     
O2CM    0.000000  -0.120000     1.700000     
CR      0.000000  -0.055000     2.175000   0.000000  -
0.010000     1.900000     
HCMM    0.000000  -0.022000     1.320000     
 
END 
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A5.7.2 File Name: Disoxaril.par 
 
* ----  
* Built parameters for disoxaril.mol2  
* Thu Mar 24 01:54:06 CET 2011  
* Jason A. Roberts 2011 RMIT University/VIDRL 
* ----  
* 
 
BONDS 
C5A  OFUR  416.469     1.3600  
CR   C5A   322.481     1.4710  
HCMM CR    342.991     1.0930  
CR   CR    306.432     1.5080  
CR   OR    363.214     1.4180  
CB   OR    404.019     1.3760  
CB   CB    401.068     1.3740  
C5A  CB    372.641     1.4360  
C5B  C5A   512.256     1.3770  
C5B  N5B   320.682     1.3690  
C5A  N5B   599.191     1.3130  
HCMM C5B   396.246     1.0800  
HCMM C5A   398.045     1.0800  
HCMM CB    381.853     1.0840  
C5B  C5B   310.390     1.4180  
C5B  CR    325.144     1.4690  
C5B  N5A   594.297     1.3350  
N5A  OFUR  342.271     1.3880  
 
ANGLES 
C5B  N5A  OFUR  128.675    103.4520  
N5A  C5B  C5B    65.921    113.5700  
N5A  C5B  CR     69.303    120.6400  
C5B  C5B  CR     55.126    128.0610  
C5B  C5B  C5A    62.322    108.2390  
C5B  C5B  HCMM   39.293    127.4050  
C5A  C5B  HCMM   36.055    126.1700  
C5B  C5A  OFUR   74.484    110.1080  
C5B  C5A  CR     53.039    131.3780  
OFUR C5A  CR     84.560    115.2530  
CB   CB   CB     48.145    119.9770  
CB   CB   OR     69.663    116.4950  
CB   CB   HCMM   40.517    120.5710  
CB   CB   C5A    64.337    120.1900  
CB   C5A  N5B    62.682    128.1300  
CB   C5A  OFUR   87.366    114.2110  
N5B  C5A  OFUR   84.991    115.5920  
C5A  N5B  C5B    86.791    103.7790  
N5B  C5B  C5A    74.700    111.6210  
N5B  C5B  HCMM   50.304    120.4780  
C5B  C5A  HCMM   41.524    131.7210  
OFUR C5A  HCMM   56.421    114.0760  
N5A  OFUR C5A   125.940    107.7550  
C5B  CR   HCMM   44.763    110.4570  
HCMM CR   HCMM   37.134    108.8360  
C5A  CR   CR     72.397    110.0580  
C5A  CR   HCMM   44.691    110.4670  
CR   CR   HCMM   45.770    110.5490  
CR   CR   CR     61.243    109.6080  
CR   CR   OR     71.390    108.1330  
OR   CR   HCMM   56.205    108.5770  
CB   OR   CR     77.363    102.8460  
C5A  OFUR C5A    91.612    106.3130  
 
DIHEDRALS 
N5A  C5B  C5B  C5A      3.500  2   180.00  
N5A  C5B  C5B  HCMM     3.500  2   180.00  
N5A  C5B  CR   HCMM     0.000  1     0.00  
N5A  OFUR C5A  C5B      3.500  2   180.00  
N5A  OFUR C5A  CR       3.500  2   180.00  
C5B  N5A  OFUR C5A      3.500  2   180.00  
C5B  C5B  C5A  OFUR     3.500  2   180.00  
C5B  C5B  C5A  CR       3.500  2   180.00  
C5B  C5B  N5A  OFUR     3.500  2   180.00  
C5B  C5B  CR   HCMM     0.000  1     0.00  
C5B  C5A  CR   CR       0.000  1     0.00  
C5B  C5A  CR   HCMM     0.000  1     0.00  
C5A  C5B  C5B  CR       3.500  2   180.00  
C5A  CR   CR   CR       0.150  3     0.00  
C5A  CR   CR   HCMM     0.150  3     0.00  
CB   CB   CB   CB       3.500  2   180.00  
CB   CB   CB   HCMM     3.500  2   180.00  
CB   OR   CR   CR       0.100  3     0.00  
CB   OR   CR   HCMM     0.053  3     0.00  
CB   CB   OR   CR       2.191  2   180.00  
CB   CB   CB   C5A      3.500  2   180.00  
CB   CB   CB   OR       3.500  2   180.00  
CB   CB   C5A  N5B      3.500  2   180.00  
CB   CB   C5A  OFUR     3.500  2   180.00  
CB   C5A  N5B  C5B      0.000  1     0.00  
CB   C5A  OFUR C5A      0.000  1     0.00  
C5A  CB   CB   HCMM     1.000  2   180.00  
C5A  N5B  C5B  C5A      3.500  2   180.00  
C5A  N5B  C5B  HCMM     3.500  2   180.00  
C5A  OFUR C5A  C5B      3.500  2   180.00  
C5A  OFUR C5A  HCMM     3.500  2   180.00  
N5B  C5A  OFUR C5A      3.500  2   180.00  
N5B  C5B  C5A  OFUR     3.500  2   180.00  
N5B  C5B  C5A  HCMM     3.500  2   180.00  
C5B  N5B  C5A  OFUR     3.500  2   180.00  
OFUR N5A  C5B  CR       3.500  2   180.00 OFUR C5A  C5B  
HCMM     3.500  2   180.00  
OFUR C5A  CR   CR       0.000  1     0.00  
OFUR C5A  CR   HCMM     0.000  1     0.00  
CR   C5B  C5B  HCMM     3.500  2   180.00  
CR   C5A  C5B  HCMM     3.500  2   180.00  
CR   CR   CR   CR       0.051  1     0.00  
CR   CR   CR   CR       0.341  2   180.00  
CR   CR   CR   CR       0.166  3     0.00  
CR   CR   CR   HCMM     0.320  1     0.00  
CR   CR   CR   HCMM    -0.315  2   180.00  
CR   CR   CR   HCMM     0.132  3     0.00  
CR   CR   CR   OR      -0.344  1     0.00  
CR   CR   CR   OR       0.878  2   180.00  
CR   CR   CR   OR       0.238  3     0.00  
OR   CB   CB   HCMM     3.500  2   180.00  
OR   CR   CR   HCMM    -0.327  1     0.00  
OR   CR   CR   HCMM     0.536  2   180.00  
OR   CR   CR   HCMM     0.140  3     0.00  
HCMM CR   CR   HCMM     0.142  1     0.00  
HCMM CR   CR   HCMM    -0.693  2   180.00  
HCMM CR   CR   HCMM     0.157  3     0.00  
HCMM CB   CB   HCMM     3.500  2   180.00  
HCMM C5A  C5B  HCMM     3.500  2   180.00  
 
IMPROPER 
C5B  C5B  N5A  CR       2.879  0     0.00  
C5A  C5B  OFUR CR       3.598  0     0.00  
CR   CR   C5A  HCMM     0.000  0     0.00  
CR   HCMM C5A  HCMM     0.000  0     0.00  
CR   CR   CR   HCMM     0.000  0     0.00  
CR   HCMM CR   HCMM     0.000  0     0.00  
CR   OR   CR   HCMM     0.000  0     0.00  
CB   CB   OR   CB       3.454  0     0.00  
CB   CB   CB   HCMM     1.079  0     0.00  
CB   CB   CB   C5A      2.519  0     0.00  
C5A  OFUR CB   N5B      3.598  0     0.00  
C5A  C5B  OFUR HCMM     2.375  0     0.00  
C5B  C5A  N5B  HCMM     3.095  0     0.00  
C5B  C5A  C5B  HCMM     0.432  0     0.00  
CR   HCMM C5B  HCMM     0.000  0     0.00  
 
NONBONDED nbxmod  5 atom cdiel shift vatom vdistance 
vswitch -  
cutnb 14.0 ctofnb 12.0 ctonnb 10.0 eps 1.0 e14fac 1.0 
wmin 1.5  
N5A     0.000000  -0.200000     1.850000     
C5B     0.000000  -0.050000     2.040000     
C5A     0.000000  -0.050000     2.040000     
CB      0.000000  -0.070000     1.992400     
N5B     0.000000  -0.200000     1.850000     
OFUR    0.000000  -0.200000     1.850000     
CR      0.000000  -0.055000     2.175000   0.000000  -
0.010000     1.900000     
OR      0.000000  -0.152100     1.770000     
HCMM    0.000000  -0.022000     1.320000     
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A5.7.3 File Name: 1EAH_SCH4.par 
* ----  
* Built parameters for 1EAH_SCH4+H.mol2  
* Fri Oct  7 00:21:01 CEST 2011  
* Jason A. Roberts 2011 RMIT University/VIDRL 
* ----  
* 
 
BONDS 
CB   CB    401.068     1.3740  
CB   CR    356.737     1.4860  
CR   OR    363.214     1.4180  
CB   OR    404.019     1.3760  
CB   CLMM  243.102     1.7210  
HCMM CB    381.853     1.0840  
HCMM CR    342.991     1.0930  
 
ANGLES 
CB   CB   CB     48.145    119.9770  
CB   CB   HCMM   40.517    120.5710  
CB   CB   OR     69.663    116.4950  
CB   CB   CLMM   68.367    118.4950  
CB   CB   CR     57.788    120.4190  
CB   OR   CR     77.363    102.8460  
CB   CR   OR     63.186    107.9780  
CB   CR   HCMM   45.122    109.4910  
OR   CR   HCMM   56.205    108.5770  
HCMM CR   HCMM   37.134    108.8360  
 
DIHEDRALS 
CB   CB   CB   CB       3.500  2   180.00  
CB   CB   CB   OR       3.500  2   180.00  
CB   CB   CB   HCMM     3.500  2   180.00  
CB   CB   OR   CR       2.191  2   180.00  
CB   CB   CB   CLMM     3.500  2   180.00  
CB   OR   CR   CB       0.100  3     0.00  
CB   OR   CR   HCMM     0.053  3     0.00  
CB   CB   CR   OR       0.075  3     0.00  
CB   CB   CR   HCMM    -0.210  2   180.00  
CB   CB   CR   HCMM     0.196  3     0.00  
CB   CB   CB   CR       3.500  2   180.00  
CLMM CB   CB   OR       3.500  2   180.00  
CLMM CB   CB   HCMM     3.500  2   180.00  
OR   CB   CB   HCMM     3.500  2   180.00  
CR   CB   CB   HCMM     3.500  2   180.00  
HCMM CB   CB   HCMM     3.500  2   180.00  
 
IMPROPER 
CB   CB   CB   HCMM     1.079  0     0.00  
CB   OR   CB   CB       3.454  0     0.00  
CB   CLMM CB   CB       2.519  0     0.00  
CR   CB   OR   HCMM     0.000  0     0.00  
CB   CB   CR   CB       2.879  0     0.00  
CB   CB   CB   OR       3.454  0     0.00  
CR   OR   CB   HCMM     0.000  0     0.00  
CB   CB   CB   CLMM     2.519  0     0.00  
CR   HCMM OR   HCMM     0.000  0     0.00  
 
NONBONDED nbxmod  5 atom cdiel shift vatom vdistance vswitch -  
cutnb 14.0 ctofnb 12.0 ctonnb 10.0 eps 1.0 e14fac 1.0 wmin 1.5  
CB      0.000000  -0.070000     1.992400     
CLMM    0.000000  -0.260000     2.040000     
OR      0.000000  -0.152100     1.770000     
CR      0.000000  -0.055000     2.175000   0.000000  -0.010000     1.900000     
HCMM    0.000000  -0.022000     1.320000    
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A5.8 NAMD NPT simulation parameters for BlueGene/P and /Q supercomputers with 
file compression activated and custom load balancing intervals. 
 
File Name: ExampleBlueGeneSimulationRun.conf 
 
############################################################# 
## JOB DESCRIPTION                                         ## 
############################################################# 
#  Generic optimization/equilibration script  
############################################################# 
## ADJUSTABLE PARAMETERS                                   ## 
############################################################# 
 
 
# structure            Examplexxxx.psf 
# coordinates          Examplexxxx.pdb 
 
usecompressedpsf     on 
 
structure          Examplexxxx.psf.inter 
binCoordinates     Examplexxxx.coor 
 
outputName         Examplexxxx_EM+1ns 
 
## Memory optimization parameters (useful for BlueGene node 0 issues) 
 
# noPatchesOnZero yes 
# ldbUnloadZero yes 
# maxSelfPart 1 
# maxPairPart 1 
# pairlistMinProcs 128 
# PMEPencils 1  
 
## Load balancing parameters 
 
ldbPeriod 50000 
firstLdbStep 5000 
 
 
############################################################# 
## SIMULATION PARAMETERS                                   ## 
############################################################# 
 
# Input 
paraTypeCharmm on 
parameters   par_all27_prot_lipid_na.inp 
parameters Picornavirus_small_molecules.par 
 
 
set Temp   310 
temperature   $Temp 
 
# constraints         on  
# consexp             2 
# consref             xxxx.pdb  
# conskfile           xxxx.pdb 
# conskcol            B 
# constraintScaling   0.001 
 
 
# Force-Field Parameters 
exclude         scaled1-4 
1-4scaling     1.0 
cutoff         12 
switching      on 
switchdist      10 
pairlistdist    14 
 
# Integrator Parameters 
timestep            2 
rigidBonds          all 
nonbondedFreq       1 
fullElectFrequency  2   
stepspercycle       10 
 
# Constant Temperature Control 
langevin            on 
langevinDamping     5   
langevinTemp        $Temp 
langevinHydrogen    off  
 
 
# Periodic Boundary Conditions 
 
cellBasisVector1 364.425 0.0 0.0 
cellBasisVector2 0.0 364.425 0.0 
cellBasisVector3 182.212 182.212 257.688 
 
cellOrigin          0  0  0 
 
wrapAll             on 
wrapNearest         on 
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# PME (for full-system periodic electrostatics) 
PME                 yes 
PMEGridSpacing     1.0 
 
# Constant Pressure Control (variable volume) 
useGroupPressure      yes  
useFlexibleCell       no 
useConstantArea       no 
 
langevinPiston        on 
langevinPistonTarget  1.01325 
langevinPistonPeriod  100. 
langevinPistonDecay   50. 
langevinPistonTemp    $Temp 
 
# Output 
 
restartfreq         50000 
dcdfreq             50000 
xstFreq             5000 
outputEnergies      5000 
outputPressure      5000 
outputTiming        5000 
 
############################################################# 
## EXECUTION SCRIPT                                        ## 
############################################################# 
 
# Minimization 
  
minimize       50000 
run            500000 
 
#  
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A5.9 Simulation Construction Flowchart 
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A5.10 Simulation Analysis Flowchart 
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A6 Supporting Grants 
 
2012-2015 Title: National Poliovirus Laboratory and AFP surveillance System 
(incorporating environmental surveillance and enterovirus surveillance). 
Department of Health and Ageing. Total grant value $691,764.  
Principle Investigator - Thorley, B. R., Investigator - Roberts, J. A., 
2011-2014 Title: Molecular Modelling of Novel Enterovirus Proteins Associated With 
Acute Flaccid Paralysis. Victorian Life Sciences Computation Initiative, 
Resource Allocation Scheme. 8.2 million service units awarded in total.  
Principle Investigators - Roberts, J. A., Thorley, B. R., Investigators - 
Hung, A., Smooker, P., Kuiper, M. 
2012-2013 Title: Examination of the Specific Mechanisms of Vaccine-Derived Poliovirus 
Antiviral Drug Interactions. Victorian Life Sciences Computation 
Initiative, Resource Allocation Scheme.  2.4 million service units awarded.  
Principle Investigators - Roberts, J. A., Thorley, B. R., Investigators - 
Hung, A., Oberste, M. S. 
2011-2012 Title: Fighting Superbugs with Supercomputers. nVidia Academic Partnership 
Program. Equipment grant in kind, to the value of $24,722. 
Principle Investigators - Roberts, J. A., Kuiper, M. J, Investigators - Hurt, 
A., Hung, A., Wilson, D., Thorley, B. 
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A7 Awards 
 
2013 – Melbourne Health, “Celebrating Excellence Awards” Healthcare Innovation 
Award, Highly Commended. 
2013 – Australian Institute of Medical and Biological Illustrators, “Illuminate” 
conference awards exhibition, two bronze, one silver and one gold award. 
2013 - CSIRO Computational and Simulation Sciences Annual Conference, Winner 
poster session. 
2012 - IDC HPC Innovation Excellence Award, International Award For the Outstanding 
Application of HPC Computing for Business and Scientific Achievements. 
November 2012. 
2012 – RMIT University, Student Graduate Research Travel Award, $2000. 
2012 – Victorian Life Sciences Computation Initiative, Travel Award, $4000. 
2011 - Association of Molecular Modellers Australasia, 2011 Meeting of Molecular 
Modellers, Best video featuring molecular modelling simulation. 
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A8 Dissemination Details 
 
A8.1 Conference Proceedings, Seminars and Public Media 
 
2014 - (Invited Speaker) Detection, Characterisation and 3D Molecular Modelling of 
Enteroviruses from Cases of Acute Flaccid Paralysis, Public Health Night and 
ASM General Meeting, Australian Society of Microbiology (Victorian Branch), 
Melbourne, Australia. 
2014 - (Invited Speaker) Supercomputer Simulation of Viruses, The Merging of Art and 
Science, Institute of Photographic Technology, Melbourne, Australia. 
2014 - (Invited Speaker). Discovery and In-Silico Reconstruction of a Novel Virus 
Identified From a Patient Suffering Paralysis, Melbourne Meeting of Molecular 
Modellers, LaTrobe University, Melbourne, Australia.  
2013 - (Invited Speaker). Supercomputer Simulation of Newly Discovered and Novel 
Enteroviruses, University of Queensland, Australian Institute for Bioengineering 
and Nanotechnology Special Seminar, Queensland, Australia.  
2013 - (Invited Speaker). Supercomputer Simulation of Viruses, The Merging of Art and 
Science 2013, Australian Institute of Medical and Biological Illustrators, 
“Illuminate” biennial conference, Melbourne Australia. 
2013 – (Television) ABC Television, “Catalyst”, Series 14, Episode 17, aired 15th 
August, Featured story - 3D Virus. 
2013 - (Invited Speaker). Molecular Dynamics Simulation of Viruses 2013, RMIT 
University, 4th Workshop on Computational Modelling of Proteins and 
Membranes, Melbourne Australia. 
2013 – (Newspaper article) The Age, Melbourne Magazine: (also Sydney Morning 
Herald.) Feature Story: Melbourne research that could change your life. Including 
cover art. 
2013 - (Poster) Refinement of the wild poliovirus capsid structure by atomistic molecular 
dynamics simulation of a complete virion. Roberts, J. A., et. al., CSIRO 
Computational and Simulation Sciences and eResearch Annual Conference, 
Melbourne, Australia.. 
2013 – (Newspaper article) The Australian, Page 3, 22nd January, Scientists zoom in on a 
killer virus. 
 233 
2012 - (Invited Speaker). Computational Biophysics. Case study: In-Silico 
Reconstruction of Poliovirus. University of Adelaide, AMSI Summer Symposium in 
Bioinformatics. Adelaide Australia. 
2012 - (Invited Speaker) Supercomputer Modelling of a Complete Human Viral 
Pathogen: Poliovirus. Centers for Disease Control and Prevention, Bioinformatics 
Seminar Series. Atlanta GA, United States. 
2012 – (Presentation) Supercomputer Modelling of a Complete Human Viral Pathogen: 
Poliovirus. Theoretical and Computational Biology Group, Beckman Institute, 
University of Illinois. Champaign-Urbana IL, United States. 
2012 - (Presentation and poster) Supercomputer Modelling of the Complete Human Viral 
Pathogen: Poliovirus. Higher Degrees Research Student Conference ‘From 
Inception to Excellence’, RMIT University, Melbourne, Australia. 
2012 - (Poster) Refinement of the wild poliovirus capsid structure by atomistic molecular 
dynamics simulation of a complete virion. Roberts, J. A., et. al., 17th European 
Study Group on the Molecular Biology of Picornaviruses conference, St Raphael, 
France. 
2012 - (Poster)Supercomputer Modelling of Infectious Poliovirus., Roberts, J. A., 
Thorley, B. R., Melbourne Health Research Week, Melbourne, Australia.. 
2012 – (Newspaper article) The Age, Page 6, 15th January, Polio research reveals devil in 
Blue Gene. 
2011 - (Poster)Atomistic Molecular Dynamics Simulation of Complete Human 
Pathogenic Virions. Roberts, J., et al. 6th Australasian Virology Group meeting, 
Kingscliff, Australia. 
2011 - (Presentation)Application of Graphics Processing Unit Technology to Large-Scale 
Atomistic Molecular Dynamics Simulation of Pathogenic Virus Structures. 
Melbourne Meeting of Molecular Modellers, Melbourne, Australia.. 
2011 - (Invited Speaker). In-silico Reconstruction of Poliovirus Virions, 4th Sino-
Australian Meeting on Infectious Diseases, VIDRL Melbourne, Australia. 
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A8.1.1 Poster: Refinement of the wild poliovirus capsid structure by 
atomistic molecular dynamics simulation of a complete virion. 
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A8.1.2 Poster: Atomistic molecular dynamics simulation of complete 
human pathogenic virions 
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A8.2 Publications 
A8.2.1 
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